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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction; in 
doing so, it provides its audience with an evidence-based picture of the 
drug phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
audience including policymakers and their advisers; professionals and 
researchers working in the field of drugs; and, more broadly, the media 
and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference for those seeking the 
latest findings on drugs in Europe.
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5This is the EMCDDA’s 17th annual report on the state of 
the drugs problem in Europe, and it is gratifying when 
looking back over the years to note how much progress 
has been made in developing a sound understanding 
of the European drug phenomenon. This is not an 
achievement of the EMCDDA alone; credit must also go 
to the Member States of the European Union, which have 
long recognised the value of developing a comprehensive 
picture of Europe’s drug problem. And, while we are very 
proud of the work of the EMCDDA staff in producing this 
publication, we also have to acknowledge that it is very 
much a collective effort. This report is only made possible 
by the support and hard work of our partners, especially 
those in the Reitox network, who provide the national data 
on which the analysis is based. We are also indebted to 
the many other European and international agencies and 
bodies that support our work.
This year’s report comes at an important and difficult 
time for Europe. Many countries are experiencing 
financial and economic problems, and this must form the 
backdrop for our reporting. The austerity measures that 
are being adopted bring multiple challenges, and present 
policymakers with difficult choices as competing priorities 
call on the public purse. In such times, it is more important 
than ever that investments are made wisely, based on 
an understanding of the nature of the problem and what 
measures are likely to deliver the greatest benefits. The 
EMCDDA’s mission is to work with experts from across 
Europe to provide this analysis. You will find here, and in 
the accompanying web-based elements, an up-to-date, 
scientifically robust and comprehensive overview of the 
contemporary European drugs problem, together with 
examples of innovative and good practice.
When considering drug issues, there can be a tendency 
to be reductive, focusing only on individual elements in 
this complex problem, as though they exist in isolation. 
This is not the approach we adopt here. In our view, 
the strength of the EMCDDA’s analysis is that it brings 
together disparate information on topics that range 
from drug markets and interdiction efforts, to drug use, 
demand reduction responses and policy and legal 
developments. This allows us to provide a holistic analysis 
which is greater than the sum of its parts. You cannot 
fully understand supply issues if you do not understand 
the drivers of drug demand and vice versa. For example, 
to understand the changes that we are seeing in heroin 
availability in Europe today, we need to take into account 
the impact of interdiction efforts that have effectively 
targeted major crime organisations. But, critically, we 
need to also consider that this has taken place at a time 
when an increase in investment in treatment has removed 
a significant part of the demand from the marketplace. 
As you will see from our report this year, these are 
equally important pieces of information that need to be 
considered together in order to achieve a sound overview 
of the developments we are seeing in the European heroin 
situation.
We need this breadth of vision if we are to respond to 
the complex and dynamic nature of the drug problem 
in Europe today. We are presented with a range of 
challenges, both new and old. They may be linked to 
advances in information and communication technology, 
the spread of new psychoactive substances, and increased 
availability and use of synthetic drugs. Or they may stem 
from long-established problems that continue to defy our 
responses, and cause damage to both individuals and 
communities. The EMCDDA is committed to providing 
the evidence base to ensure that the debate on drugs 
in Europe remains informed by a comprehensive, 
dispassionate and, most importantly, helpful understanding 
of this complex issue.
João Goulão 
Chairman, EMCDDA Management Board
Wolfgang Götz 
Director, EMCDDA
Foreword
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9This annual report is based on information provided to 
the EMCDDA by the EU Member States, the candidate 
countries Croatia and Turkey, and Norway in the form of 
a national report. The statistical data reported here relate 
to the year 2010 (or the last year available). Graphics and 
tables in this report may reflect a subset of EU countries; 
the selection may be made on the basis of those countries 
from which data are available for the period of interest, or 
to highlight certain trends.
Analysis of trends is based only on those countries 
providing sufficient data to describe changes over the 
period specified. Figures for 2009 may substitute for 
missing 2010 values in trend analysis of drug market 
data; for the analysis of other trends, missing data may be 
interpolated.
Background information and a number of caveats that 
should be borne in mind when reading this annual report 
are presented below.
Drug supply and availability data
Systematic and routine information to describe illicit drug 
markets and trafficking is still limited. Production estimates 
of heroin, cocaine and cannabis are obtained from 
cultivation estimates based on fieldwork (sampling on the 
ground) and aerial or satellite surveys. These estimates 
have some important limitations linked, for example, to 
variations in yield figures or the difficulty of monitoring 
crops such as cannabis, which may be grown indoors or 
are not restricted to certain geographical areas.
Drug seizures are often considered as an indirect indicator 
of the supply, trafficking routes and availability of drugs. 
They are a more direct indicator of drug law enforcement 
activities (e.g. priorities, resources, strategies), while also 
reflecting both reporting practices and the vulnerability of 
traffickers. Data on purity or potency and retail prices of 
illicit drugs may also be analysed in order to understand 
retail drug markets. Retail prices of drugs reported to the 
EMCDDA reflect the price to the user. Trends in price are 
adjusted for inflation at national level. Reports on purity 
or potency, from most countries, are based on a sample of 
all drugs seized, and it is generally not possible to relate 
the reported data to a specific level of the drug market. 
For purity or potency and retail prices, analyses are based 
on the reported mean or mode or, in their absence, the 
median. The availability of price and purity data may be 
limited in some countries and there may be questions of 
reliability and comparability.
The EMCDDA collects national data on drug seizures, 
purity and retail prices in Europe. Other data on drug 
supply comes from UNODC’s information systems and 
analyses, complemented by additional information from 
Europol. Information on drug precursors is obtained 
from the European Commission, which collects data 
on seizures of these substances in the EU, and the 
International Narcotics Control Board (INCB), which is 
involved in international initiatives to prevent the diversion 
of precursor chemicals used in the manufacture of illicit 
drugs.
The data and estimates presented in this report are the 
best approximations available, but must be interpreted 
with caution as many parts of the world still lack 
sophisticated information systems related to drug supply.
Prevalence of drug use as measured  
by general population surveys
Drug use in the general or school population can be 
measured through representative surveys, which provide 
estimates of the proportion of individuals that report 
having used specific drugs over defined periods of time. 
Surveys also provide useful contextual information on 
patterns of use, socio-demographic characteristics of users 
and perceptions of risks and availability.
Introductory note
Accessing this annual report and its data 
sources on the Internet
This annual report is available for downloading in 
22 languages on the EMCDDA website. The electronic 
version contains links to all online sources cited in this 
annual report.
The following resources are available only on the Internet.
The 2012 statistical bulletin presents the full set of source 
tables on which the statistical analysis in this annual report 
is based. It also provides further detail on the methodology 
used and about 100 additional statistical graphs.
The national reports of the Reitox focal points give 
a detailed description and analysis of the drugs problem 
in each country.
Country overviews provide a top-level, graphical summary 
of key aspects of the drug situation for each country.
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The EMCDDA, in close collaboration with national 
experts, has developed a set of core items for use in adult 
surveys (the ‘European Model Questionnaire’, EMQ). 
This protocol has now been implemented in most EU 
Member States. However, there are still differences in 
the methodology used and year of data collection, and 
this means that small differences, in particular between 
countries, should be interpreted with caution.
Surveys are expensive to conduct and few European 
countries collect information each year, although many 
collect data at intervals of two to four years. In this 
report, data are presented based on the most recent 
survey available in each country, which, in most cases, is 
between 2006 and 2010. Prevalence data for the United 
Kingdom refer to England and Wales, unless otherwise 
stated, although separate data for Scotland and Northern 
Ireland are also available.
Of the three standard time frames used for reporting 
survey data, lifetime prevalence (use of a drug at any 
point in one’s life) is the broadest. This measure does not 
reflect the current drug-use situation among adults, but can 
be helpful to understand patterns of use and incidence. 
For adults, the EMCDDA’s standard age ranges are 15–64 
(all adults) and 15–34 (young adults). Countries using 
different upper or lower age limits include: Denmark (16), 
Germany (18), Hungary (18), Malta (18), Sweden (16) and 
the United Kingdom (16–59). The focus is on the last year 
and last month time frames (use during the last 12 months 
or last 30 days before the survey) (for more information, 
see the EMCDDA website). For school students, lifetime 
and last year prevalence are often similar, as illicit drug 
use before age 15 is rare.
The European school survey project on alcohol and 
other drugs (ESPAD) uses standardised methods and 
instruments to measure drug and alcohol use among 
representative samples of school students who turn 16 
during the calendar year. In 2011, data were collected 
in 36 countries, including 24 EU Member States, Croatia 
and Norway, and the results were published in 2012. 
In addition, Spain and the United Kingdom carry out 
national surveys of school students, which provide data on 
drug use comparable to the results of the ESPAD surveys.
Treatment demand
Data on those entering treatment in Europe for problems 
related to their drug use are reported anonymously to the 
EMCDDA treatment demand indicator. Each client entering 
treatment is queried on their drug use, treatment contact 
and social characteristics. The time frame for annual 
treatment entry data is 1 January to 31 December. Clients 
in continuous treatment at the start of the year in question 
are not included in the data. Where the proportion of 
treatment demands for a primary drug is given, the 
denominator is the number of cases for which the primary 
drug is known.
Interventions
Information on the availability and provision of various 
interventions in Europe is generally based on the informed 
judgement of national experts collected through structured 
questionnaires. However, for some indicators, quantitative 
monitoring data are also available.
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Enhancing coordination and cooperation
A strong message emerging from the EMCDDA’s latest 
analysis of the European drug situation is that there is 
a need to keep ‘an eye on the ball’ with regard to the 
problems related to established drugs, while at the same 
time developing responses to new threats and challenges. 
Heroin and cocaine continue to account for a large share 
of the harm, morbidity and mortality associated with 
drug use in Europe. Here, it will be necessary to maintain 
momentum in the development and implementation 
of evidence-based responses. In many respects, 
considerable, if uneven, progress has been made, but this 
could easily be put at risk by changing circumstances or 
by a failure to continue to scale up responses. The analysis 
also highlights the need to strengthen Europe’s capacity 
to identify and respond to the challenges posed by an 
increasingly complex and dynamic drug marketplace.
These needs must be seen in the context of the difficult 
financial situation in many European countries, which 
means that resources for addressing health and social 
problems of all descriptions are in short supply. In these 
circumstances, it is essential to ensure that the available 
funds are invested in well-targeted activities of proven 
effectiveness. One way that this can be achieved is by 
cooperation between EU Member States, in which they 
seek to maximise the benefits of activities through sharing 
experiences, working together or better coordinating their 
actions. The policy framework for this is provided by the 
EU drug strategy and its accompanying action plans. 
The current EU strategy (2005–12) has been positively 
evaluated, with particular importance given to its role in 
facilitating information exchange.
A new policy framework is now under consideration 
to follow on from the 2005–12 drug strategy. The new 
framework is likely to maintain its emphasis on the need 
for an evidence-based and balanced approach which 
encompasses a comprehensive set of demand and supply 
reduction measures. Monitoring, research and evaluation, 
as well as respect for fundamental human rights, are also 
likely to remain key elements of the EU approach. The 
new policy framework will also ensure synergy between 
activities in the drugs field and broader issues related 
to security and health, in which drugs are only one 
component, such as HIV prevention or the fight against 
organised crime. The new framework will also help to 
ensure that Europe speaks with a strong and united voice 
in the international debate on drugs.
A complicated picture: the cannabis market in Europe
This year, the EMCDDA undertook a major new analysis 
of the cannabis market, which revealed an increasingly 
complex and diverse picture for Europe’s most used illicit 
drug. A number of different cannabis ‘products’ are now 
available on the European market, with the most important 
distinction being between herbal cannabis and cannabis 
resin. The rise of cannabis production within the European 
Union has resulted in the increasing displacement of 
imported cannabis resin by home-produced herbal 
cannabis products. Domestic cannabis production varies 
considerably. It can take the form of large plantations, 
where the plant is grown intensively using sophisticated 
techniques to maximise yield and potency. At the other 
end of the spectrum, small numbers of cannabis plants 
may be grown by users for personal consumption.
Although most cannabis offences are still related to the 
use or possession of the drug, many countries report that 
their policy is to prioritise measures targeting trafficking 
and supply. In this context, greater emphasis is now 
reported to be given to targeting intensive production 
sites. However, despite increases in the number of plants 
seized and the development of some innovative new 
detection methods, Europe still seizes far more cannabis 
resin than herbal cannabis. This suggests that domestic 
herbal cannabis production can pose a greater challenge 
for interdiction efforts, especially when it takes the form 
of intensive indoor production. Concern is growing about 
developments in this area: both because of the collateral 
damage that the presence of drug production sites can 
cause to local communities and because of evidence of 
the involvement of organised criminal gangs.
The scale and complexity of the cannabis market is not 
surprising as it reflects the position of the drug as Europe’s 
Commentary
Building on achievements, maintaining momentum and responding 
to change — the challenge for drug policy in Europe today
14
Annual report 2012: the state of the drugs problem in Europe
most popular illicit substance. Correspondingly, it is also 
the substance where political and public sentiment is most 
divided. Interestingly, levels of cannabis consumption 
overall appear relatively stable, and there may even be 
a decline in use in some countries. Although difficult to 
measure, cannabis-related problems are also now better 
understood and known to be associated with the intensive 
and long-term use of the drug. Some worries exist here. 
The shift towards herbal cannabis, for example, may be 
exposing users to more potent forms of the drug. Moreover, 
studies report that the age of initiation is now quite low 
for many users. An estimated 1 % of the European adult 
population is using the drug on a daily basis, and among 
young males in particular, intensive patterns of use can be 
relatively common in some countries. Taken as a whole, any 
optimism engendered by a stabilisation in prevalence levels 
needs to be tempered by the recognition that this drug 
remains an important public health issue, reflected in the 
number of demands for drug treatment related to its use.
Today’s European students: a more cautious cohort
The latest results from the European school survey 
project on alcohol and other drugs (ESPAD) provide an 
important window on time trends in substance use among 
schoolchildren. Promisingly, for all the major substances, 
the 2011 findings suggest a reduction or stable situation. 
Over the five rounds of the survey, recent cigarette use 
steadily decreased between 1999 and 2007, then stabilised. 
Students’ recent use of alcohol has gradually declined overall 
in Europe since 2003, while the latest data indicate that the 
upward trend for heavy episodic drinking, observed from 
1995 to 2007, may now be past its peak. Overall, students’ 
experience of illicit drugs — predominantly cannabis — was 
rising until 2003, dropped slightly in 2007 and since then 
has remained stable. These findings may provide us with an 
indication of future trends, as patterns found here may later 
feed through into older age cohorts.
An interesting observation is that countries that report 
high prevalence estimates for one substance, tend also to 
report relatively high estimates for other substances, both 
licit and illicit, thus high levels of recent use of alcohol and 
heavy episodic drinking are associated with the use of 
illicit drugs and inhalants. This finding supports prevention 
approaches that recognise the need to target both drugs 
and alcohol when working with young people.
Drugs and the family: an overlooked issue  
and underused resource
Individuals take drugs, but often their families must 
share the problems that their consumption can cause. 
Families and the related issue of drug users with parental 
responsibility are analysed in a new EMCDDA study. 
The report finds that although those with drug problems 
do not necessarily make bad parents, they are likely 
to require additional support. Treatment services, in 
particular, must be sensitive to the needs of those who 
have parental responsibility, as worries about childcare 
or child protection can act as a barrier to seeking help. 
Working with drug-using parents is also challenging for 
services, as it requires balancing the rights of the parent 
and of the child; however, the report concludes that 
good practice and well-targeted interventions can make 
a real difference. This finding is echoed in the analysis 
of interventions that target pregnant drug users, where 
there is strong evidence that the provision of appropriate 
advice and support can improve the outcome for both 
mother and child.
Many studies have explored the stress and social 
disruption that can result from having a family member 
with a drug problem. Family support services, however, 
are generally poorly developed in most European 
countries. This can mean that an important resource for 
supporting recovery is being overlooked. A focus on 
the family environment is also becoming increasingly 
important for drug prevention work, where a growing 
evidence base points to the effectiveness of broad-based 
prevention strategies that target both the environment and 
the individual. The family is particularly important in this 
respect, and environmental prevention strategies that work 
to establish stronger families may lower the risk of a range 
of problematic behaviours, including drug use. Despite 
the positive findings for interventions in this area, the fact 
that they remain, to a large extent, poorly developed, 
highlights the more general problem that findings from 
research on prevention often fail to be translated into 
policies and practice.
Drug-using prisoners: a vulnerable population
Despite increasing interest in providing ‘alternatives to 
prison’, many people with drug problems continue to 
pass through Europe’s prisons every year. This is reflected 
in study data showing that drug problems are far more 
common in prisoners than in the general population. 
Although some do stop using drugs when incarcerated, 
the availability of drugs in some prisons also means that 
others may initiate drug use, or start engaging in more 
damaging behaviours. Injecting drug users, for example, 
may share equipment more frequently, heightening the risk 
of the transmission of blood-borne pathogens such as HIV 
and hepatitis C virus.
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Overcrowding, poor hygiene and a lack of healthcare 
provision affect many prisons, and contribute to the overall 
poor health status found in prison populations. Prisoners 
with drug problems may be doubly disadvantaged in this 
respect, and may be especially vulnerable to both physical 
and mental health problems while incarcerated — with 
particular concerns existing about their elevated risk of 
self-harm and suicide. A strong argument therefore exists 
that any successful approach to improving prison health 
must recognise the importance of including drug treatment 
alongside, and integrated with, more generic physical and 
mental healthcare responses.
Where adequate services are in place, periods of 
incarceration may provide an opportunity for some 
to reduce their drug use and engage with services. 
Opportunities in this area have been increasing, as many 
countries have scaled up the provision of interventions 
within prisons, particularly substitution treatment for those 
who are opioid-dependent. Typically, developments 
in treatment availability in prison mirror those in the 
community, but with a considerable time lag. Provision 
of health services in prisons also varies widely between 
countries, and there remains an overall need to further 
develop and improve the quality of the services provided. 
Rarely do prisons offer a standard of care equivalent and 
comparable to that provided to the wider community.
Release from prison can also be a critical time for 
interventions, as the risk of overdose is greatly increased 
during this post-release period, when ex-prisoners may 
resume using heroin while their tolerance to opioids is 
reduced. Pre-release counselling and continuity of care on 
release are, therefore, essential, as by helping to ensure 
that vulnerable individuals remain in contact with services 
they can support recovery and, ultimately, be an extremely 
cost-effective way of saving lives.
White powders and pills: a less discriminating  
stimulants market
Cocaine, amphetamines, ecstasy and, sometimes now, 
synthetic cathinones may be viewed as competing and, to 
some extent, interchangeable products in the eyes of the 
consumer. In this context, it is likely that the availability 
of these substances, as well as price and quality, will 
influence consumer choices and account for the volatility 
seen within the contemporary stimulants market. Some 
recent studies even suggest that it is not uncommon for 
users to report having taken stimulant drugs in the form of 
unknown pills or white powders.
In Europe, overall prevalence estimates for amphetamines 
and ecstasy use are relatively stable, although supply-
related factors appear to have affected the availability 
of both drugs. The ecstasy market is now recovering 
from a shortage of MDMA (3,4-methylenedioxy-
methamphetamine), when many tablets contained other 
substances. Similarly, methamphetamine has recently 
Commentary: The challenge for drug policy in Europe today
At a glance — estimates of drug use in Europe
The estimates presented here relate to the adult population 
(15–64) and are based on the most recent data available 
(surveys conducted between 2004 and 2010/11, mainly 
2008–10). For the complete set of data and information on 
the methodology see the accompanying statistical bulletin.
Cannabis
Lifetime prevalence: about 80.5 million  
(23.7 % of European adults)
Last year use: about 23 million European adults (6.8 %)  
or one in three lifetime users
Last month use: about 12 million (3.6 %)
Country variation in last year use:  
overall range 0.3 % to 14.3 %
Cocaine
Lifetime prevalence: about 15.5 million  
(4.6 % of European adults)
Last year use: about 4 million European adults (1.2 %)  
or one in four lifetime users
Last month use: about 1.5 million (0.5 %)
Country variation in last year use:  
overall range 0.1 % to 2.7 %
Ecstasy
Lifetime prevalence: about 11.5 million  
(3.4 % of European adults)
Last year use: about 2 million (0.6 %)  
or one in six lifetime users
Country variation in last year use:  
overall range 0.1 % to 1.6 %
Amphetamines
Lifetime prevalence: about 13 million  
(3.8 % of European adults)
Last year use: about 2 million (0.6 %)  
or one in six lifetime users
Country variation in last year use:  
overall range 0.0 % to 1.1 %
Opioids
Problem opioid users: estimated at about  
1.4 million Europeans
About 710 000 opioid users received substitution  
treatment in 2010
Principal drug in about 50 % of all drug  
treatment requests
Drug-induced deaths accounted for 4 % of all deaths of 
Europeans aged 15–39, with opioids being found in about 
three quarters of cases
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replaced, to some extent, amphetamine in parts of Europe. 
This is worrying as, historically, use of this drug has been 
largely restricted to the Czech Republic and Slovakia. 
This could now be changing, and although the available 
data are limited, they do raise concerns. Seizure data 
suggest that the drug is becoming more widely available 
and production has been scaled up in some countries. 
Overdose deaths have been reported in Germany, and the 
drug is more commonly mentioned in reports from other 
countries. Of concern, the EMCDDA has noted sporadic 
reports of methamphetamine smoking and the availability 
of crystal methamphetamine, a highly pure form of the 
drug. Methamphetamine smoking has historically been 
extremely rare in Europe, but evidence from elsewhere 
suggests a strong association with negative consequences.
A European Union risk assessment on 4-methylamphetamine 
is being conducted in the context of the EU early warning 
system on new psychoactive substances. This exercise 
was prompted by clusters of deaths associated with this 
substance, which appeared to be sold as, or mixed with, 
amphetamine. It is likely that this form of amphetamine, 
which is currently uncontrolled in most of Europe, was 
manufactured in clandestine laboratories by producers 
seeking new chemical routes for amphetamine production. 
As such, it represents an example of both the increasing 
innovation seen in synthetic drug production and the 
potential for unintended negative health consequences 
that this can bring.
More diversity in synthetic drug use
While attention has largely been focused on either 
concerns about established stimulants or on the emergence 
of new uncontrolled psychoactive substances, a number 
of other synthetic drugs have entered and established 
themselves on the European drug market. Although the 
numbers of Europeans using drugs such as GHB (gamma-
hydroxybutyrate), GBL (gamma-butyrolactone), ketamine 
and, more recently, mephedrone are low, high levels 
of use are found in some sub-populations, and these 
drugs appear to have the potential for more widespread 
diffusion. There are now reports of health problems 
linked with all of these substances, including dependence 
among chronic users, and some unexpected problems 
such as the bladder disease seen in ketamine users. These 
developments have, to a large extent, taken place beneath 
the monitoring radar, and they point to a need not only 
to improve the sensitivity of drug information systems to 
emergent trends and new health problems, but also to 
understand better what constitutes appropriate demand 
reduction interventions in this area.
Cocaine: signs of falling use and status
Widespread cocaine use may be limited to some southern 
and western countries, but the drug still remains, in terms 
of overall numbers, the most widely used illicit stimulant 
in Europe. Now, however, after a decade of increasing 
popularity, the latest data suggest that the trend may be 
downward. Perceptions of the drug may also be changing, 
with some studies reporting that cocaine may be losing its 
image as a high status drug.
A number of factors may be important here. Quality has 
been cited as a possible factor, with the suggestion that 
low cocaine purity may be causing some users to switch 
to other stimulants. It is also possible that potential users 
are now more aware of the negative consequences that 
can accompany cocaine consumption. A recent EMCDDA 
review on the health consequences of cocaine use 
concluded that problems were probably underestimated 
in available data sources. The data that did exist on acute 
presentations to hospital emergency services suggested 
that there had been a threefold increase in cocaine-
related emergency admissions since the end of the 1990s, 
but that presentations appeared to peak around 2008. 
Similarly, the data available on cocaine-related deaths 
also show a peak year in 2008. This trend is also found 
in treatment admission data, where the numbers entering 
treatment for cocaine-related problems for the first time 
in their lives increased until 2008, but then fell. A similar 
picture can be seen in the supply data. Cocaine seizures 
now appear to be on the decline in Europe: the volume of 
cocaine seized reached a peak in 2006 and the number 
of seizures in 2008.
Heroin: evidence of a decline
Since the 1970s, the use of heroin, especially by injection, 
has been the source of many of Europe’s drug-related 
problems. Given the harm associated with heroin, 
which includes overdose deaths, the spread of HIV 
and hepatitis C virus among injecting drug users, and 
associated criminality, it is unsurprising that European 
drug policy has mainly concentrated on addressing heroin 
problems. And, while these problems continue today, they 
do so at lower levels, in some cases considerably so, as 
we observe the impact of effective policies and the long-
term decline in the use of this drug, especially by injection. 
It seems increasingly likely that we are now moving into 
a new era in which heroin will play a less central role 
in Europe’s drug problem.
Such analysis must be made with caution, as future 
trends are difficult to predict. Moreover, the long-term 
and chronic nature of heroin problems means that many 
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current users will remain in need of help for years to 
come. Nevertheless, indicators point to a decline in overall 
use and, more importantly, a decline in new recruitment. 
Across Europe, the number of new treatment demands has 
fallen, and the average age of those entering treatment for 
heroin problems has increased.
Market indicators suggest that heroin has become 
less available in Europe in recent years, and, in 
some countries, the drug has been replaced by other 
substances, including synthetic opioids such as fentanyl 
and buprenorphine. The heroin market collapsed almost 
a decade ago in some northern European countries and 
never fully recovered. More recently, short-term market 
shocks, probably resulting from successful interdiction 
efforts, have also been reported. The latest European 
figures for purity, seizures, drug law offences and retail 
price all show a decrease. Developments in the illicit 
drug markets will need to be followed closely to ascertain 
whether recent heroin shortages will lead to the lasting 
disappearance of the drug in some countries, and what 
substances will replace it. In this respect, in addition to 
synthetic opioids, methamphetamine, cathinones and 
benzodiazepines have all been identified as possible 
candidates.
Overall, both demand and supply-side factors appear to 
be important in the changes in heroin use identified here. 
Successful interdiction efforts need to be viewed alongside 
a dramatic increase in treatment availability, particularly 
substitution treatment, which has removed a significant 
proportion of the demand from the market. An open question 
is the relationship between opium production in Afghanistan 
and patterns of heroin consumption in Europe, where no 
simple link can be seen in the data. Although concern exists 
that increased production could result in a wave of new 
heroin use in EU Member States, the historical data do not 
point strongly in this direction. On the contrary, the European 
Union may now represent, in some respects at least, a more 
difficult marketplace for this product.
Injecting in decline too, but still a serious public health risk
Indicators of injecting trends also suggest that this 
particularly damaging behaviour is now also in decline. 
Reported levels of injection among new clients entering 
treatment for drug problems provide the best available 
data source here. A downward trend is evident among 
new heroin users entering treatment, and this is most 
visible in western Europe, but can also be seen in some 
eastern European countries. Overall, just over a third 
(36 %) of those entering treatment for heroin problems 
now report injecting the drug as their main route of 
administration. Other drugs may also be injected: around 
a quarter of those entering treatment for amphetamine 
problems report injecting their drug, as do about 3 % of 
those entering treatment for cocaine problems. The move 
away from injecting is clearly encouraging. Nevertheless, 
drug injecting remains a major cause of avoidable health 
problems and death among young Europeans. Injecting 
is particularly associated with drug overdose, as well 
as serious infections. Recent outbreaks of HIV in Greece 
and Romania remind us that despite Europe’s success 
in fighting the transmission of this virus among drug 
users, it retains the potential to spread rapidly in certain 
populations. This also underlines the need to ensure 
adequate coverage of HIV prevention and harm reduction 
services for at-risk populations. 
Bacterial infections are another potentially serious 
consequence of injecting, and can be life-threatening. In 
June and July 2012, anthrax cases were reported in five 
EU countries, possibly related to a common source of 
contaminated heroin. This outbreak has prompted a joint 
EMCDDA–ECDC rapid risk assessment.
Finding a new perspective on new drugs
The Internet has reduced the restrictions imposed by time 
and place, allowing new patterns and trends in drug use 
to rapidly transcend geographical boundaries. Evidence 
for this conclusion was plentiful at the second international 
forum on new psychoactive substances, organised this 
year by the EMCDDA and the US National Institute on 
Drug Abuse. Similar ‘legal high’ products are now being 
marketed in parts of south-east Asia, European countries, 
Japan and the United States. The European Union 
has, by international standards, a sophisticated early 
warning and risk assessment mechanism for responding 
to the emergence of new psychoactive substances. This 
mechanism is currently under review, and a new legal 
framework is expected. Responses in this area are likely to 
be most effective if they are coordinated across countries 
and with clear added value offered by an EU-level 
mechanism. In 2012, new psychoactive substances 
continue to be reported to the system at a rate of around 
one a week. Synthetic cannabinoid receptor agonists and 
cathinones are still prominent, but substances from more 
obscure chemical groups are increasingly being reported. 
To date, new substances have tended to mimic the effects 
of cannabis or stimulant drugs such as ecstasy or cocaine, 
and their packaging suggests that the recreational drug 
market is the main target. However, there have been 
reports from a few countries of problem drug users 
switching to injecting cathinones, such as mephedrone 
and MDPV (3,4-methylenedioxypyrovalerone).
Commentary: The challenge for drug policy in Europe today
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‘Bath salts’ and ‘plant food’: the challenge posed by 
complex and changing products and mixtures
An important task of the EU early warning system is 
the sharing of forensic and toxicological information. 
Identifying the psychoactive chemicals in products can 
be challenging as they may be obscure compounds or 
mixtures of chemicals. The number of products containing 
multiple psychoactive substances appears to be rising, 
and some test purchase samples have been found to 
include both controlled and non-controlled substances. 
The commonly used term ‘legal highs’ is therefore often 
a misnomer, and consumers of these products are likely 
to be both unaware of what they are consuming and 
ignorant of the health and legal implications. Confusion 
is apparent at the international level, where a lack of 
a clear terminology and forensic information impedes 
debate. In the United States, for example, the generic 
term ‘bath salts’ covers a range of products containing 
new psychoactive substances, and which are often sold as 
‘plant food’ in the European Union.
New psychoactive substances also pose problems for 
drug-use surveys, as many users may not know what 
they have actually taken. The few studies available paint 
a picture of considerable heterogeneity between countries, 
with rates of use relatively low, but not negligible. They 
also suggest that use of these substances can rise and fall 
quickly within specific populations. Availability appears 
to be an important factor here. In Poland, the opening 
of a large number of retail outlets was accompanied by 
increases in reported use and visits to hospital emergency 
units attributed to new psychoactive substances, both 
of which decreased after measures were taken to limit 
availability. In Germany, some data suggest that use of 
‘Spice’ — often found to contain synthetic cannabinoid 
receptor agonists — declined, but did not disappear 
after emergency banning measures were introduced. 
Similarly, despite the introduction of EU control measures, 
mephedrone still appears to be available on the illicit 
market in some countries.
To date, the policy debate around new drugs has largely 
focused on the development of control measures, with 
countries using a mixture of market regulations, existing 
drug control legislation and specially drafted new laws. 
However, there is growing interest in addressing the 
wider issues surrounding new drugs and, in particular, 
the need to understand the potential health and social 
impact of these drugs and to identify appropriate demand 
reduction strategies. The EMCDDA has received reports 
of acute medical emergencies and deaths associated with 
the use of new psychoactive substances. Currently, the 
data are difficult to interpret, and the improvement of our 
surveillance and analysis capacity in this area is clearly 
a priority. EU Member States are also beginning to report 
the introduction of specific responses to new psychoactive 
substances. Among the new approaches being studied are 
innovative Internet-based prevention programmes and the 
delivery of targeted school based prevention messages.
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(1) Available online.
(2) See the box ‘COSI: the Standing Committee on operational cooperation on internal security’ (Chapter 2). 
(3) COM(2011) 689/2. 
(4) See Country overviews on the EMCDDA website.
Introduction
This chapter explores recent policy developments in 
the European Union, and examines the extent to which 
Member States have integrated their licit and illicit drug 
strategies, and established links between drug and 
security strategies. Also presented are a range of national 
and transnational strategies in non-EU countries, which are 
considered in terms of their similarities or differences to 
the European approach to drugs.
The extent to which national drug strategies are linked with 
budgets is considered, alongside an update on trend data 
from drug-related public expenditure studies. Also presented 
is a new analysis of how Member States are configuring 
their national laws to address the growing challenge posed 
by new drugs. This chapter concludes with an update on 
European developments in drug-related research.
EU and international policy developments
Towards a new EU drug strategy
The current EU drugs strategy (2005–12) is the first to be 
submitted to external evaluation. The evaluators found that 
the strategy has provided added value to the efforts of the 
Member States in the drugs field and that the promotion 
of evidence-based interventions in the EU strategy was 
commended by stakeholders (Rand Europe, 2012). The 
report highlighted the area of information, research and 
evaluation, where the EU approach and infrastructures 
actively support knowledge transfer within Europe. For 
the next strategy, which will be drafted during 2012, 
the evaluators recommended maintaining the balanced 
approach, adopting integrated policy approaches across 
licit and illicit substances including new psychoactive 
substances, building up the evidence base in drug supply 
reduction and clarifying the roles of EU coordination bodies.
Given the current political interest in the topic and its clear 
European dimension, an important issue for the upcoming 
strategy will be responses to new psychoactive substances. 
The strategy will be informed by a number of initiatives 
launched in 2011, which include a European pact against 
synthetic drugs (1), an operational action plan on synthetic 
drugs and new psychoactive substances (2), both adopted 
by the Council of the European Union, and a communication 
‘Towards a stronger European response to drugs’ adopted 
by the European Commission and announcing a series of 
measures on illicit drugs (3). These measures include new 
European legislation designed to address more rapidly 
and effectively the emergence of harmful new psychoactive 
substances (‘legal highs’, see Chapter 8). Other legislative 
developments are planned in the areas of drug trafficking, 
precursor control, money laundering and criminal assets 
recovery. Furthermore, a proposal is being prepared on the 
establishment of minimum quality standards in prevention, 
treatment and harm reduction.
Drug policies in the Western Balkans
The evaluation of the EU drug strategy noted that 
international cooperation was a useful and influential 
policy tool, particularly with candidate and pre-accession 
countries. Prior to the most recent enlargements of the 
European Union in 2004 and 2007, the future EU Member 
States were given assistance to develop drug policies that 
were in line with those of the European Union’s balanced 
and evidence-based approach.
A similar process is currently underway in the Western 
Balkans, where three candidate countries and three 
potential candidate countries have all recently adopted 
comprehensive and balanced drug strategies and action 
plans (see Table 1). The countries in this region share 
many common issues, including their location along 
one of Europe’s historical drug trafficking routes, with 
its attendant heroin and other drug-related problems (4). 
These national policy documents cover drug demand and 
drug supply reduction and, in some cases, adopt strategic 
goals, objectives and structures reflecting those of the 
EU drug policy documents, incorporating monitoring and 
evaluation systems, as well as coordination mechanisms. 
The action plans are often detailed, with a time frame, 
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responsible parties, implementation indicators and cost 
estimates identified for each action.
National drug strategies
One recommendation for the next EU drug strategy is 
to move towards a more integrated approach for both 
licit and illicit drugs, possibly also including behavioural 
addictions. Another topic for consideration is improved 
linkage between drug policy and broader security 
policies, such as those targeting organised crime. On 
both issues, the current situation in the EU Member States, 
Croatia, Turkey and Norway is explored below.
Integration of licit and illicit drugs
The adoption of national drug strategies and action plans 
is a cornerstone of EU drug policy and an established 
tool used by European countries to set out the aims and 
objectives of their drug policies. Differences can be seen 
in the extent to which countries have moved towards policy 
documents that cover both licit and illicit drugs (Figure 1).
Table 1: Recent drug policy documents in candidate and potential candidate countries in the Western 
Balkans
Country Name of policy document Time span Main focus Note
Albania National strategy against drugs 2004–10 Illicit drugs Potential candidate country
Bosnia and Herzegovina National strategy on supervision of narcotic 
drugs, prevention and suppression of the 
abuse of narcotic drugs
2009–13 Illicit drugs Potential candidate country
Former Yugoslav 
Republic of Macedonia
National drug strategy 2006–12 Illicit drugs Candidate country
Kosovo (1) National anti-drug strategy and action plan 2009–12 Illicit drugs Potential candidate country
Montenegro National strategic response to drugs 2008–12 Illicit drugs Candidate country
Serbia National strategy for the fight against drugs 2009–13 Illicit drugs Candidate country
(1) This designation is without prejudice to positions on status, and is in line with UNSCR 1244 (1999) and the ICJ Opinion on the Kosovo declaration of independence.
Transnational drug strategies
The next EU drug strategy will be the ninth drug strategy 
or action plan to be adopted by the European Union since 
1990. During this period, transnational organisations in 
other parts of the world have also been developing such 
documents.
In Africa, a ‘plan of action on drug control and crime 
prevention (2007–12)’ was developed by the African Union, 
while the 15 Member States of the Economic Community 
of West African States (ECOWAS) agreed on a political 
declaration and a ‘regional action plan on illicit drug 
trafficking, organised crimes and drug abuse (2008–11)’. 
In Asia, the Association of Southeast Asian Nations 
(ASEAN), comprising 10 countries, adopted the ‘ASEAN 
work plan on combating illicit drug production, trafficking 
and use (2009–15)’. And, in 2010, the Organisation of 
the American States (OAS) adopted a ‘hemispheric drug 
strategy’ covering the 35 states of the Americas.
While the OAS’s strategy is the closest to the EU approach, 
the plans of the other transnational organisations focus 
mainly on supply reduction and law enforcement. The 
ASEAN work plan, for example, aims at eradicating 
illicit drug production, processing, trafficking and abuse, 
with the objective of making ASEAN a drug-free area by 
2015. The overall aim of the African Union’s plan is the 
strengthening of law enforcement for drug control, with six 
of the seven key priority areas focusing on drug control 
and crime prevention. Although incorporating a more 
balanced approach, the ECOWAS strategy has a strong 
focus on security issues linked with drug trafficking.
Figure 1: Scope of national drug strategies
Global strategy
Separate strategies
for illicit and licit drugs
Illicit drug strategy
No national drug 
strategy
NB: Global strategies cover licit and illicit drugs and, in some cases, 
addictive behaviours. Some illicit drug strategies include a focus 
on licit drugs. While the United Kingdom has separate strategies 
for illicit and licit drugs, England and Scotland have separate 
strategies for illicit drugs, alcohol and tobacco, and Wales and 
Northern Ireland have global drug strategies that cover alcohol 
as well as separate tobacco strategies.
Sources: Reitox national focal points.
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Five countries have adopted strategies or action plans that 
have a ‘global’ scope, covering licit and illicit drugs and, 
in some cases, addictive behaviours. The broad approach 
is reflected in the policy document titles: Belgium’s 
‘Comprehensive and integrated policy on drugs’; France’s 
‘Governmental plan to fight drugs and drug addiction’; 
Germany’s ‘National strategy for drug and addiction 
policy’; Sweden’s ‘Cohesive strategy for alcohol, narcotic 
drugs, doping and tobacco (ANDT) policy’; and Norway’s 
‘Action plan for the drugs and alcohol field’. With the 
exception of Norway, which has separate tobacco and 
gambling strategies, there are no separate national 
strategies for other licit drugs or addictive behaviours in 
these countries.
Ten countries have separate strategies or action plans 
for illicit and licit drugs. These countries differ in the licit 
drugs that have specific policy documents and whether 
these documents address individual substances or not. 
The Netherlands and Slovakia have separate strategies 
for alcohol and tobacco, whereas Lithuania has a joint 
alcohol and tobacco strategy. In the seven other countries, 
licit drug strategies address only alcohol or tobacco; both 
Ireland and Portugal are currently considering the process 
of integrating illicit drug and alcohol strategies.
Fourteen countries have only one drug strategy or action 
plan, which is focused on illicit drugs. Measures for 
licit drugs may, however, be included in these policy 
documents to a greater or lesser extent. In some of these 
countries, for example Spain, there is a strong tendency 
to include specific measures targeting alcohol or tobacco 
use, where appropriate. Other countries make occasional 
references to licit drugs or medicines (Bulgaria, Malta), 
or call for better integration of drugs and alcohol issues 
in the future (Greece, Luxembourg). Only one country, 
Estonia, has a strategy that is focused solely on illicit 
drugs.
The trend towards an integrated approach to substance 
use appears to exist primarily among the pre-2004 EU 
Member States. It is these countries that have adopted 
a global strategy, or that are in the process of integrating 
their illicit drug and alcohol strategies or that have 
included many licit drug objectives in their illicit drug 
strategy. In central and eastern Europe, the picture is 
mainly one of separate strategies or just illicit drug 
strategies, with limited mention of licit drugs.
Despite this trend towards integration of licit and illicit 
substances in policy documents, the supporting national 
coordination and budgetary structures may not have been 
modified in a complementary way.
Drug strategies and security issues
Supply reduction is a major component of drug policies in 
Europe. The planning and coordination of activities in this 
area is associated not only with the drug strategy, but is 
also linked to broader policy developments in the area of 
security. At EU level, for example, serious organised crime 
and its involvement in drug trafficking is one of the threats 
targeted by the European Union’s internal security strategy 
(European Council, 2010).
At national level, 15 countries reported having at least 
one policy document, in addition to their drug strategy, 
defining activities in the area of drug supply reduction. 
Of these countries, two mentioned a strategy in the 
area of security, 11 mentioned a strategy to fight crime 
or organised crime, and two mentioned both types of 
strategies. In another 14 countries, the national drug 
strategy was reported as being the only document 
defining drug supply reduction activities, while Austria has 
no national policy document in this area.
In most of those countries where supply reduction is 
incorporated in both the drug strategy and in another 
strategy, drug experts report that the national drug 
strategy is the most important document in this area. 
Two countries (Netherlands, United Kingdom) report 
that both documents are of equal importance, while the 
Belgian ‘National security plan’ and Slovenia’s ‘National 
programme for the prevention and suppression of 
criminality’ are considered more important than the drug 
strategy in defining supply reduction activities.
During the last 20 years, drugs have been a highly visible 
policy priority, largely because of growing levels of 
drug use and drug-related problems. A more stable drug 
situation and new policy priorities at national level (public 
deficits, unemployment) now appear to be contributing 
to the increasing integration of drugs policies with 
broader policies. In practice, this could mean that drug 
demand reduction increasingly moves closer to health 
and behavioural addiction policies, while drug supply 
reduction moves closer to security strategies targeting 
organised crime. This raises the question as to whether the 
comprehensive and balanced drug strategies of today will 
have a place in the future.
Public expenditure
National drug strategies and action plans contain measures 
to reduce drug-related problems, the implementation of 
which is funded primarily by government. Accounting for 
such public funds can provide an important tool in the 
policy evaluation process. This section explores whether 
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specific budgets are associated with drug policy documents, 
and whether information on actual expenditure is made 
available. However, as funds are allocated at various levels 
of government and budgetary accounting practices vary 
across Europe, only a preliminary overview of national 
practices in this area is available.
Public expenditure related to the drug problem may 
be affected by austerity programmes, such as those 
implemented by some countries following the recent global 
economic recession. A first review of trend data in drug-
related public expenditure explores this issue.
Drug strategies and budgets
Of the 29 European countries with national drug 
strategies or action plans, seven report that their current 
drug policy document has either a comprehensive 
or a sectoral budget. In Cyprus, a yearly budget is 
annexed to the drug strategy 2009–12, and annual 
expenditure is also published. In Estonia, national drug 
strategies are budgeted and annual expenditure is 
estimated. In the Czech Republic, the 2010–12 action 
plan was accompanied for the first time by an indicative 
budget. In Greece, the 2011–12 action plan has an 
accompanying budget. A budget is also provided for the 
French national plan 2008–11 (extended into 2012), but 
its execution is not publicly assessed. Under the United 
Kingdom drug strategy, there is no central budget, but in 
Northern Ireland, Scotland and Wales, there are budgets 
associated to strategies and estimates of expenditure 
are published. In England, although there is no specific 
budget, expenditure accounts are regularly published. 
In some cases, dedicated budgets cover only part of 
the drug strategy: for example, in Romania, a budget is 
provided for the health and social care measures of the 
2009–12 drug action plan.
Three countries report that they no longer have budgets 
linked to their drug strategy. Ireland, Portugal and 
Slovakia had provided budgets and annual expenditure 
estimates for previous action plans, but not for the current 
plan. However, both Portugal and Slovakia have inter-
ministerial committees developing this area.
In eight countries, a budget which covers all or part of the 
national drug strategy or action plan is defined every year 
within the overall national budget. In Luxembourg, the 
multi-annual action plan is supported by an annual drug 
budget, and comprehensive expenditure estimates are 
also provided. In Croatia, the annual drug-related budget 
is closely linked to the action plan. In Bulgaria, Denmark, 
Hungary, Finland, Sweden and Norway, governments 
approve annual budgets to finance drug initiatives.
Eleven countries have not recently linked drug-related 
budgets to national policy documents. In these cases, the 
funding needed for the drug strategy or action plan comes 
directly from the agencies in charge of its implementation.
There is a wide variety of practices in Europe and only 
a few countries have adopted a clear and transparent 
approach to budgetary allocation and review in the drugs 
field. While this might be due to technical difficulties, 
it nevertheless contributes to the problems that exist in 
estimating drug-related public expenditure in Europe, and 
to developing the economic evaluation of drug policy.
Trends in drug-related public expenditure
A key current issue is the impact of the recent economic 
crisis and the ensuing austerity measures on drug policy 
Advising on drug policy
Governments seek advice on drug policy for various 
reasons: for example, when they are developing new drug 
strategies, considering legislative changes or evaluating 
earlier policy decisions.
Twenty-eight out of 30 countries report the existence of 
a structure with a formal drug policy advisory role: in 
some cases, the structure is established by law, in others 
it is non-statutory. Half of the countries have dedicated 
advisory bodies; in the others, existing structures — mostly 
national drug coordination bodies — have an advisory 
role. The membership of advisory structures ranges from 
eight to over 30 people, primarily policymakers, civil 
servants, researchers, drug workers and representatives of 
civil society. The chair may be a politician (Sweden), an 
academic (Belgium) or a senior civil servant (Estonia). Their 
tasks may include supporting the scheduling of substances 
under drug laws, undertaking and funding research and 
advising policymakers.
Examples of advisory structures in Europe include: the 
National Advisory Committee on Drugs in Ireland, 
with 16 members and chaired by an academic; the 
United Kingdom’s 24-member Advisory Council on 
the Misuse of Drugs both schedules drugs and advises 
government; the German Drugs and Addiction Council, 
comprising 27 members and chaired by the Federal 
Drugs Commissioner, supports the implementation and 
development of the national drug strategy and cooperation 
between the national and local levels; in the Czech 
Republic, scheduling and advisory work is conducted by 
five committees and several working groups linked to the 
Government Council for Drug Policy Coordination.
While advisory bodies appear to be a standard policy 
structure in Europe, they have different forms, functions 
and membership. Generally, they provide a forum for 
government and other sectors to communicate, coordinate 
and consider policy relevant information.
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(5) England accounts for 84 % of the United Kingdom’s population, and its drug-related budget is usually more than 80 % of the total. Labelled 
expenditure accounts for a small part of the United Kingdom’s total drug-related expenditure.
(6) For a summary of policy issues in European countries, see EMCDDA (2011d).
and drug-related budgets. This topic is explored with 
reference to recent estimates of drug-related public 
expenditure in European countries. Some caution 
is required, however, as the amount and quality of 
information available varies greatly between countries 
with studies covering different years, using a range of 
methodologies, and not always estimating the same 
proportion of budgets.
Some of the funds allocated by governments for 
expenditure on tasks related to drugs are identified as 
such in the budget (labelled). Often, however, the bulk of 
drug-related expenditure is not identified (unlabelled) and 
must be estimated by modelling approaches. The total 
budget is the sum of both labelled and unlabelled drug-
related expenditure.
In recent years, decreases in drug-related public 
expenditure have been identified in six countries. In the 
United Kingdom, a reduction of 5 % in labelled public 
expenditure in 2010/11 in England (5) compared with the 
previous year was not offset by small increases in labelled 
expenditure in Northern Ireland, Scotland and Wales. 
In 2010, labelled expenditure in Estonia fell by 3 % 
compared with 2009, but by 54 % compared with 2008; 
in Ireland, labelled expenditure fell by 3 % compared 
with the previous year. In Hungary, a mid-year revision of 
the 2010 budget saw the funding for labelled activities 
reduced by 25 %. In Croatia, available data point to 
a 10 % cut in labelled drug-related public expenditure 
in the 2010 budget compared with 2009. In the Czech 
Republic, despite better data coverage suggesting 
increasing expenditure in 2010, detailed analysis shows 
less funding available for treatment and harm reduction.
For another four countries, there are no signs of 
budgetary cuts in the most recent estimates of drug-
related expenditure. In Belgium, total drug-related public 
expenditure increased by 18.5 % between 2004 and 
2008 (before the recession). In Sweden, total drug-
related public expenditure in 2011 increased substantially 
compared with 2007. In Luxembourg, in 2010, there 
was an annual increase of 5.6 % in total drug-related 
expenditure. In Finland, in 2009, total drug-related public 
expenditure increased by 1.6 %.
Studies carried out up to now suggest the existence of 
considerable variation between countries in terms of the 
nature and severity of the impact of the economic crisis on 
their drug-related budgets and expenditure.
National laws addressing new psychoactive 
substances
In recent years, Europe has seen a diverse range of new 
psychoactive substances becoming widely available at 
an unprecedented pace. The speed with which these 
new substances are launched, combined with a lack of 
information on the risks associated with their use, challenges 
the established procedure of adding individual substances 
to the list of those controlled by drug laws. While the 
majority of European countries continue to do this, several 
have responded with innovative changes to their legislation 
or enforcement policies (6).
The most fundamental changes have involved the passing 
of new criminal laws penalising unauthorised distribution 
of psychoactive substances, as has occurred in Ireland, 
Austria and Romania. There are some similarities, but also 
key differences, between these three examples. Regarding 
the substance, all three countries define a psychoactive 
substance as one that stimulates or depresses the central 
nervous system and is associated with dependency, 
hallucinations or disturbances in motor function or 
behaviour. In Ireland, these disturbances should be 
‘significant’; in Austria, substances can only be listed if they 
are likely to be abused by certain sections of society with 
a possible threat to consumer health. In Romanian law, 
there is no longer a specified requirement for harmfulness, 
unlike in a government order issued earlier in the same year. 
In Austria, the Minister for Health must name the substances 
or groups of substances in a regulation, whereas in Ireland 
and Romania, naming of the substances is not required — 
any substance that possesses the properties defined in the 
legislation is implicitly covered. Supply is a crime in Austria 
if the supplier has intention to benefit, and intends that the 
product will be used for its psychoactive effects; in Ireland, 
only knowledge of likely human consumption is necessary; 
in Romania, neither is required. Maximum penalties for 
supply are two years’ imprisonment in Austria, five in Ireland 
and eight in Romania, rising significantly in Austria and 
Romania if supply causes serious injury or death.
While maintaining their existing drug laws, a number of 
countries have introduced refinements in order to strengthen 
or accelerate the procedures used to list new substances 
as drugs. Scientific risk assessment panels were formally 
created in Hungary (2010) and Finland (2011) to provide 
the evidence base for decisions to control new substances. 
In 2011, the United Kingdom enacted a new procedure 
(temporary class drug orders) that would allow named 
substances to be quickly controlled under drug laws for up to 
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one year, during which time the need for permanent control 
could be investigated. A similar proposal for a temporary 
control list was passed by the Slovak parliament, but was 
suspended before the 2012 election. Another refinement 
implemented by some countries has been to extend the 
coverage of existing drug laws by listing substances as 
defined groups, rather than individually as had been done 
previously. In 2009 and 2011, synthetic cannabinoids were 
defined as groups of substances controlled by Luxembourg 
and Italy, respectively; Italy later added a group definition 
of cathinones. In 2011, Cyprus added group definitions of 
synthetic cannabinoids, cathinones and phenethylamines to 
its drug law, while Germany and France have been studying 
the feasibility of this approach.
Legislative change can be a lengthy process, and some 
countries use other existing laws to speed up their response 
to new substances. Medicines laws have been used to control 
non-therapeutic substances in at least eight countries. And 
different types of consumer safety laws have been enforced 
in Italy, Poland, Portugal and the United Kingdom, targeting 
psychoactive products in general (resulting in shop closures), 
or directed towards individual substances. For example, 
mephedrone was being sold as ‘plant food’ or ‘bath salts’ 
despite having no such uses. These may be rapid interventions 
before drug law control can be enacted, but they have also 
allowed countries time to design innovative responses.
Another option to control potentially harmful substances 
is to adapt existing laws. In 2010, Poland excluded the 
requirement for harmfulness and any application of general 
product safety laws from the definition of a ‘substitute 
drug’ (a substance to be used instead of a drug or for the 
same purposes). In parallel, the health protection law was 
updated to be enforceable on suspicion that a substitute 
drug poses a threat to human health. In Hungary, in 2012, 
a temporary schedule was added to the Medicines Law 
to list non-therapeutic drugs that affect the central nervous 
system, have the ability to change mental state, behaviour 
or perception, and therefore can pose as serious a threat to 
public health as the substances listed in the drug schedules. 
Under the amended drugs section of the Criminal Code, 
offering or distribution of such substances is punishable 
by up to three years in prison. In Sweden, in 2011, law 
enforcement bodies were given new powers to act on 
the grounds of protecting public safety and to seize and 
destroy specified substances assumed to be used for 
intoxication and likely to cause injury or death. Under 
the new laws in Austria and the United Kingdom, under 
certain circumstances, police may confiscate any amount of 
a substance, even if no offence has been committed.
There are an increasing number of responses targeting the 
advertising and open sale of new psychoactive substances. 
Advertising the psychoactive effects of a substance for 
sale is punishable by up to five years in prison in Ireland 
and one to three years in Romania. In the Czech Republic, 
promotion of addiction to a psychoactive substance can 
be punished by up to eight years in prison. In Romania, 
advertising that the products are sold lawfully is punishable 
by 3–10 years in prison. In Poland, supply of ‘substitute 
drugs’ can be punished with a large fine, and advertising 
them may lead to a year in prison. In Romania, there will 
be a heavy fine if an offending website is not taken down 
within 12 hours of a Ministry request.
The rapid emergence of new and unknown drugs has 
prompted many different responses, which continue 
to evolve: since 2009, at least seven countries have 
implemented one innovative response and later initiated 
another. The size of the criminal penalties, and the degree 
of psychoactivity or potential harm that would trigger them, 
vary widely across Europe. Nevertheless, two trends are 
visible: the use of the threat of prison to deter suppliers; 
and the exclusion of criminal sanctions for those possessing 
a substance for personal use.
Drug-related research
To complement and support the priorities set out in the 
EU drug strategy, the European Commission funds a range 
of drug-related research and studies. Since 2007, it 
has invested over EUR 18 million under FP7, the seventh 
framework programme for research and innovation.
Two major European studies have focused on drug and 
alcohol dependence in the context of brain disorders. 
The recently concluded study ‘Psychosocial factors relevant 
to brain disorders in Europe’ (PARADISE) showed that 
substance abuse disorder is associated with a heavy 
burden and impact on daily life. The most common 
difficulties were found to be in cognitive functions, 
emotional functions, self-care, relationships with others, 
employment and economic life. In 2011, another major 
European project reported that disorders of the brain, as 
measured by disability-adjusted life years, are the largest 
contributor to the European Union’s total disease burden, 
accounting for 26.6 % of the total (Wittchen et al., 2011). 
This study ranked drug and alcohol dependence among 
the most common brain disorders and only surpassed 
by anxiety disorders, insomnia, major depression and 
somatoform disorders.
The ‘Access to opioid medication in Europe’ (ATOME) 
project investigates the reasons why opioid medicines for 
moderate to severe pain and for the treatment of opioid 
dependence are often not available where needed and not 
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(7) More information on research into Europe’s drug problem is available on the EMCDDA research web page.
used adequately. The project will run until the end of 2014, 
and its first results include the publication of new WHO 
(2011) policy guidelines (available in 14 languages) and 
a review of potential barriers to the access and availability 
of opioids. The project will deliver country reports with 
concrete recommendations for legislative changes.
The ‘Addictions and lifestyles in contemporary Europe — 
reframing addictions project’ (ALICE RAP) will run 
until 2016, receiving input from over 100 researchers and 
70 research institutions in more than 30 countries. Through 
seven major work packages, the project aims to strengthen 
the scientific evidence that can inform the public and 
political dialogue about the challenges to European 
society posed by drugs and other addictions, and to 
stimulate debate on approaches to addictions.
The ‘Grasping the links in the chain: understanding 
the unintended consequences of international 
counter-narcotics measures for the EU (LINKSCH)’ project 
started in February 2012, and brings together seven 
partners from four countries, with a view to contributing 
to a more comprehensive counternarcotics policy aimed 
at minimising unintended consequences. Finally, the 
FP7-funded European research area network (ERA-NET) on 
illicit drugs will be underway by 2013.
The European Commission’s ‘Drug prevention and 
information’ programme (DPIP) has also funded a number 
of projects, including a study ‘Further analysis of the EU 
illicit drugs market and responses to it’, which analysed 
the characteristics and operations of the European Union’s 
markets for cannabis, cocaine, amphetamines and ecstasy; 
and the project ‘New methodological tools for policy 
and programme evaluation’ (DPE), which is developing 
indicators to monitor illicit drug supply and demand and to 
evaluate policies and interventions (7).
DRUID: driving under the influence of drugs, 
alcohol and medicines
The DRUID project, which finished in 2011, aimed to provide 
new insights into the impact of alcohol, illicit drugs and 
medicines on road safety, and produce recommendations 
for road safety policy. Harmonised data collection 
protocols were used to collect samples of body fluids 
from approximately 50 000 randomly selected drivers in 
13 European countries, and from 4 500 drivers who were 
seriously injured or killed in an accident. The study found that 
3.5 % of the drivers tested had alcohol in their system and 
1.5 % of drivers were over the common legal blood-alcohol 
limit of 0.5 grams per litre, significantly increasing their risk 
of dying in a traffic accident compared to drivers who had 
not consumed alcohol.
Traces of illicit drugs most commonly found among the drivers 
randomly tested were tetrahydrocannabinol (THC) (1.3 %) and 
cocaine (0.4 %). The presence of THC was associated with 
a slightly increased risk of the driver being injured or being 
responsible for a fatal accident, while the presence of cocaine 
and amphetamine significantly increased the risk to the driver. 
Psychoactive medicines, mainly benzodiazepines, were found 
in 1.4 % of drivers and could significantly increase the risk of 
dying in a traffic accident. All risks greatly increased when 
substances were combined with alcohol or other drugs, as is 
often the case in Europe.
Looking at responses, the project found that most roadside 
drug-testing devices and techniques are not sufficiently 
accurate. Effective interventions include the withdrawal 
of driving licences for up to 12 months and rehabilitation 
programmes. However, their effectiveness depends on 
drawing a distinction between different types of offenders. 
Nevertheless, one of the main conclusions of DRUID was that 
efforts to stop drug driving should not divert resources from 
efforts to stop drink-driving.
Developments in addiction research (1)
Levels of addiction research have almost tripled in 
EU Member States in the past year, although US scientists 
continue to produce one third of the new publications. 
The number of papers on alcohol, nicotine or 
psychostimulants increased in 2011, while strong increases 
were also seen in genetic and imaging studies in the 
addiction field. However, less than 7 % of the studies 
are on clinical trials on new therapeutic strategies on 
addiction, a field in need of development.
Among the most relevant clinical trials published in this 
area were those exploring the use of substitution therapy 
or anti-craving drugs in methamphetamine addiction, the 
use of buprenorphine/naloxone in opioid addiction, or 
new therapies for opioid withdrawal (such as tetrodotoxin). 
Other studies focused on the behavioural, physiological 
and molecular basis of associative, or conditioned, 
learning in drug abuse paradigms, exploring new potential 
targets for therapeutic development.
Much addiction neuroscience research focuses on the 
brain’s reward system and dopamine; however, new data 
indicate other possibilities. For example, neuroimaging 
studies in animals and humans have shown that the 
prefrontal cortex has a major influence on drug-taking 
behaviour. Interactions between the dorsal and ventral 
prefrontal cortex regions change in the course of the 
addiction process, suggesting the interventions of 
neurotransmitters such as noradrenaline, serotonin, 
glutamate and cannabinoids.
(1) Prepared by EMCDDA Scientific Committee members Fernando 
Rodríguez de Fonseca and Jean-Pol Tassin.
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Introduction
This chapter presents an overview of the responses to drug 
problems in Europe, highlighting, where possible, trends 
and developments. Prevention measures are reviewed first, 
followed by interventions in the areas of treatment, social 
reintegration and harm reduction. All these measures are 
part of a comprehensive drug demand reduction system 
and are increasingly coordinated and integrated. The final 
section focuses on priority setting in drug law enforcement 
and drug law offences.
Prevention
Drug prevention can be divided into different levels 
or strategies, which range from targeting society as 
a whole (environmental prevention) to focusing on at-risk 
individuals (indicated prevention). The main challenges 
for prevention policies are to match these different 
strategies to the degree of vulnerability of the target 
groups (Derzon, 2007), and to ensure that interventions 
are evidence-based and sufficient in coverage. Most 
prevention strategies focus on substance use in general, 
some also consider associated problems, such as violence 
and sexual risk behaviour; only a limited number of 
programmes focus on a specific substance, for example 
alcohol, tobacco or cannabis.
Environmental strategies
Environmental prevention strategies are designed to 
change the cultural, social, physical and economic 
environments in which people make their choices 
about drug use. These strategies typically include 
measures such as alcohol pricing, and bans on tobacco 
advertising and smoking where there is good evidence 
of effectiveness. Other environmental strategies focus on 
developing protective school environments. Among the 
examples reported by European countries are: promotion 
of a positive and supportive learning climate (Poland, 
Finland); provision of education in citizenship norms and 
values (France); and making schools safer through the 
presence of police in the neighbourhood (Portugal).
It has been argued that a range of social problems, 
including substance use, teenage pregnancy and 
violence, are more prevalent in countries with high 
levels of social and health inequality (Wilkinson and 
Pickett, 2010). Many Scandinavian countries, such as 
Finland, invest heavily in broader environmental policies 
that are geared towards increasing social inclusion at 
family, school, community and society level and which 
contribute to, and help maintain, lower levels of drug 
use. Prevention programmes and interventions targeting 
specific problems or drugs are less used in these 
countries.
Chapter 2
Responding to drug problems in Europe — an overview
Prevention: the environmental context
Recent findings in social neuroscience (Steinberg, 2008) 
support the evidence from social studies that environmental 
context heavily influences adolescents’ involvement in risk 
behaviour.
Around the time of puberty, risk-taking increases as a result 
of changes in the brain’s socio-emotional system, leading 
to increased reward-seeking and less impulse control in 
the presence of peers. Such increased sensitivity to others’ 
opinions and perceived norms can help explain why much 
adolescent risk-taking behaviour, such as uncontrolled drug 
and alcohol use and reckless driving, occurs almost only 
in social contexts. At decisive moments, young people in 
groups may not make ‘informed choices’ or assess risks 
rationally.
The research indicates that, rather than concentrating 
on information provision, prevention interventions for 
young people should target norms and perceptions of 
normality. It underlines the importance, from a prevention 
perspective, of focusing on environmental contexts, such as 
school, family and recreational settings. The research also 
highlights the importance of parental control, and provides 
support for measures aimed at limiting the opportunities 
for harmful consequences in those environments where 
young people interact in groups, especially leisure and 
nightlife settings. Above all, this evidence supports the 
environmental prevention approach, which relies more on 
changing contexts than on persuasion alone.
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(8) Differing from the recent use of ‘early intervention’ as ‘early in career’ of substance use.
(9) Available on the Exchange on Drug Demand Reduction Action (EDDRA) website.
Universal prevention
Universal prevention addresses entire populations, 
predominantly in school and community settings. It aims 
to reduce substance-related risk behaviour by providing 
young people with the necessary competences to 
avoid or delay initiation into substance use. A recent 
evaluation of the ‘Unplugged’ prevention programme 
in the Czech Republic found that participating students 
reported significantly reduced rates of smoking, as well 
as less frequent smoking, drunkenness, cannabis use, 
and use of any drug (Gabrhelik et al., 2012). However, 
there have been recent reports of reductions in the 
provision of universal prevention in Greece and Spain, 
and in prevention staffing levels in Latvia, which supports 
earlier suggestions that prevention is an area affected 
by budgetary cuts in this period of economic downturn 
(EMCDDA, 2011a).
The EU prevention standards manual (EMCDDA, 2011b) 
is designed to assist Member States to ensure the quality 
of their prevention programmes, and improvements have 
been reported by a number of countries. Recently, Ireland 
has assessed the implementation of its national prevention 
programme in post-primary schools. The Czech Republic 
has made improvements to its prevention grants scheme, 
introducing Europe’s first certification system, under which 
funding is available only to certified programmes. The 
certification of professionals is designed to improve the 
quality of delivery of prevention programmes, and ensure 
that public funds are spent efficiently.
Selective prevention
Selective prevention intervenes in specific groups, 
families or communities who, due to their reduced social 
ties and resources, may be more likely to develop drug 
use or progress into dependency. Denmark, Germany, 
Spain, Austria and Portugal have implemented targeted 
prevention interventions for pupils in vocational schools, 
a group of young people identified as being at elevated 
risk of developing drug use problems. Ireland has taken 
a broader approach in terms of prevention work with 
at-risk youth, by working to improve literacy and numeracy 
among disadvantaged students. Community-level 
interventions targeting high-risk groups of young people, 
such as reported by Italy and municipalities in the north of 
Europe, combine individual and environmental strategies 
through outreach, youth work, and formal cooperation 
between local authorities and non-governmental 
organisations. Such approaches aim to target high-risk 
youth without recruiting them into specific programmes.
Early intervention approaches have frequently been 
reported in Europe, but the goal and content of such 
programmes has varied between countries. Recent 
prevention policy in the United Kingdom has taken ‘early 
intervention’ back to its original meaning: to provide 
social, emotional and learning support to children living 
in disadvantaged circumstances, during the early years 
of life (8). The aim is to delay or prevent the onset of 
problems (including substance use), rather than wait and 
respond when problems appear (Allen, 2011). Parenting 
programmes can also play an important role in early 
intervention approaches; however, proactive parental 
work and training remain rare in the area of selective 
prevention.
Indicated prevention
Indicated prevention aims to identify individuals with 
behavioural or psychological problems that may be 
predictive for developing substance use problems later 
in life, and to target them individually with special 
interventions. In most European countries, indicated 
prevention continues to be based on the provision of 
counselling to young substance users. One exception is 
Preventure (9), a Canadian programme adapted to the 
United Kingdom’s situation, which selectively targets 
young sensation-seeking drinkers. This is one of the most 
positively evaluated programmes currently available, and 
is now also being implemented in the Czech Republic and 
the Netherlands.
Treatment
Psychosocial interventions, opioid substitution and 
detoxification are the main modalities used for the 
treatment of drug problems in Europe. The relative 
importance of the different treatment modalities in each 
country is influenced by several factors, including the 
organisation of the national healthcare system. Drug 
treatment services may be provided in a variety of 
settings: specialist treatment units, including outpatient 
and inpatient centres, mental health clinics and hospitals, 
units in prison, low-threshold agencies and by office-based 
general practitioners.
There is no data set allowing a description of the full 
population of drug users currently undergoing drug 
treatment in Europe. However, information on an important 
subgroup of this population is gathered by the EMCDDA’s 
treatment demand indicator, which collects data on those 
entering specialist drug treatment services during the 
calendar year, enabling insights into their characteristics 
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(10) The treatment demand indicator received data for specialised drug treatment centres from 29 countries. Most countries provided data for more than 
60 % of their units, though for some countries the proportion of units covered is unknown (see Table TDI-7 in the 2012 statistical bulletin).
(11) See the box ‘Estimating the number of drug users in treatment in Europe’, and Table HSR-10 in the 2012 statistical bulletin.
(12) More detailed information on specific types of treatment for the different substances is available in the respective chapters.
(13) See Table TDI-19 in the 2012 statistical bulletin. 
(14) See Table TDI-16 in the 2012 statistical bulletin.
(15) For information on treatment clients according to primary substance, see the respective chapters. 
(16) See Table TDI-21 in the 2012 statistical bulletin.
(17) See Tables TDI-9 (part iv) and TDI-103 in the 2012 statistical bulletin.
(18) For information on treatment according to primary substance, see the respective chapters.
and drug-use profiles (10). In 2010, the indicator registered 
about 472 000 treatment entrants, 38 % (178 000) of 
whom were reported to have entered drug treatment for 
the first time in their life. Heroin, cannabis and cocaine 
have been the main primary drugs reported by treatment 
entrants during the last five years, with the largest increase 
observed for cannabis (see Figure 2).
Based on a range of different sources, including the 
treatment demand indicator and national opioid 
substitution registers, it can be estimated that at least 
1.1 million people received treatment for illicit drug use in 
the European Union, Croatia, Turkey and Norway during 
2010 (11). While more than half of these clients received 
opioid substitution treatment, a substantial number 
received other forms of treatment for problems related to 
opioids, stimulants, cannabis and other illicit drugs (12). 
This estimate of drug treatment in Europe, though in 
need of refinement, does suggest a considerable level of 
provision, at least for opioid users. This is the consequence 
of a major expansion during the last two decades 
of specialised outpatient services, with a significant 
involvement of primary healthcare, general mental 
health services, and outreach and low-threshold service 
providers.
Outpatient treatment
Information is available on about 400 000 drug users 
entering specialist outpatient treatment during 2010. 
Almost half of the treatment entrants (48 %) report opioids, 
mainly heroin, as their primary drug, while 27 % report 
cannabis, 17 % cocaine and 4 % stimulants other than 
cocaine (13). The most common route into treatment is self-
referral (35 %), followed by referral from health or social 
services (29 %) and the criminal justice system (20 %). The 
remaining clients are referred through family, friends and 
informal networks (14).
Drug users entering outpatient treatment are on average 
31 years old. Among this group, males outnumber 
females by almost four to one, which in part reflects the 
predominance of males among the more problematic drug 
users. Male to female ratios are high for all substances, 
although varying with drug and country (15). Gender ratios 
are generally higher in countries in the south of Europe 
and among cocaine and cannabis clients; lower ratios 
are reported in the north of Europe and among stimulant 
and opioid clients (16). Among clients entering outpatient 
treatment, primary cannabis users are almost 10 years 
younger (25) than primary users of cocaine (33) and 
opioids (34). Overall, the youngest clients (26–27) are 
reported by Hungary, Poland, Romania and Slovakia, and 
the oldest by Italy, Portugal and Norway (34–35) (17).
The two main modalities of outpatient treatment in Europe 
are psychosocial interventions and opioid substitution 
treatment. Psychosocial interventions include counselling, 
motivational interviewing, cognitive behavioural therapy, 
case management, group and family therapy, and relapse 
prevention. Psychosocial interventions offer support to 
users as they attempt to manage and overcome their 
drug problems, and they are the main form of treatment 
for users of stimulant drugs, such as cocaine and 
amphetamines (18). They are also provided for opioid 
users, often in combination with substitution treatment.
In nearly all countries, responsibility for provision of 
outpatient psychosocial treatment is shared by public 
institutions and non-governmental organisations. While 
Figure 2: Trends in estimated number of clients entering treatment 
by primary drug
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(19) Public institutions and non-governmental organisations are equally involved in terms of client share in the provision of outpatient (and inpatient) 
psychosocial treatment in Bulgaria. 
(20) See the 2012 ‘Selected issue’ on drug users in prison.
(21) See Tables HSR-1 and HSR-2 in the 2012 statistical bulletin.
(22) See Table HSR-3 in the 2012 statistical bulletin. For more information on availability, accessibility and trends for substitution treatment, see 
Chapter 6.
(23) This figure should be interpreted with caution as it does not include all users who enter inpatient care. 
(24) See Tables TDI-7, TDI-10, TDI-19, TDI-21 and TDI-24 in the 2012 statistical bulletin.
public institutions are the main provider in 20 countries, 
non-governmental organisations are the main provider 
in eight (19) and the second most important provider in 
terms of client share in a further 11 countries. Commercial 
providers generally play a lesser role in the provision of 
this treatment modality, but are the second most important 
provider in eight countries (Belgium, Bulgaria, Denmark, 
Cyprus, Latvia, Lithuania, Slovakia, Turkey) with a client 
share of between 5 % and 35 %.
In a 2010 survey, national experts reported outpatient 
psychosocial treatment in Europe to be available to nearly 
all who seek it in 14 countries, and to the majority of those 
who seek it in 11 countries. In three countries (Bulgaria, 
Estonia, Romania) however, outpatient psychosocial 
treatment is estimated to be available to fewer than half 
of those who actively seek it. These ratings may hide 
considerable variation within countries and differences in 
the availability of specialised treatment programmes for 
specific target groups, such as older drug users or ethnic 
minorities. Some countries report difficulties in providing 
specialised services at a time of economic recession and 
budgetary cuts.
Regarding access to outpatient psychosocial treatment, 
experts from 12 of the 29 reporting countries reported 
no waiting time, while in 11 countries, average waiting 
times are estimated to be less than a month. In Norway, 
the average waiting time is estimated to be about eight 
weeks, while experts from four countries could not provide 
an estimate. Denmark requires that treatment takes place 
within 14 days by law.
Substitution treatment is the predominant treatment option 
for opioid users in Europe. It is generally provided in 
specialist outpatient settings, though in some countries it 
is also available in inpatient settings, and is increasingly 
provided in prisons (20). In addition, office-based general 
practitioners, often in shared-care arrangements with 
specialist centres, increasingly play a role. Opioid 
substitution is available in all EU Member States and in 
Croatia, Turkey and Norway (21). Overall, it is estimated 
that there were about 710 000 substitution treatments 
in Europe in 2010. Compared with 2009, the number 
of clients in substitution treatment increased in most 
countries, though Spain and Slovakia report small 
decreases (22).
Inpatient treatment
Data are available for about 50 000 drug users who have 
entered drug treatment in inpatient settings in Europe 
during 2010 (23). Opioids were reported as the primary 
drug by half of these clients (48 %), followed by cannabis 
(16 %), amphetamines and other non-cocaine stimulants 
(13 %) and cocaine (6 %). Inpatient clients are mainly 
young men, with a mean age of 31 years and about three 
males to every female (24).
Inpatient or residential treatment requires clients to stay 
overnight for a duration of several weeks to several 
months. In many cases, these programmes aim to enable 
clients to abstain from drug use, and do not allow 
substitution treatment. Drug detoxification, a short-term, 
medically supervised intervention aimed at resolving the 
withdrawal symptoms associated with cessation of chronic 
drug use, is sometimes a prerequisite for starting long-
term, abstinence-based inpatient treatment. Detoxification 
is usually provided as an inpatient intervention in 
hospitals, specialised treatment centres or residential 
facilities with medical or psychiatric wards.
In inpatient settings, clients receive accommodation and 
individually structured psychosocial treatments, and 
take part in activities geared towards rehabilitating and 
Estimating the number of drug users in 
treatment in Europe
Since 2008, the EMCDDA has collected data annually 
on the total number of clients who have received drug 
treatment in Europe. In the most recent data collection, 
14 countries provided reliable minimum estimates of 
the total number of people in contact with treatment 
services in 2010, which resulted in a total estimate of 
900 000 clients. For the remaining 16 countries, a data 
subset was used of either the number of treatment 
demands or clients in opioid substitution treatment in 
that year, whichever total was highest. Thus, data on 
those receiving opioid substitution treatment were used 
for seven countries (171 000 clients) and data from the 
treatment demand indicator were used for nine countries 
(48 000 clients). Taken together, these data indicate that at 
least 1.1 million individuals were in contact with treatment 
services in Europe in 2010. The EMCDDA is working 
with Member States on the quality assurance of national 
estimates of the total treatment population, which will 
further improve the European-level estimate.
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(25) See the box ‘Therapeutic communities for the rehabilitation of drug users in Europe’.
reintegrating them into society. A therapeutic community 
approach is often used in this context (25). Inpatient drug 
treatment is also provided by psychiatric hospitals, notably 
for clients with co-morbid psychiatric disorders.
Public institutions are the main providers of detoxification 
in 22 countries, while the private sector is the main 
provider in Cyprus and Luxembourg and the second 
largest in an additional 12 countries. Non-governmental 
organisations are the largest providers in the Netherlands, 
and the second largest in another eight countries. 
National experts estimate that detoxification is available 
to almost all who seek it in 12 countries and is available to 
the majority of those seeking it in a further nine countries. 
In seven countries (Estonia, Ireland, Greece, Hungary, 
Latvia, Romania, Norway), detoxification is estimated to 
be available to less than half of those who actively seek 
it. In 15 countries, the estimated average waiting time for 
detoxification is less than two weeks. An average waiting 
time of two weeks to one month is estimated in eight 
countries, while in Austria and Slovenia it is estimated at 
more than one month. Experts from three countries did not 
provide an estimate. National estimates of waiting times 
for any of the modalities may, however, hide important 
variations within countries.
Public institutions are the main providers of inpatient 
treatment in 14 countries, and non-governmental 
organisations are the main providers in 11 countries. 
Private institutions are the main providers in Denmark 
and the second most important providers in six countries. 
National experts estimate that inpatient psychosocial 
treatment is available to almost all who seek it in 
10 countries, and to the majority of those seeking it 
in another 11 countries. However, in seven countries 
(Bulgaria, Denmark, Estonia, Cyprus, Hungary, Romania, 
Finland), this treatment modality was considered to be 
available to less than half of those who actively seek it.
Experts from Greece, Poland, Portugal, Slovakia and 
Croatia estimated that there is no waiting time for 
inpatient treatment. In 13 countries, the average waiting 
time was estimated to be less than one month, and more 
than one month in four countries.
Social reintegration
The level of social exclusion among problem drug users is 
generally high, especially among opioid users. Data on 
the social conditions of those entering drug treatment in 
2010 show that over half (56 %) were unemployed and, in 
the last five years, this percentage has increased in 15 of 
the 24 countries reporting trend data. Low educational 
attainment is common among clients entering treatment, 
with 38 % having completed only primary education, 
and 2 % not even achieving this level. And many are 
homeless, with 10 % of drug treatment clients reporting no 
stable accommodation.
Improving a person’s capability for gaining and 
maintaining employment (employability) is a key element 
in the social reintegration of drug users. Interventions in 
this area recognise that drug use and problems related 
to it may jeopardise not only entry and re-entry into the 
labour market, but also the ability to retain employment. 
Vocational training in Europe encompasses a wide range 
of programmes that aim to improve the skills and qualities 
needed to find and secure employment including interview 
and presentation skills, time management, computer literacy, 
self-efficacy and commitment to work. In addition, schemes 
to develop particular occupational competencies and 
qualifications may be offered by drug treatment services 
and by specialist providers, such as national training 
authorities and employment services (EMCDDA, 2011a).
One promising approach involves the integration of 
support, such as vocational counselling, skills training and 
job placement, within drug treatment programmes. Among 
the models that have been studied is the provision of skills 
training to unemployed drug users receiving psychosocial 
treatment in outpatient settings. The effectiveness has 
also been assessed of individual vocational counselling, 
job-seeking support, supported employment, case 
management and other interventions for substitution 
treatment clients. A number of studies have produced 
encouraging results with regard to outcome measures 
including employment rate, income, and welfare utilisation 
(EMCDDA, 2012b). However, interventions that produce 
Therapeutic communities for the rehabilitation 
of drug users in Europe
The therapeutic community has historically been identified 
as a drug-free environment in which people with drug 
(and other) problems live together in an organised 
and structured way in order to promote social and 
psychological change. Clients are viewed as active 
participants in their own and each other’s treatment, 
and responsibility for the daily running of the community 
is shared by the clients and staff. In recent years, this 
approach has been increasingly adapted to serve the 
needs of opioid substitution clients, adolescents, homeless 
men and women, mothers and children, those infected with 
HIV or with mental health problems.
A 2013 publication in the EMCDDA Insights series will 
review the role of therapeutic communities in the treatment 
of drug users in Europe.
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(27) COM(2007) 199 final.
(28) See the box ‘HIV outbreaks in Greece and Romania’ (Chapter 7).
consistently positive outcomes have not been identified, 
and differences in approach, study populations, outcomes 
assessed, and lack of replication prevent any firm 
conclusions being made about the overall effectiveness 
of these measures (Foley et al., 2010). In addition, the 
available evidence focuses almost exclusively on social 
reintegration interventions for opioid users, while the 
needs of treatment clients who use other drugs are yet to 
be systematically addressed.
Work and other activities that foster a sense of inclusion 
and provide opportunities for social contact can help to 
prevent lapse and relapse among drug users (McIntosh et 
al., 2008). In some European countries, social enterprise 
organisations are experimenting with so-called recovery 
work cooperatives as a transition from treatment to 
mainstream employment (Belgium, Czech Republic, Spain, 
Latvia, Finland). These recovery work cooperatives are 
small businesses within the community that support people 
entering or returning to mainstream employment and, at 
the same time, have a focus on support, community service 
and participation in community life. Other specialist 
interventions exist that, when integrated into drug treatment 
and rehabilitation programmes, can improve the likelihood 
of positive outcomes. These include employment support 
for hard-to-place groups such as drug-using offenders, or 
drug users with mental health problems (EMCDDA, 2012b). 
Nevertheless, while programmes may successfully teach 
employability skills, drug users still have to compete on 
the labour market with other applicants at a time of high 
unemployment in many countries.
Harm reduction
Since the emergence of HIV among drug users more 
than 25 years ago, Europe has seen a growth and 
strengthening of harm-reduction responses to drug use, 
and their increasing integration with a range of other 
health, treatment and social care services. Harm reduction 
now addresses the broader health and social needs of 
problem drug users, especially those who are socially 
excluded. Core harm-reduction interventions include 
opioid substitution treatment and needle and syringe 
programmes, which target overdose deaths and the 
spread of infectious diseases. Additional approaches 
include outreach work, health promotion and education, 
and the provision of injecting equipment other than 
needles and syringes. Harm reduction covers a wide 
range of behaviours and harms, including those related to 
alcohol and recreational drug use (EMCDDA, 2010b).
In 2003, the Council of the European Union recommended 
a number of policies and interventions to the EU Member 
States to tackle health-related harm associated with 
drug dependence (26). In a follow-up report in 2007, the 
Commission of the European Communities confirmed 
that the prevention and reduction of drug-related harm is 
a public health objective in all countries (27). National drug 
policies have been increasingly covering the harm-reduction 
objectives defined in the EU drugs strategy, and there is 
now broad agreement among countries on the importance 
of reducing the spread of infectious diseases and overdose-
related morbidity and mortality and other harms.
During the past two decades, harm-reduction policies 
have promoted the adoption of evidence-based 
approaches and helped to remove barriers to service 
access. One result has been a significant increase in 
the number of drug users that are in contact with health 
services and undergoing treatment in Europe. Harm-
reduction interventions for drug users now exist in all 
EU Member States, and while some are just starting to 
develop services, most can report high levels of provision 
and coverage.
Although harm-reduction measures have contributed to 
the control of HIV among injecting drug users in Europe, 
with a substantial decline in reports of new infections, 
HIV continues to be a major public health concern, and 
new outbreaks have been reported (28). Together with 
the European Centre for Disease Prevention and Control 
‘Insights’ on improving labour market 
participation of drug users in treatment
The new EMCDDA Insights publication reviews recent 
developments concerning the social reintegration of drug 
users and evidence for the effectiveness of interventions 
that aim to increase employability. This publication is 
designed to assist policymakers and practitioners in the 
drugs field in developing effective strategies to promote the 
social reintegration of drug users.
‘Selected issue’ on drug users with children
An EMCDDA Selected issue published this year focuses on 
drug users with children. Among the topics explored are 
treatment options for pregnant drug users, reducing the 
barriers to accessing treatment for drug-using parents with 
children, and prevention programmes targeted at drug-
using parents.
These publications are available in print and on the 
EMCDDA website in English only.
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(ECDC), the EMCDDA issued guidance for policymakers 
in the fields of drugs and infectious diseases, presenting 
a synthesis of current evidence on the prevention and 
control of infectious diseases among injecting drug users 
(ECDC and EMCDDA, 2011). This joint guidance aims to 
improve Europe’s chances of preventing most, if not all, 
injecting-related HIV infections.
Quality standards
The European Commission’s EQUS study aimed to develop 
a European consensus on minimum quality standards in 
the field of drug demand reduction. The 2012 final report 
suggested 33 minimum standards for drug prevention, 
22 for drug treatment or rehabilitation and 16 for harm 
reduction in Europe (29). These minimum standards operate 
at three different levels (intervention, service and system) 
appropriate to the different needs of practitioners, service 
managers and policy planners.
The EQUS study also included a review, involving experts 
from 24 European countries, of existing quality standards 
already implemented at the national level. With regard to 
drug treatment processes, the standards most frequently 
reported as already implemented were in the areas of 
client data confidentiality and assessment of clients’ drug 
use history, whereas the standards concerned with routine 
cooperation with other services, and those focusing on 
continuous staff training, were less often implemented. In 
the area of treatment outcomes, the two types of standard 
most frequently reported as implemented were those with 
goals linked to health improvement and reduced substance 
use. Among the standards less likely to be applied were 
those focusing on external evaluation and monitoring 
client discharge; problems related to the implementation of 
these standards were reported.
The study identifies a broad level of consensus around 
a set of minimum quality standards in the European 
drug demand reduction field, and may provide a useful 
baseline for monitoring future developments in Europe. The 
full list of EQUS study standards and results can be found 
on the Best practice portal.
Drug law enforcement and offences
Drug law enforcement is an important component of 
national and EU drug policies. It includes a wide range 
of interventions that are mainly implemented by police 
and similar institutions (e.g. customs). An important issue 
for law enforcement agencies, the setting of strategic and 
operational priorities, is briefly reviewed here. A summary 
of drug law offences concludes the section.
Strategic and operational priority setting
Most drug offences are consensual crimes, and are subject 
to an individual or institutional assessment as to whether 
an investigation is warranted, its depth, and how long it 
will continue. It is not possible for a police unit to work 
on all detectable drug law offences and a degree of 
discretion is necessary (Dvorsek, 2006). The priority-setting 
process is informed by both law enforcement data and by 
the ‘investigative experience’ or a drug law enforcement 
officer’s knowledge. However, while the priorities of drug 
law enforcement units are not always transparent, they 
are not arbitrary, being generally constrained by a range 
of legal and organisational obligations. On occasion, 
a unit may be tasked with investigating a particular type 
of crime, such as intermediary or wholesale drug cases, 
or given an official mandate to focus on one area such as 
criminal asset recovery. At other times, a particular drug 
may be prioritised for reasons of harm or public nuisance, 
or even because of intense media coverage (Kirby et al., 
2010). Priority setting may also be influenced by the need 
for strong performance figures (Stock and Kreuzer, 1998). 
High levels of investigated cases can serve to emphasise 
the importance and urgency of the drug problem 
compared to other security threats and, in turn, justify the 
need for specific law enforcement activities in this field. In 
all cases, the availability of human and financial resources 
will facilitate certain options while limiting others.
While data are used to inform the setting of strategic and 
operational priorities, the priorities themselves will also 
influence the data that will be collected and made public 
(Stock and Kreuzer, 1998). Drug seizures, for example, 
may influence the priority-setting process and also be one 
of the outcomes of the process. The judicial process may 
use information on seizure levels as an indicator of the 
seriousness of the offence being prosecuted. In addition, 
‘Selected issue’ on drugs and prison
Drug users represent a substantial part of the prison 
population and they are disproportionately affected by 
health and social problems related to drug use. In Europe, 
assistance to drug users inside prison is available, with 
different types of interventions, treatment and services.
An EMCDDA Selected issue on drugs and prison, 
published this year, presents an up-to-date European 
overview of drug use and related problems among 
prisoners, their health and social conditions and 
the interventions targeting drug consumption and its 
consequences.
This publication is available in print and on the EMCDDA 
website in English only.
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high seizure levels may indicate a need for additional 
investigations and resources. It is generally accepted 
that seizure figures are primarily an indicator of law 
enforcement activity, and their interpretation requires an 
understanding of the context in which they are produced. 
Seizures result from the proactive investigation of specific 
suspects or, more generally, from law enforcement 
positioning in particular locations such as harbours and 
airports. In particular, the use of covert surveillance 
and undercover operations focused around illicit drug 
deliveries can lead to significant drug seizures. What 
remains less clear is the proportion of drug seizures that 
result directly from operational priority setting compared 
to the proportion made by chance.
Data on drug law offences (see next section) are also 
a direct indicator of law enforcement activity, since they 
refer to consensual crimes, which usually go unreported 
by potential victims. They are often viewed as indirect 
indicators of drug use and drug trafficking, although 
they include only those activities that have come to 
the attention of law enforcement. Understanding law 
enforcement data, whether drug law offences, arrests or 
seizures, therefore requires that the underlying strategic 
and operational priority-setting processes as well as their 
consequences are taken into account.
Drug law offences
The only data on drug-related crime routinely available 
in Europe are initial reports on offences against 
national drug laws, mainly from the police (30). These 
data usually refer to offences related to drug use (use 
and possession for use) or drug supply (production, 
trafficking and dealing), although other types of offences 
may be reported (e.g. related to drug precursors) in 
some countries. These data are likely to reflect national 
differences in legislation, priorities and resources. In 
addition, national information systems differ across 
Europe, especially in relation to recording and reporting 
practices. For these reasons, it is difficult to make 
robust comparisons between countries, and it is more 
appropriate to compare trends rather than absolute 
numbers.
Overall, the upward trend in the number of reported drug 
law offences has slowed since 2009. An EU index, based 
on data provided by 22 Member States, representing 
93 % of the population aged 15–64 in the European 
Union, shows that reported offences increased by an 
estimated 15 % between 2005 and 2010, with a more 
stable trend since 2008. If all reporting countries are 
considered, the data reveal upward trends in 19 countries 
and an overall decline in seven countries over the 
period (31).
Use- and supply-related offences
There has been no major shift in the balance between 
drug law offences related to use and those related 
to supply compared with previous years. In most (22) 
European countries, offences related to drug use or 
possession for use continued to comprise the majority of 
drug law offences in 2010, with Spain, France, Hungary, 
Austria and Turkey reporting the highest proportions 
(85–93 %) (32).
Between 2005 and 2010, there was an estimated 19 % 
increase in the number of offences related to drug use 
in Europe. Some country differences can be seen in 
this analysis, as the number of offences related to use 
COSI: the Standing Committee on operational 
cooperation on internal security
European-level priority setting in the area of operational 
drug law enforcement lies within the remit of the Council’s 
Standing Committee on operational cooperation on 
internal security (COSI) and relies on Europol’s Organised 
Crime Threat Assessments (1). COSI was established in 
2010 on the basis of the Treaty of Lisbon and set up 
by a Council Decision (Council of the European Union, 
2009). The committee, which includes high-level officials 
from Member States’ interior ministries and Commission 
representatives, has a broad remit: to facilitate, promote 
and strengthen the coordination of operational actions of 
the authorities competent in the field of internal security.
COSI’s key tasks include the development, monitoring 
and implementation of the internal security strategy and 
supporting the implementation of a multi-annual policy 
cycle that aims to tackle the most important criminal threats 
facing the European Union through increased cooperation 
between the law enforcement authorities of Member 
States, EU institutions and EU agencies. With support from 
COSI, the Council recently adopted eight policy priorities 
for the period 2011 to 2013, of which three concern drug 
law enforcement. One of these priorities aims to reduce the 
production and distribution of synthetic drugs, including 
new psychoactive substances, in the European Union. 
In the related operational action plan, Europol and the 
EMCDDA are tasked with establishing routine monitoring of 
the dismantling of synthetic drugs facilities in Europe. The 
next policy cycle, 2013–17, will be based on the 2013 EU 
Serious and Organised Crime Threat Assessment.
(1) European-level priority setting in the area of drug policy is the 
task of the Horizontal Working Party on Drugs.
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increased in 18 countries and fell in seven during this 
period. There has, however, been an overall decrease 
in drug use offences reported in the most recent data 
(2009–10) (Figure 3). Offences related to the supply 
of drugs show an estimated increase during the period 
2005–10 of about 17 % in the European Union. Over this 
period, 20 countries report an increase in supply-related 
offences, while Germany, Estonia, the Netherlands, 
Austria and Poland report an overall decline (33).
Trends by drug
Cannabis continues to be the illicit drug most often 
mentioned in reported drug law offences in Europe (34). 
In the majority of European countries, offences involving 
cannabis accounted for between 50 % and 90 % of 
reported drug law offences in 2010. Offences related 
to other drugs exceeded those related to cannabis in 
only four countries: the Czech Republic and Latvia with 
methamphetamine (54 % and 34 %); and Lithuania and 
Malta with heroin (34 % and 30 %).
In the period 2005–10, the number of drug law offences 
involving cannabis increased in 15 reporting countries, 
resulting in an estimated increase of 20 % in the European 
Union. Downward trends are reported by Germany, Italy, 
Malta, the Netherlands and Austria (35).
Cocaine-related offences increased over the period 
2005–10 in 12 reporting countries, while Germany, 
Greece, Austria and Croatia reported decreasing trends. 
In the European Union, overall, offences related to cocaine 
increased by an estimated 12 % over the same period, but 
fell in the last two years (36).
The decline in the number of heroin-related offences 
observed in 2009 continued in 2010. The EU average for 
such offences has remained overall relatively stable, with 
an estimated 7 % increase over 2005–10. The number of 
heroin-related offences has decreased in more than half of 
the reporting countries (12), while an overall increase was 
reported in nine other countries over the same period (37).
The number of offences related to amphetamines 
reported in the European Union has increased 
by an estimated 24 % over 2005–10, although it 
appears to have stabilised in the last two years. 
In contrast, the number of ecstasy-related offences 
fell by an estimated two thirds over the same period 
(a 71 % decrease).
Figure 3: Reports for offences related to drug use or possession 
for use and to drug supply in the EU Member States: indexed 
trends 2005–10 and breakdown by drug of reports for 2010
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NB: The trends are based on available information on the number of 
reported drug law offences (criminal and non-criminal) in the EU 
Member States; all series are indexed to a base of 100 in 2005 
and weighted by country population sizes to form an overall 
EU trend; the breakdown by drugs refers to the total number of 
reports for 2010. For further information, see Figures DLO-4 and 
DLO-5 in the 2012 statistical bulletin.
Sources: Reitox national focal points.
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Eurojust: judicial cooperation in the European Union
Organised criminal networks operate across borders and 
this requires cooperation between countries to ensure that 
criminals are apprehended and prosecuted wherever they are 
located. Eurojust, the European Union’s judicial cooperation 
body, was created in 2002 to address this situation. 
It represents the last step of a historical process that has 
seen judicial cooperation in the European Union grow from 
a purely intergovernmental concept to a more direct field of 
interaction among judicial authorities.
The role of Eurojust, for cross-border criminal cases, is 
to facilitate and coordinate: information exchange; joint 
investigation teams; controlled deliveries; the execution of 
European arrest warrants; transfer of evidence or criminal 
proceedings; the implementation of mutual legal assistance 
requests; the prevention and solution to conflicts of jurisdiction 
and international asset recovery. A recent analysis reveals 
that drug trafficking is the most common type of crime in 
Eurojust’s casework, accounting for about one fifth of the 
cases registered (Eurojust, 2012). In 2011, 242 drug trafficking 
cases were referred to Eurojust and eight joint investigation 
teams were active in this field. Data show that the Member 
States most often involved in judicial cooperation relating to 
drug trafficking are the Netherlands and Spain, followed at 
a distance by Italy, Germany and France.
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(38) This designation is without prejudice to positions on status, and is in line with UNSCR 1244 (1999) and the ICJ Opinion on the Kosovo declaration of 
independence.
Introduction
Cannabis is the illicit drug most widely available in Europe, 
where it is both imported and produced domestically. In 
most European countries, cannabis use increased during the 
1990s and early 2000s. Europe may now be moving into 
a new phase, as data from general population surveys and 
a new round of data from the ESPAD school survey points 
to relatively stable trends in cannabis use in many countries. 
Levels of use, nevertheless, remain high by historical 
standards. The last few years have also seen a growing 
understanding of the public health implications of the long-
term and widespread use of this drug and rising levels of 
treatment demand for cannabis-related problems.
Supply and availability
Production and trafficking
Cannabis can be cultivated in a wide range of 
environments and grows wild in many parts of the 
world. It has been estimated that cannabis is cultivated 
in 172 countries and territories (UNODC, 2009). The 
difficulties in arriving at accurate figures for global 
cannabis production are acknowledged in the UNODC’s 
most recent estimates, which place global production 
for 2008 at between 13 300 tonnes and 66 100 tonnes 
of herbal cannabis and between 2 200 tonnes and 
9 900 tonnes of cannabis resin.
Cannabis cultivation in Europe is widespread and 
appears to be increasing. All 29 European countries 
reporting information to the EMCDDA mentioned domestic 
cannabis cultivation, though the scale and nature of the 
phenomenon seem to vary considerably. A significant 
proportion of cannabis used in Europe is, nevertheless, 
likely to be the result of intra-regional trafficking. 
According to a recent EMCDDA analysis, Russia and 
Switzerland are also mentioned as sources of herbal 
cannabis available in Europe. In addition, Albania and, to 
a lesser extent, Kosovo (38), the former Yugoslav Republic 
of Macedonia and Serbia are significant sources of the 
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Table 2: Seizures, price and potency of cannabis resin and herbal cannabis
Cannabis resin Herbal cannabis Cannabis plants (1)
Global quantity seized 1 136 tonnes 6 251 tonnes n.a.
Quantity seized 
EU and Norway  
(Including Croatia and Turkey)
534 tonnes
(563 tonnes)
62 tonnes
(106 tonnes)
3.1 million plants and 35 tonnes
(3.1 million plants and 35 tonnes) (2)
Number of seizures 
EU and Norway 
(Including Croatia and Turkey)
341 000 
(358 000)
332 000
(382 000)
25 000
(37 000)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (3)
3–17
(7.0–10.2)
3–25
(6.5–9.9)
n.a.
Mean potency (THC content, %) 
Range 
(Interquartile range) (3)
1–12
(4.5–10.0)
1–17
(5.1–8.0)
n.a.
(1) Countries report the quantity seized either as a number of plants seized or by weight; the totals for both quantities are given here.
(2) Half of the total amount of cannabis plants seized in 2010 is accounted for by the Netherlands. The figures are not complete, but may be considered as a reasonable 
indication.
(3) Range of the middle half of the reported data.
NB: All data for 2010; n.a., not applicable or data not available.
Sources: UNODC (2012) for global values, Reitox national focal points for European data.
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(39) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-1 to SZR-6 in the 2012 statistical bulletin.
(40) Due to differences in shipment size and distances travelled, as well as the need to cross international borders, cannabis resin may be more at risk of 
being seized than domestically produced herbal cannabis.
(41) The analysis does not include seizures made in Turkey as these have not been reported since 2005. Previous data show substantial seizures in Turkey 
(20 million cannabis plants in 2004).
(42) See Tables PPP-1 and PPP-5 in the 2012 statistical bulletin for potency and price data. For definitions of cannabis products, see the online glossary.
herbal cannabis seized in central and south-eastern 
Europe (EMCDDA, 2012a).
Some herbal cannabis in Europe is also imported, mostly 
from Africa (especially South Africa), and less often 
from the Americas (especially the Caribbean islands) 
(EMCDDA, 2012a).
A recent survey suggests that Afghanistan has displaced 
Morocco as the largest global producer of cannabis resin. 
Production of cannabis resin in Afghanistan is estimated 
to be between 1 200 tonnes and 3 700 tonnes a year 
(UNODC, 2011a). Although some of the cannabis resin 
produced in Afghanistan is sold in Europe, it is likely that 
Morocco remains Europe’s main supplier of this drug. 
Cannabis resin from Morocco is smuggled into Europe 
primarily through the Iberian Peninsula, with Belgium and 
the Netherlands having a role in secondary distribution 
and storage. Recent reports suggest that Moroccan 
cannabis resin is being transited through Estonia, Lithuania 
and Finland en route to Russia.
Seizures
In 2010, an estimated 6 251 tonnes of herbal cannabis 
and 1 136 tonnes of cannabis resin were seized 
worldwide (Table 2), an overall stable situation compared 
with the previous year. North America continued to 
account for the bulk of herbal cannabis seized (69 %), 
while quantities of cannabis resin seized remained 
concentrated in western and central Europe (47 %) 
(UNODC, 2012).
The number of herbal cannabis seizures made in Europe 
has increased steadily since 2005, and, with an estimated 
382 000 seizures in 2010, has surpassed that of cannabis 
resin for the first time (Table 2). In 2010, an estimated 
106 tonnes of herbal cannabis was intercepted, of which 
Turkey accounted for nearly half (44 tonnes), a record 
amount (39). Diverging trends are noted, with the amount 
of herbal cannabis intercepted between 2005 and 2010 
remaining relatively stable in the European Union, while 
increasing fourfold in Turkey.
In 2010, after a steady increase over the last decade, the 
number of cannabis resin seizures declined to 358 000. 
The amount of cannabis resin intercepted has been 
decreasing overall in the last 10 years, reaching a new 
low in 2010 with an estimated 563 tonnes seized. The 
quantities of cannabis resin recovered continue to greatly 
exceed those of herbal cannabis (40). In 2010, as in 
previous years, Spain reported half of the total number 
of cannabis resin seizures and about two thirds of the 
quantity seized.
The number of seizures of cannabis plants has increased 
since 2005, reaching an estimated 37 000 cases in 2010. 
Countries report the quantity seized either as an estimate 
of the number of plants seized or by weight. Seizures 
reported by number of plants remained stable at about 
2.5 million in 2005–07 in Europe (41); trends in 2008 and 
2009 cannot be determined due to the lack of reliable 
data from the Netherlands, a country historically reporting 
large quantities. In 2010, that country was estimated to 
account for more than half of the 3.1 million plants reported 
seized in Europe, followed by the United Kingdom. Seizures 
reported by weight of plants trebled between 2005 and 
2008, before slightly decreasing to 35 tonnes in 2010, 
most of which continued to be accounted for by Spain 
(27 tonnes) and Bulgaria (4 tonnes).
Potency and price
The potency of cannabis products is determined by their 
content of delta-9-tetrahydrocannabinol (THC), the primary 
active constituent. Cannabis potency varies widely 
between and within countries, between different cannabis 
products and between genetic varieties. Information on 
cannabis potency is mainly based on forensic analysis of 
selected samples of cannabis seized. The extent to which 
the samples analysed reflect the overall market is unclear 
and for this reason, data on potency should be interpreted 
with caution.
In 2010, the reported mean THC content of cannabis 
resin ranged from 1 % to 12 %. The mean potency of 
herbal cannabis (including sinsemilla — the form of herbal 
cannabis with the highest potency) ranged from 1 % to 
16.5 %. The mean potency of sinsemilla was reported by 
only three countries: 8 % in Sweden, 11 % in Germany, 
and 16.5 % in the Netherlands. Over the period 
2005–10, the mean potency of cannabis resin has been 
diverging in the 15 countries reporting sufficient data. The 
potency of herbal cannabis remained relatively stable or 
decreased in 10 countries, and increased in Bulgaria, 
Estonia, France, Italy, Slovakia and Finland. Between 
2005 and 2010, the potency of sinsemilla remained stable 
in Germany, and declined slightly in the Netherlands (42).
The mean retail price of cannabis resin, in 2010, 
ranged from EUR 3 per gram to EUR 17 per gram in the 
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26 countries providing information, with 14 countries 
reporting values from EUR 7 per gram to EUR 10 
per gram. The mean retail price of herbal cannabis 
ranged from EUR 3 per gram to EUR 25 per gram in 
the 23 countries supplying information, with 13 of them 
reporting prices of between EUR 6 per gram and EUR 10 
per gram. Over the period 2005–10, the mean retail 
price of both cannabis resin and herb remained stable or 
increased in most countries providing data.
Estimated market shares of cannabis products
Various data sources point to a predominance of herbal 
cannabis throughout Europe in 2009. Herbal cannabis 
appears to be the most used cannabis product in two 
thirds of the 30 reporting countries, while cannabis resin is 
the product of choice in the remaining third (see Figure 4). 
These market shares appear to have remained stable 
over time in some countries, where they may reflect long-
established consumption patterns; in others, they are the 
product of recent changes (EMCDDA, 2012a).
Prevalence and patterns of use
Cannabis use among the general population
It is conservatively estimated that cannabis has been used 
at least once (lifetime prevalence) by about 80.5 million 
Europeans, that is almost one in four of all 15- to 
64-year-olds (see Table 3 for a summary of the data). 
Considerable differences exist between countries, with 
national prevalence figures varying from 1.6 % to 32.5 %. 
For most countries, the prevalence estimates are in the 
range of 10–30 % of all adults.
An estimated 23 million Europeans have used cannabis in 
the last year or, on average, 6.8 % of all 15- to 64-year-
olds. Estimates of last month prevalence will include those 
using the drug more regularly, though not necessarily in a 
daily or intensive way. It is estimated that about 12 million 
Europeans used the drug in the last month: on average, 
about 3.6 % of all 15- to 64-year-olds.
Cannabis use among young adults
Cannabis use is largely concentrated among young people 
(15–34), with the highest prevalence of ‘last year use’ 
generally being reported among 15- to 24-year-olds (43).
Population survey data suggest that, on average, 32.5 % 
of young European adults (15–34) have used cannabis 
at some time, while 12.4 % have used the drug in the last 
year and 6.6 % have used it in the last month. Still higher 
proportions of Europeans in the 15–24 age group are 
estimated to have used cannabis in the last year (15.4 %) 
or last month (7.8 %). National prevalence estimates 
of cannabis use vary widely between countries in all 
measures of prevalence (Table 3).
Cannabis use is generally higher among males with, for 
example, the ratio of males to females among young 
adults reporting use of cannabis in the last year ranging 
from just over six to one in Portugal to just under unity in 
Norway (44).
International comparisons
Figures from Australia, Canada and the United States 
on lifetime and last year use of cannabis among young 
adults are all above the European averages, which are 
32.5 % and 12.4 % respectively. For example, in Canada 
(2010) lifetime prevalence of cannabis use among young 
adults was 50.4 % and last year prevalence 21.1 %. In 
the United States, the Substance Abuse and Mental Health 
Services Administration (SAMHSA) (2010) estimated 
a lifetime prevalence of cannabis use of 52.1 % (16–34, 
recalculated by the EMCDDA) and a last year prevalence 
of 24.5 %, while in Australia (2010) the figures are 
43.3 % and 19.3 % for young adults.
Trends in cannabis use
During the late 1990s and early 2000s, many European 
countries reported increases in cannabis use, both in 
Figure 4: Estimated market shares of cannabis products consumed 
in Europe, 2008/09
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Source: EMCDDA, 2012a.
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(45) See Figure GPS-4 (part ii) in the 2012 statistical bulletin.
general population surveys and in school surveys. Since 
then, stabilising or even decreasing trends in cannabis use 
have been reported by many countries (45).
Although, in recent years, almost all European countries 
have carried out general population surveys, only 
16 countries have provided sufficient data to analyse 
trends in cannabis use over a longer period of time. 
Among these, five countries (Bulgaria, Greece, Hungary, 
Sweden, Norway) have always reported low last year 
prevalence of cannabis use among 15- to 34-year-olds, 
at levels not exceeding 10 %.
A further six countries (Denmark, Germany, Estonia, 
Ireland, Slovakia, Finland) have reported higher 
prevalence levels, but not exceeding 15 % in their latest 
survey. Denmark, Germany and Ireland reported notable 
increases in cannabis use in the 1990s and early 2000s, 
which was followed by an increasingly stable or declining 
trend. Increases observed in Estonia and Finland over the 
past decade or longer show no sign of levelling off.
The Czech Republic, Spain, France, Italy and the United 
Kingdom have all, at some point in the past 10 years, 
reported last year use among young adults at 20 % or 
Table 3: Prevalence of cannabis use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 80.5 million 23 million 12 million
European average 23.7 % 6.8 % 3.6 %
Range 1.6–32.5 % 0.3–14.3 % 0.1–7.6 %
Lowest-prevalence countries Romania (1.6 %)
Bulgaria (7.3 %)
Hungary (8.5 %)
Greece (8.9 %)
Romania (0.3 %)
Greece (1.7 %)
Hungary (2.3 %)
Bulgaria, Poland (2.7 %)
Romania (0.1 %)
Greece, Poland (0.9 %)
Sweden (1.0 %)
Lithuania, Hungary (1.2 %)
Highest-prevalence countries Denmark (32.5 %)
Spain, France (32.1 %)
Italy (32.0 %)
United Kingdom (30.7 %)
Italy (14.3 %)
Spain (10.6 %)
Czech Republic (10.4 %)
France (8.4 %)
Spain (7.6 %)
Italy (6.9 %)
France (4.6 %)
Czech Republic, Netherlands (4.2 %)
15–34 years
Estimated number of users in Europe 42.5 million 16 million 8.5 million
European average 32.5 % 12.4 % 6.6 %
Range 3.0–49.3 % 0.6–20.7 % 0.2–14.1 %
Lowest-prevalence countries Romania (3.0 %)
Greece (10.8 %)
Bulgaria (14.3 %)
Poland (16.1 %)
Romania (0.6 %)
Greece (3.2 %)
Poland (5.3 %)
Hungary (5.7 %)
Romania (0.2 %)
Greece (1.5 %)
Poland (1.9 %)
Sweden, Norway (2.1 %)
Highest-prevalence countries Czech Republic (49.3 %)
France (45.1 %)
Denmark (44.5 %)
Spain (42.4 %)
Czech Republic (20.7 %) Italy 
(20.3 %)
Spain (19.4 %)
France (17.5 %)
Spain (14.1 %)
Italy (9.9 %)
France (9.8 %)
Czech Republic (8.0 %)
15–24 years
Estimated number of users in Europe 18 million 9.5 million 5 million
European average 29.7 % 15.4 % 7.8 %
Range 3.0–52.2 % 0.9–23.9 % 0.5–17.2 %
Lowest-prevalence countries Romania (3.0 %)
Greece (9.0 %)
Cyprus (14.4 %)
Portugal (15.1 %)
Romania (0.9 %)
Greece (3.6 %)
Portugal (6.6 %)
Slovenia, Sweden (7.3 %)
Romania (0.5 %)
Greece (1.2 %)
Sweden (2.2 %)
Norway (2.3 %)
Highest-prevalence countries Czech Republic (52.2 %)
Spain (39.1 %)
France (38.1 %)
Denmark (38.0 %)
Spain (23.9 %)
Czech Republic (23.7 %)
Italy (22.3 %)
France (20.8 %)
Spain (17.2 %)
France (11.8 %)
Italy (11.0 %)
United Kingdom (9.0 %)
NB: European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of the 
overall number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population). Populations 
used as basis: 15–64, 338 million; 15–34, 130 million; 15–24, 61 million. As European estimates are based on surveys conducted between 2004 and 2010/11 
(mainly 2008–10), they do not refer to a single year. The data summarised here are available under ‘General population surveys’ in the 2012 statistical bulletin.
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(46) See Figure GPS-2 in the 2012 statistical bulletin.
(47) Surveys completed between 2003 and 2011 using a range of methodologies and contexts. See Tables GPS-10 and GPS-121 in the 2012 statistical 
bulletin.
(48) This is a minimum estimate due to under-reporting in surveys, certain populations of intensive cannabis users falling outside of the sampling frame, 
and the exclusion of individuals with episodes of intensive cannabis use in the last year, but low levels of use in the last month. 
(49) Only data collected after 2000 were taken into account in this analysis.
higher. Patterns among these countries diverged from the 
mid 2000s, with Spain and France observing generally 
stable trends, whereas Italy has reported an increase 
in 2008, and the United Kingdom has seen substantial 
decreases, with last year prevalence of cannabis use 
among young adults now at the EU average.
In 2010/11, seven countries reported new survey data, 
which permitted some consideration of recent trends in 
cannabis use. When compared with their previous survey, 
between one year and five years earlier, six of these 
countries reported relatively stable levels of last year 
prevalence of use among young adults, and one country 
(Finland) showed an increase.
Patterns of cannabis use
Available data point to a variety of patterns of cannabis 
use, ranging from experimental use to dependent use. 
Many individuals tend to discontinue their cannabis use 
after one or two experiments; others use it occasionally 
or during a limited period of time. Perceptions of risk play 
a part in patterns of use, and it is worth noting that in 
an EU-wide attitude survey, the majority (91 %) of young 
Europeans recognise health risks associated with regular 
use of cannabis, although the perception of risk to health 
posed by occasional use was less (52 %).
Of those aged 15–64 who have used cannabis at some 
time, 70 % have not done so during the last year (46). 
Among those who have used the drug in the last year, 
on average, nearly half have done so in the last month, 
possibly indicating more regular use. These proportions, 
however, vary considerably across countries and between 
males and females. Cannabis prevalence levels that 
are much higher than the European average are found 
among some groups of young people, for example 
those attending certain nightlife or dance music settings. 
Cannabis use is also often associated with heavy alcohol 
use: among young adults (15–34), frequent or heavy 
alcohol users were, in general, between two and six times 
more likely to report the use of cannabis compared to the 
general population (EMCDDA, 2009b).
The types of cannabis product and the ways they are used 
can have different associated risks. Patterns of cannabis 
use that result in high doses being consumed may put the 
user at greater risk of developing dependence or other 
problems (EMCDDA, 2008). Examples of these practices 
include using cannabis with very high THC content or in 
large amounts, and inhaling from a water pipe. 
Surveys seldom distinguish between the different 
types of cannabis used; however, the 2009/10 British 
Crime Survey estimated that around 12.3 % of adults 
(15–59) had taken what they believed to be ‘skunk’ (the 
street name given to a generally high potency form of 
the drug) at some time. While similar proportions of 
cannabis users reported lifetime use of herbal cannabis 
(50 %) and cannabis resin (49 %), those using the drug 
in the last year were more likely to have used herbal 
cannabis (71 %) than cannabis resin (38 %) (Hoare and 
Moon, 2010). Data from general population surveys in 
17 countries (47), accounting for almost 80 % of the adult 
population of the European Union and Norway, suggest 
that just over 40 % of cannabis users who reported 
using the drug during the last month had used it on one 
to three days. It can be estimated that around 1 % of 
adults (15–64) in the European Union and Norway, 
about 3 million (48), are using cannabis daily or almost 
daily (country prevalence ranging from 0.1 % to 2.6 %). 
Around three quarters of these users will be young adults, 
aged between 15 and 34 years. In this age group, males 
are about 3.5 times more likely than females to be daily 
cannabis users. Of the 11 countries, covering 70 % of the 
EU population, for which trends in intensive cannabis use 
can be determined, nine report a stable situation since 
about 2000 (49). In the other two countries, changes were 
observed over periods of five to six years with the United 
Kingdom appearing to have seen a decrease in intensive 
cannabis use, while Portugal reported an increase 
in 2007.
Dependence is increasingly recognised as a possible 
consequence of regular cannabis use, even among 
younger users, and the number of individuals seeking 
help due to their cannabis use is growing in some 
European countries (see following). Some cannabis 
users — particularly, intensive users — can experience 
problems without necessarily fulfilling the clinical criteria 
for dependence.
Cannabis use among school students
The 2011 ESPAD survey (Hibell et al., 2012) gathered 
information on cannabis use patterns and trends from 
school students in 26 of the 30 EMCDDA countries. The 
highest levels of lifetime use of cannabis among 15- to 
16-year-olds were reported by the Czech Republic (42 %) 
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and France (39 %) (Figure 5). None of the other countries 
included in the survey, or Spain, reported a level of 
lifetime use above 27 %. Only the Czech Republic and 
France report levels of lifetime prevalence of cannabis use 
that exceed those reported for a comparable age group in 
the United States in 2011 (35 %).
Reported use of cannabis over the last month ranges from 
24 % of 15- to 16-year-olds in France to 2 % in Romania 
and Norway.
The extent of the gender difference varies across Europe, 
with the ratio of boys to girls among those who have used 
cannabis at some time ranging from unity in Spain, France 
and Romania to about 2.5 boys to each girl in Greece 
and Cyprus.
Trends among school students
Over the 16 years covered by the ESPAD survey, lifetime 
prevalence of cannabis use among European school students 
has increased overall. During this period, an upward trend in 
lifetime use of cannabis among 15- to 16-year-olds that was 
observed until 2003 fell back in 2007, and was at that same 
level in 2011. Of the 23 countries that participated in the 
2011 round and either the 1995 or 1999 rounds, prevalence 
of cannabis use is now at least four percentage points higher 
in 14 countries and lower in two.
The trends over this period can be grouped by prevalence 
levels and geography. Eight countries, located mainly 
in northern and southern Europe (Figure 6, left), have 
The 2011 ESPAD report: European school survey 
on substance use
The European school survey project on alcohol and other 
drugs (ESPAD) provides regular snapshots of levels of 
drug use, trends and attitudes of 15- to 16-year-old school 
students across Europe.
This standardised survey takes place every four years, 
providing comparable data on the use of illicit drugs, 
alcohol, cigarettes and other substances by school 
students. It also reports on perceived availability, age of 
onset for these substances, and perception of risks and 
harms.
The 2011 survey (Hibell et al., 2012) interviewed school 
students born in 1995 from 36 European countries, 
including 26 of the 30 EMCDDA countries. For the first 
time, statistical methods have been used to determine if 
differences are significant (95 % level) both between the 
2007 and 2011 surveys and between boys and girls. In 
previous ESPAD reports, only differences of at least four 
percentage points were considered to be relevant.
The ESPAD findings on cannabis use are examined in this 
chapter. Where appropriate, results from comparable 
surveys carried out in Spain and the United Kingdom are 
also presented. Findings for ecstasy, amphetamines and 
cocaine use are reported in the following chapters.
Figure 5: Lifetime prevalence of cannabis use among 15- to 
16-year-old school students in the ESPAD and comparable 
surveys carried out in 2010 and 2011
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(1) Limited comparability: data for Belgium refer to the Flemish 
Community; data for Germany refer to five Länder; only a small 
proportion of schools sampled in the United Kingdom took part 
in the ESPAD survey — however, an established national survey 
reported very similar prevalence in 2010 (27  %); data for 
Spain, which does not participate in ESPAD, are from a national 
survey conducted in 2010; data for the United States, also not 
participating in ESPAD, were collected in 2011, with an estimated 
average age of 16.2, which is above the ESPAD average of 15.8.
(2) Unweighted average of the European countries is presented here.
Sources: ESPAD and Reitox national focal points for European data; 
Johnston et al. (2012) for United States data.
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reported low lifetime prevalence of cannabis use during 
the whole period. In five of these countries, the prevalence 
of cannabis use in 2011 is within three percentage points 
of its level in the earliest ESPAD survey (1995 or 1999). 
In three of these countries, however, the prevalence of 
cannabis use is now notably higher compared with the 
earliest 1990s survey: Portugal (by nine percentage 
points), Romania (by six percentage points) and Finland 
(by six percentage points). Between 2007 and 2011, 
five of these countries reported a statistically significant 
increase and one a significant decrease.
A second group is made up of eight western European 
countries that reported relatively high cannabis prevalence 
in their earliest ESPAD surveys (Figure 6, centre). In two of 
these countries, cannabis prevalence levels among school 
students have dropped dramatically over the 16-year 
period: Ireland, by 19 percentage points, and the United 
Kingdom by 16 percentage points. Decreases have also 
been observed between the first surveys in 2003 and the 
most recent in 2011 in Germany (nine percentage points) 
and Belgium (seven percentage points). The two countries 
in this group with the lowest levels of cannabis use in 
1995, Denmark and Italy, report similar levels in 2011. 
Among this group, France alone has observed an increase 
of at least four percentage points between its first (1999) 
and most recent ESPAD survey. In addition, while the trend 
between 2007 and 2011 has been downward or stable 
in seven of the eight countries, France reports an increase 
(eight percentage points).
In a third group of 10 countries, situated between the Baltic 
Sea and the Balkan Peninsula, the prevalence of cannabis 
use increased between the first survey in 1995 or 1999 
and 2011, with eight countries reporting increases of at 
least 10 percentage points (Figure 6, right). The Czech 
Republic stands out as having higher prevalence levels 
than other countries. For most of the other countries in this 
group, lifetime prevalence of cannabis use among school 
students has increased from a low level to one around 
or above the European average. Much of the change in 
cannabis prevalence in this group of countries took place 
by 2003, and by 2007 there were indications of levelling 
off. Since 2007, the prevalence of cannabis use among 
school students has significantly increased in three of these 
countries (Latvia, Hungary, Poland), decreased in one 
(Slovakia) and remained stable in six.
Comparing the last two rounds of the ESPAD survey, a stable 
trend in lifetime cannabis use among school students is seen 
in half of the 26 participating EMCDDA countries; significant 
decreases are observed in four countries, and nine countries 
show significant increases. The most pronounced increases, 
between six and eight percentage points, are reported by 
France, Latvia, Hungary and Poland.
Patterns among school students
The 2011 ESPAD survey shows that, overall, cannabis use 
is perceived as more risky by students in those countries 
with fewer users. In terms of perceived risks and harms, 
students make a clear distinction between experimental 
Figure 6: Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five 
rounds of the ESPAD survey
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(50) See Figure EYE-1 (part iv) in the 2012 statistical bulletin.
(51) See Table EYE-23 (part i) in the 2012 statistical bulletin.
(52) See Figure TDI-2 (part ii) and Tables TDI-5 (part ii) and TDI-22 (part i) in the 2012 statistical bulletin. 
(53) In addition, many opioid users in France are treated by general practitioners and are not reported to the treatment demand indicator, thereby 
inflating the proportions of users of other drugs.
(54) See Tables TDI-10 (part iii), (part iv), TDI-21 (part ii) and TDI-111 (part viii) in the 2012 statistical bulletin.
and regular use, with between 12 % and 47 % reporting 
that trying cannabis once or twice poses a great risk to 
health, while regular use of the drug was regarded as 
a great health risk by between 56 % and 80 % (50).
Early initiation of cannabis use has been associated with 
the later development of more intensive and problematic 
forms of drug consumption, and eight countries (Bulgaria, 
Czech Republic, Estonia, Spain, France, Netherlands, 
Slovakia, United Kingdom) reported rates of 5 % or more 
for those who had initiated cannabis use at age 13 or 
younger (51); in the United States, the level reached 15 %.
Boys are more likely than girls to report both early initiation 
and frequent use of cannabis, with between 5 % and 11 % 
of 15- to 16-year-old male school students in nine European 
countries reported having used cannabis on 40 or more 
occasions in their lifetime. In most countries, this proportion 
was at least double that found among the female students.
Adverse health effects of cannabis use
The health risks to the individual related to cannabis use 
are generally accepted to be lower than those associated 
with heroin or cocaine. However, due to the high 
prevalence of cannabis use, the impact on public health 
may be significant.
A range of acute and chronic health problems associated 
with cannabis use have been identified. Acute adverse 
effects include nausea, impaired coordination and 
performance, anxiety, and psychotic symptoms, which 
may be more commonly reported by first-time users. 
Observational epidemiology studies showed that cannabis 
consumption by drivers also increases the risk of being 
involved in a motor vehicle collision (Asbridge et al., 2012).
Chronic effects of cannabis use include dependence and 
respiratory diseases. Regular cannabis use in adolescence 
might adversely affect mental health in young adults, with 
evidence of an increased risk of psychotic symptoms and 
disorders that increase with frequency and quantity of use 
(Hall and Degenhardt, 2009).
Treatment
Treatment demand
In 2010, cannabis was the primary drug of about 
108 000 reported treatment entrants in 29 countries 
(25 % of all drug clients), making it the second most 
reported drug after heroin. In addition, cannabis was 
the most reported secondary drug, mentioned in around 
98 000 citations. Primary cannabis users account for more 
than 30 % of treatment entrants in Belgium, Denmark, 
Germany, France, Cyprus, Hungary, the Netherlands 
and Poland, but for less than 10 % in Bulgaria, Estonia, 
Luxembourg, Malta, Romania and Slovenia, and for 
between 10 % and 30 % in the remaining countries (52). 
Nearly 70 % of all cannabis users entering treatment in 
Europe are reported by Germany, Spain, France and the 
United Kingdom.
Differences in the prevalence of cannabis use and its 
related problems help to explain some of the variation 
in the levels of treatment entry between countries. 
Other factors, such as referral practices and the type 
of treatment provision are also important. France, for 
example, has a system of counselling centres, which target 
young clients, who are mainly cannabis users (53), while in 
Hungary, cannabis offenders are offered drug treatment 
as an alternative to punishment; both systems will increase 
the numbers entering treatment.
Over the last five years, there has been an overall 
increase (from 73 000 in 2005 to 106 000 in 2010) in 
the number of cannabis clients entering treatment in the 
25 countries for which data are available, especially for 
those who entered treatment for the first time in their life.
Profile of treatment clients
Cannabis clients mainly enter treatment in outpatient 
settings and are reported to be one of the youngest 
client groups entering treatment, with a mean age of 
25 years. Young people citing cannabis as their primary 
drug represent 76 % of reported treatment entrants aged 
15–19 and 86 % of those younger than 15 years. The 
male to female ratio is the highest among drug clients 
(about five males to every female). Overall, around half 
of primary cannabis clients are daily users, about 21 % 
use it two to six times a week, 13 % use cannabis weekly 
or less often and 17 % are occasional users, some of 
whom have not used it in the month before entering 
treatment. Considerable differences exist between 
countries. In Hungary, for example, where most cannabis 
users entering treatment are referred by the criminal 
justice system, the majority of them are occasional users 
or have not used the drug during the month before 
entering treatment (54).
47
Chapter 3: Cannabis
Treatment provision
In Europe, cannabis treatment includes a broad range of 
measures including Internet-based treatment, counselling 
and structured psychosocial interventions, and treatment 
in residential settings. There is also a frequent overlap 
between selective and indicated prevention and treatment 
interventions (see Chapter 2).
In 2011, more than half of European countries reported 
that specific cannabis treatment programmes were 
available for users who actively seek treatment, an 
increase of a third since 2008. In their most recent 
assessment, national experts from Germany, Greece, 
Italy, Lithuania, Luxembourg, the Netherlands, Slovenia, 
Slovakia, the United Kingdom and Croatia estimated 
that these programmes were available to the majority of 
cannabis users in need of treatment, while experts from 
Belgium, the Czech Republic, Denmark, Spain, Austria, 
Portugal, Romania and Norway estimated that they were 
available only to a minority of them. Bulgaria, Estonia, 
Cyprus, Hungary and Poland reported that specific 
treatment programmes for cannabis users are planned for 
the next three years.
Cannabis treatment is mainly provided in outpatient 
facilities, with the criminal justice system, accident and 
emergency departments, and mental health treatment units 
acting as important referral agencies. In Hungary, about 
two thirds of all reported cannabis treatment entrants in 
2010 received counselling, provided by a network of 
accredited organisations.
Multidimensional family therapy and cognitive behavioural 
therapy are provided to young people (along with their 
parents) with problems related to cannabis use in Belgium, 
Germany, France and the Netherlands, as part of an 
ongoing clinical trial which is also being conducted 
in Switzerland (see following). In Denmark, a group-
based, brief treatment approach is being introduced 
as a treatment for cannabis use problems, following 
a successful pilot phase in Copenhagen. The treatment 
includes elements of motivational interviewing, cognitive 
behavioural therapy and solution-focused therapy.
A growing number of European countries offer Internet-
based cannabis treatment in order to facilitate treatment 
access to individuals who may be unable or unwilling 
to seek help within the specialist drug treatment system. 
In Hungary, an online programme offers web-based 
treatment for people who want to cut down or stop using 
cannabis, and has links with outpatient treatment centres 
in Budapest. This self-help programme draws on the 
experience of Internet-based treatment for cannabis users 
in other European countries.
Recent studies on treatment of cannabis users
There has been a gradual increase in the availability of 
cannabis treatment evaluation studies, most with a focus 
on psychosocial interventions such as family therapy and 
cognitive behavioural therapy.
The EMCDDA has recently commissioned a meta-analysis 
of European and US studies on multidimensional family 
therapy. The US studies showed a number of positive 
results for this approach in terms of reducing substance 
use and delinquency compared to both individually 
delivered cognitive behavioural therapy and a manual-
guided adolescents’ group therapy based on social 
learning principles and cognitive behavioural therapy 
(Liddle et al., 2009). With regard to young people in 
treatment in US criminal justice settings, multidimensional 
family therapy led to reductions in cannabis use among 
the more severe cases (Henderson et al., 2010). The 
European analysis also indicates that it is a viable 
treatment option for adolescents with severe substance 
use and behavioural disorders. These were the provisional 
conclusions from the European multi-site International 
cannabis need of treatment study (INCANT), which has 
been running since 2003 in Belgium, Germany, France, 
the Netherlands and Switzerland.
Brief interventions can be defined as advice, counselling, 
or both, directed at reducing consumption of drugs, licit 
and illicit. A recent international study linked screening 
for alcohol, smoking and substance use with brief 
interventions, and reported reduced cannabis use at 
follow-up (Humeniuk et al., 2011).
Research is also being conducted on pharmaceuticals that 
may support psychosocial interventions in the treatment 
of cannabis problems by reducing withdrawal symptoms, 
cravings or use. With regard to cannabis dependence, 
studies are exploring the potential of oral synthetic THC 
as a substitution therapy, while rimonabant, an agonist, 
has shown positive results for reducing acute physiological 
problems linked to cannabis smoking (Weinstein and 
Gorelick, 2011).

49
Introduction
In many European countries, amphetamines (a generic term 
that includes both amphetamine and methamphetamine) or 
ecstasy is the second most commonly used illicit substance 
after cannabis. In addition, in some countries, use of 
amphetamines constitutes an important part of the drug 
problem, accounting for a substantial proportion of those in 
need of treatment.
Amphetamine and methamphetamine are central nervous 
system stimulants. Of the two drugs, amphetamine is 
more commonly available in Europe, whereas significant 
methamphetamine use has historically been restricted 
to the Czech Republic and, more recently, Slovakia. 
Methamphetamine has also appeared on the drug markets 
of other countries in the last few years, particularly in the 
north of Europe (Latvia, Sweden, Norway and, to a lesser 
extent, Finland), where it appears to have partially 
replaced amphetamine. In 2010, further signs of problem 
methamphetamine use, albeit probably at very low levels, 
were reported by Germany, Greece, Hungary, Cyprus 
and Turkey, while seizures of the drug have increased in 
Estonia and Austria.
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines, but which differ to some extent 
in their effects. The best-known member of the ecstasy 
group of drugs is 3,4-methylenedioxy-methamphetamine 
(MDMA), but other analogues are also sometimes found 
in ecstasy tablets (3,4-methylenedioxy amphetamine 
(MDA), 3,4-methylenedioxy-ethylamphetamine (MDEA)). 
The drug’s popularity has historically been linked with the 
electronic dance-music scene, although recent years have 
seen some decline in the use and availability of ecstasy in 
Europe. Latest data, however, indicate a return of MDMA 
in some European countries.
The overall prevalence levels of hallucinogenic drugs such 
as lysergic acid diethylamide (LSD) and hallucinogenic 
mushrooms are generally low and have been largely 
stable in recent years.
Since the mid 1990s, recreational use of ketamine and 
gamma-hydroxybutyrate (GHB) — both anaesthetics — 
has been reported among subgroups of drug users in 
Europe. This is becoming a more recognised problem, 
with services beginning to target the users of these drugs. 
Recognition is also growing of the health problems 
related to these substances, particularly bladder disease 
associated with long-term ketamine use.
Supply and availability
Drug precursors
Amphetamine, methamphetamine and ecstasy are 
synthetic drugs requiring chemical precursors in the 
manufacturing process. Insights into the illicit production of 
these substances can be gleaned from reports of seizures 
of controlled chemicals — diverted from licit trade — that 
are necessary for their manufacture.
International efforts to prevent the diversion of precursor 
chemicals used in the illicit manufacture of synthetic drugs 
are coordinated through ‘Project Prism’. The project uses 
a system of pre-export notifications for licit trade, and the 
reporting of shipments stopped and seizures made when 
suspicious transactions occur (INCB, 2012b).
The International Narcotics Control Board reports that 
global seizures of 1-phenyl-2-propanone (P2P, also known as 
benzyl methyl ketone, BMK), which can be used for the illicit 
manufacture of both amphetamine and methamphetamine, 
increased fivefold from 4 900 litres in 2009 to 26 300 litres 
in 2010. Seizures in Mexico (14 200 litres in 2010), Canada 
(6 000 litres) and Belgium (5 000 litres) accounted for 95 % 
of the global total reported to the INCB (2012a). In the 
European Union, seizures of P2P also rose dramatically, 
from 863 litres in 2009 to 7 493 litres in 2010 (European 
Commission, 2011). World seizures of phenylacetic acid, 
a precursor of P2P, quadrupled in 2010 (INCB, 2012a). 
Seizures of this chemical in the European Union in 2010 
(1.5 kg) were small compared with 2009 (277 kg) (European 
Commission, 2011). World seizures of ephedrine and 
pseudoephedrine, two key precursors of methamphetamine, 
decreased in 2010 (INCB, 2012a). However, in the 
European Union, seizures of these precursors increased 
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(55) Ten of these 28 sites were also involved in the production, tableting or storage of other drugs, methamphetamine in most cases. 
(56) Three quarters of the amphetamine tablets intercepted were labelled as captagon, and recovered in Turkey. Tablets sold on the illicit drug market as 
captagon are commonly found to contain amphetamine mixed with caffeine.
(57) The data on European drug seizures mentioned in this chapter can be found in Tables SZR-11 to SZR-18 in the 2012 statistical bulletin.
(58) The data on European drug purities mentioned in this chapter can be found in Table PPP-8 in the 2012 statistical bulletin. EU trend indexes can be 
found in Figure PPP-2 in the 2012 statistical bulletin.
in 2010: to 1.2 tonnes of ephedrine (685 kg in 2009) and 
1.5 tonnes of pseudoephedrine (186 kg in 2009) (European 
Commission, 2011).
Two precursor chemicals are primarily associated with 
the manufacture of MDMA: 3,4-methylenedioxyphenyl- 
2-propanone (3,4-MDP2P, also known as 
piperonylmethylketone, PMK) and safrole. In 2010, world 
seizures of PMK amounted to 2 litres, down from 40 litres 
in 2009, while seizures of safrole fell from 1 048 litres 
in 2009 to 168 litres in 2010. In the European Union, 
no PMK was seized in 2010, while only four seizures of 
safrole were made, amounting to 85 litres.
In 2010, gamma-butyrolactone, a precursor of GHB, 
continued to be intercepted in the European Union, with 
a total of 139 seizures amounting to 253 litres.
Amphetamine
Global amphetamine production remains concentrated in 
Europe, which accounted for almost all of the amphetamine 
laboratories reported in 2010 (UNODC, 2012). Global 
seizures of amphetamine declined by 42 % in 2010 to about 
19 tonnes (see Table 4). Authorities in western and central 
Europe continued to seize large amounts of amphetamine 
in 2010, although seizures also declined, from 8.9 tonnes 
in 2009 to 5.4 tonnes in 2010. The largest decrease in 
amphetamine seizures was reported in the UNODC’s 
Near and Middle East and south-west Asia region. A large 
proportion of the amphetamine seized in this region is in the 
form of ‘captagon’ tablets (UNODC, 2012), some of which 
may originate from the European Union.
Most amphetamine seized in Europe is produced, in 
order of importance, in the Netherlands, Belgium, Poland, 
Bulgaria, Turkey and Estonia. Some 28 sites involved in 
the production, tableting or storage of amphetamine were 
discovered in the European Union in 2010 and reported to 
Europol (55).
In 2010, an estimated 36 600 seizures amounting 
to 5 tonnes of amphetamine powder and 1.4 million 
amphetamine tablets (56) were made in Europe. Within 
an overall downward trend, the number of amphetamine 
seizures has been fluctuating for the last five years. The 
number of amphetamine tablets confiscated in Europe 
has decreased sharply over the period 2005–10 due 
to falling seizures in Turkey. After record interceptions 
of about 8 tonnes between 2007 and 2009, quantities 
of amphetamine powder intercepted have decreased to 
around 5 tonnes in 2010 (57).
The purity of amphetamine samples intercepted in Europe 
in 2010 continued to vary widely, ranging from less than 
8 % in Bulgaria, Italy, Austria, Portugal, Slovenia, Croatia 
and Turkey, to around 20 % or more in countries where 
amphetamine production is reported (Belgium, Latvia, 
Lithuania, Netherlands) or where consumption levels are 
relatively high (Finland, Sweden, Norway) and in the 
Czech Republic and Slovakia (58). Over the past five years, 
Table 4: Seizures, price and purity of amphetamine, methamphetamine, ecstasy and LSD
Amphetamine Methamphetamine Ecstasy LSD
Global quantity seized  
(tonnes)
19 45 3.8 n.a.
Quantity seized 
EU and Norway  
(Including Croatia and Turkey)
 
5.1 tonnes
(5.4 tonnes)
 
500 kg
(600 kg)
Tablets
3.0 million
(3.9 million)
Units
97 900
(98 000) (1)
Number of seizures  
EU and Norway  
(Including Croatia and Turkey)
 
36 200
(36 600)
7 300
(7 300)
7 800
(9 300)
970
(990)
Mean retail price (EUR) 
Range 
(Interquartile range) (2)
Gram
6–41
(9.6–21.2)
Gram 
10–70
Tablet 
2–17 
(3.9–8.4)
Dose 
3–26 
(6.5–13.1)
Mean purity  
(or MDMA content for ecstasy)
Range
(Interquartile range) (2)
 
 
5–39 % 
(7.8–27.2 %)
 
 
5–79 % 
(28.6–64.4 %)
 
 
3–104 mg 
(33.0–90.4 mg)
 
 
n.a.
(1) The total amount of LSD seized in 2010 is underestimated, due to the lack of 2010 data for Sweden, a country reporting relatively large seizures in 2009.
(2) Range of the middle half of the reported data.
NB: All data are for 2010; n.a.: not applicable or data not available.
Sources: UNODC (2012) for global values, Reitox national focal points for European data.
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(59) The data on European drug prices mentioned in this chapter can be found in Table PPP-4 in the 2012 statistical bulletin.
the purity of amphetamine has fallen or remained stable in 
most countries reporting sufficient data for trend analysis.
In 2010, the mean retail price of amphetamine ranged 
from EUR 10 per gram to EUR 22 per gram for over 
half of the 18 reporting countries. Amphetamine retail 
prices either decreased or remained stable in 14 out of 
20 countries reporting data over 2005–10 (59).
Methamphetamine
In 2010, 45 tonnes of methamphetamine was seized 
worldwide, a marked increase from the 31 tonnes seized 
in 2009. Most of the drug was seized in North America 
(34 %), where Mexico, an important producer country, 
accounted for an exceptionally high 13 tonnes seized in 
2010. Large amounts were also seized in east and south-
east Asia, a region which accounted for 32 % of the world 
total in 2010, with 20 tonnes; here, Myanmar is identified 
as a key producer country (UNODC, 2012).
In Europe, illicit methamphetamine production is 
concentrated in the Czech Republic, where 307 
production sites, mostly small-scale ‘kitchen laboratories’, 
were detected in 2010 (down from 342 in 2009). 
Production of the drug also occurs in Slovakia, as well 
as Germany, Lithuania, the Netherlands and Poland. 
Germany reported a substantial increase in quantities of 
methamphetamine seized in 2010 (26.8 kg, from 7.2 kg 
in 2009); most of the drug was intercepted in Saxony and 
Bavaria, which border the Czech Republic where the drug 
appears to be sourced.
In 2010, almost 7 300 seizures of methamphetamine, 
amounting to about 600 kg of the drug, were reported 
in Europe. Both the number of seizures and the quantities 
of methamphetamine seized increased over the period 
2005–10, with a strong increase between 2008 and 
2009 and a stabilisation in 2010.
Methamphetamine purity varied greatly in 2010 in the 
20 countries reporting data, with mean purities ranging 
from less than 15 % in Belgium and Denmark to more than 
60 % in the Czech Republic, Slovakia, United Kingdom 
and Turkey. The retail price for methamphetamine also 
varied greatly in 2010 in the seven countries reporting it: 
from EUR 10–15 per gram in Bulgaria, Latvia, Lithuania 
and Hungary to about EUR 70 per gram in Germany and 
Slovakia.
Ecstasy
The reported number of dismantled laboratories producing 
ecstasy declined in 2010 to 44 (52 in 2009). Most 
of these laboratories were situated in Australia (17), 
Canada (13) and Indonesia (12). Production of the drug 
appears to have continued to spread geographically, 
with manufacture occurring closer to consumer markets 
in east and south-east Asia, North and South America 
and Oceania. Despite this, it is likely that western Europe 
remains an important location for ecstasy production.
Worldwide, seizures of ecstasy amounted to 3.8 tonnes in 
2010 (UNODC, 2012), with North America reporting 20 % 
of the total followed by western and central Europe (13 %).
Overall, both the number of ecstasy seizures and amounts 
intercepted have declined in Europe since 2005. Over the 
period 2005–10, the quantity of ecstasy tablets seized 
in Europe fell by a factor of four, while an increase was 
reported in 2010, mainly due to seizures in France and 
Turkey. In 2010, about 9 300 ecstasy seizures were 
reported in Europe, resulting in the interception of over 
3.9 million ecstasy tablets, of which 1.6 million were 
seized in France and Turkey.
The average MDMA content of ecstasy tablets tested in 
2010 was 3–104 mg in the 19 countries providing data. 
In addition, the availability of high-dose ecstasy tablets 
containing over 130 mg MDMA was reported by several 
countries (Belgium, Bulgaria, Germany, Netherlands, 
Croatia). Over the period 2005–10, the MDMA content of 
ecstasy tablets declined in 10 countries but increased in 
nine other countries.
During the last few years, there has been a change in the 
content of illicit drug tablets in Europe: from a situation 
where most tablets analysed contained MDMA or 
another ecstasy-like substance (MDA, MDEA) as the only 
psychoactive substance, to one where the contents are 
more diverse, and MDMA-like substances less present. 
This shift was most pronounced in 2009, when only three 
countries reported that MDMA-like substances accounted 
for a large proportion of the tablets analysed. In 2010, the 
number of countries reporting a predominance of tablets 
containing MDMA-like substances increased to eight.
Amphetamines, sometimes in combination with MDMA-
like substances, are relatively common in tablets analysed 
in Poland, Slovenia and Turkey. Most of the reporting 
countries mention that piperazines, and in particular mCPP 
(1-(3-chlorophenyl)piperazine), were found, alone or in 
combination with other substances in tablets analysed; 
these substances were found in over 20 % of tablets 
analysed in Belgium, Denmark, Germany, Cyprus, Hungary, 
Austria, Finland, the United Kingdom and Croatia.
Ecstasy is now considerably cheaper than it was in 
the 1990s with most countries reporting mean retail 
prices in the range of EUR 4–9 per tablet. Over the 
52
Annual report 2012: the state of the drugs problem in Europe
(60) See Table EYE-11 in the 2012 statistical bulletin.
(61) Problem amphetamines use is defined as the injecting or long duration and/or regular use of the substances.
period 2005–10, the retail price of ecstasy fell or 
remained stable in 18 out of the 23 countries for which the 
analysis could be made.
Hallucinogens and other substances
Use and trafficking of LSD in Europe is considered 
marginal. The number of LSD seizures increased between 
2005 and 2010, while quantities have fluctuated between 
50 000 units and 150 000 units, after an all-time peak 
of 1.8 million units in 2005. Over the same period, the 
retail price of LSD decreased or remained stable in most 
reporting countries. In 2010, the mean price was between 
EUR 6 per unit and EUR 14 per unit for the majority of the 
14 reporting countries.
Seizures of hallucinogenic mushrooms, ketamine, and 
GHB and GBL were only reported in 2010 by three or four 
countries, depending on the drug. The extent to which the 
reported seizures reflect the limited availability of these 
substances, or merely the fact that they are not routinely 
targeted by law enforcement services, is not clear.
Prevalence and patterns of use
In a few countries, the use of amphetamines, often by 
injection, accounts for a substantial proportion of the 
overall number of problem drug users and those seeking 
help for drug problems. In contrast, amphetamines and 
ecstasy, usually taken orally or snorted, have an association 
with attendance at nightclubs and dance events. The 
combined use of ecstasy or amphetamines with alcohol has 
been noted, with frequent or heavy alcohol users reporting 
levels of amphetamine or ecstasy use that are much higher 
than the population average (EMCDDA, 2009b).
Amphetamines
Drug prevalence estimates suggest that about 13 million 
Europeans have tried amphetamines, and about 2 million 
have used the drug during the last year (see Table 5 
for a summary of the data). Among young adults 
(15–34), lifetime prevalence of amphetamines use varies 
considerably between countries, from 0.1 % to 12.9 %, 
with a weighted European average of 5.5 %. Last year 
use of amphetamines in this age group ranges from 0 % 
to 2.5 %, with most countries reporting prevalence levels 
of 0.5–2.0 %. It is estimated that about 1.5 million (1.2 %) 
young Europeans have used amphetamines during the last 
year. Levels of last year use of amphetamines are higher 
in surveys among young people linked with dance-music 
or nightlife settings, with results from 2010 studies in the 
Czech Republic, the Netherlands and United Kingdom 
ranging from 8 % to 27 %.
Among 15- to 16-year-old school students, lifetime 
prevalence of amphetamines use ranged from 1 % to 
7 % in the 24 EU Member States, Croatia and Norway 
with ESPAD surveys in 2011, although only Belgium, 
Bulgaria and Hungary reported prevalence levels of more 
than 4 % (60). The Spanish national school survey reports 
1 %, while the United States reports 9 %.
Between 2005 and 2010, last year amphetamines use 
has remained relatively low and stable among the general 
population in most European countries, with prevalence 
levels of less than 3 % in all reporting countries. During 
this period, an increase was reported by only one country, 
Bulgaria, which observed an increase of one percentage 
point in last year prevalence of amphetamines use among 
young adults (Figure 7). ESPAD school surveys conducted 
in 2011 suggest, overall, little change in the levels of 
experimentation with amphetamines and ecstasy among 
students aged 15 to 16 years.
Problem amphetamines use
Recent estimates of the prevalence of problem 
amphetamines use are available for two countries (61). 
Figure 7: Trends in last year prevalence of use of amphetamines 
among young adults (15–34)
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NB: Only data for countries with at least three surveys are presented. 
See Figure  GPS-8 in the 2012 statistical bulletin for further 
information.
Sources: Reitox national reports, taken from population surveys, reports 
or scientific articles.
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(62) In Germany, Lithuania and Norway, it is not possible to distinguish between amphetamine, MDMA and other stimulants users in the data reported 
to the EMCDDA, as these are reported as users of ‘stimulants other than cocaine’. Overall, in countries where the data are reported, users of 
amphetamines account for around 90 % of all the ‘stimulants other then cocaine’ drug category.
In 2010, the number of problem methamphetamine users in 
the Czech Republic was estimated to be 27 300–29 100 
(3.7–3.9 cases per 1 000 aged 15–64), an increase 
compared with previous years, and more than double the 
estimated number of problem opioid users. In Slovakia, 
there were an estimated 5 800–15 700 problem 
methamphetamine users in 2007 (1.5–4.0 cases per 1 000 
aged 15–64), about 20 % fewer than the estimated number 
of problem opioid users.
Methamphetamine has also appeared on the drug markets 
in other countries, particularly in the north of Europe 
(Latvia, Sweden, Norway and, to a lesser extent, Finland), 
where it appears to have partially replaced amphetamine. 
In 2010, further signs of problem methamphetamine use, 
albeit probably at very low levels, were reported by 
Germany, Greece, Cyprus, Hungary and Turkey, while 
seizures of the drug have increased in Estonia and Austria.
A small proportion of those entering treatment in Europe 
mention amphetamines as their primary drug: about 6 % 
of reported drug clients in 2010 (23 000 clients) (62). In 
addition, stimulants (other than cocaine) are mentioned 
as a secondary drug by almost 20 000 clients entering 
treatment for problems related to other primary drugs. 
Primary amphetamines users account for a sizeable 
proportion of reported treatment entries in Sweden 
(28 %); Poland (24 %), Latvia (19 %) and Finland (17 %), 
and methamphetamine is cited as the primary drug by 
a large proportion of clients reported entering treatment 
in the Czech Republic (63 %) and Slovakia (35 %). 
Amphetamines clients make up between 5 % and 15 % of 
reported treatment entrants in six other countries (Belgium, 
Denmark, Germany, Hungary, Netherlands, Norway); 
elsewhere the proportion is less than 5 %. Between 2005 
and 2010, trends in primary users of amphetamines 
entering treatment have remained stable in most countries, 
Table 5: Prevalence of amphetamines use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 13 million 2 million
European average 3.8 % 0.6 %
Range 0.1–11.6 % 0.0–1.1 %
Lowest-prevalence countries Greece, Romania (0.1 %)
Cyprus (0.7 %)
Portugal (0.9 %)
Slovakia (1.2 %)
Greece, Romania (0.0 %)
France, Portugal (0.2 %)
Czech Republic, Cyprus,  
Slovakia (0.3 %)
Highest-prevalence countries United Kingdom (11.6 %)
Denmark (6.2 %)
Sweden (5.0 %)
Ireland (4.5 %)
Estonia, United Kingdom (1.1 %)
Bulgaria, Latvia (0.9 %)
Finland, Sweden (0.8 %)
15–34 years
Estimated number of users in Europe 7 million 1.5 million
European average 5.5 % 1.2 %
Range 0.1–12.9 % 0.0–2.5 %
Lowest-prevalence countries Romania (0.1 %)
Greece (0.2 %)
Cyprus (1.2 %)
Portugal (1.3 %)
Romania (0.0 %)
Greece (0.1 %)
Portugal (0.4 %)
France (0.5 %)
Highest-prevalence countries United Kingdom (12.9 %)
Denmark (10.3 %)
Ireland (6.4 %)
Latvia (6.1 %)
Estonia (2.5 %)
Bulgaria (2.1 %)
Denmark, United Kingdom (2.0 %)
Germany, Latvia (1.9 %)
NB: European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of 
the overall number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 6 % of the target population for 
young adults, last year use estimates, and not more than 3 % of the target population for the other estimates). Populations used as basis: 15–64, 338 million; 15–34, 
130 million. As European estimates are based on surveys conducted between 2004 and 2010/11 (mainly 2008–10), they do not refer to a single year. The data 
summarised here are available under ‘General population surveys’ in the 2012 statistical bulletin.
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(63) See Tables TDI-5 (part ii) and TDI-22 in the 2012 statistical bulletin.
(64) See Tables TDI-5 (part iv) and TDI-37 in the 2012 statistical bulletin. 
(65) See Tables TDI-2 (part i), TDI-3 (part iii), TDI-5 (part ii) and TDI-36 (part iv) in the 2012 statistical bulletin. See also Table TDI-17 in the 2007 and 
2012 statistical bulletins.
(66) See Table GPS-1 (part iii) in the 2012 statistical bulletin. 
(67) See Table EYE-11 in the 2012 statistical bulletin.
(68) See Tables TDI-5, TDI-8 and TDI-37 in the 2012 statistical bulletin.
with the exception of the Czech Republic and Slovakia: 
both countries report an increase in the number and 
overall proportion of new treatment entrants related to 
methamphetamine over that period and a substantial 
increase between 2009 and 2010 (63).
Amphetamines users entering treatment are on average 
30 years old, with a lower male to female ratio (two to 
one) than for any other illicit drug. In countries where 
amphetamines users make up high proportions of 
treatment entrants, many of them report injecting the 
drug. In the Czech Republic, Latvia, Finland, Sweden 
and Norway, between 63 % and 80 % of primary 
amphetamines clients reported injecting the drug (64). 
A lower level of injecting is reported in Slovakia (34 %), 
where it has been declining since 2005 (65).
Ecstasy
Drug prevalence estimates suggest that about 11.5 million 
Europeans have tried ecstasy, and about 2 million 
have used the drug during the last year (see Table 6 
for a summary of the data). Use of the drug in the last 
year is concentrated among young adults, with males 
generally reporting higher levels of use than females in all 
countries. Lifetime prevalence of ecstasy use among the 
15–34 age group ranges from under 0.6 % to 12.4 %, 
with most countries reporting estimates in the range 
of 2.1–5.8 % (66).
Lifetime prevalence of ecstasy use among 15- to 16-year-
old school students ranged from 1 % to 4 % in the 
European countries surveyed in 2011 (67) with only the 
United Kingdom reporting a prevalence level of 4 %, in 
both the ESPAD survey and the English national school 
survey. The Spanish national school survey reports 2 %. 
For comparison, lifetime use of the drug among school 
students of a similar age in the United States is estimated 
at 7 %.
Targeted studies provide a window into ‘recreational’ 
use of stimulant drugs by young adults attending a range 
of different nightlife venues across Europe. Information 
on last year prevalence of ecstasy use among attendees 
at dance and nightlife settings in 2010/11 is available 
for two countries: the Czech Republic (43 %) and the 
Netherlands (Amsterdam, 33 %). Ecstasy use was more 
common than amphetamines use in the two samples. 
A 2012 Internet study conducted in the United Kingdom 
reported that for UK regular clubbers, last year use of 
ecstasy exceeded that of cannabis (Mixmag, 2012). In a 
nightclub survey carried out in Denmark, 40 % of those 
interviewed (average age 21) reported having tried, at 
some point in their lives, an illicit drug other than cannabis 
(typically cocaine, amphetamines or ecstasy). Data from 
site samples and Internet surveys, however, must be 
interpreted with caution.
In five of the six countries that report higher than average 
levels of last year ecstasy use, and for which trends can 
be described, consumption of the drug among 15- to 
34-year-olds typically peaked in the early 2000s, before 
declining (Czech Republic, Estonia, Spain, Slovakia, 
United Kingdom) (Figure 8). Over the period 2005–10, 
these countries have reported stable or downward trends 
in last year use in young adults (15–34).
Few drug users enter treatment for problems relating to 
ecstasy. In 2010, ecstasy was mentioned as the primary 
drug by 1 % or less (almost 1 000 clients in total) of 
reported treatment entrants in all European countries (68).
Figure 8: Trends in last year prevalence of use of ecstasy among 
young adults (15–34)
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NB: Only data for countries with at least three surveys are presented. 
See Figure  GPS-21 in the 2012 statistical bulletin for further 
information.
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or scientific articles.
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(69) See Table GPS-1 in the 2012 statistical bulletin.
(70) Data from ESPAD for all countries but Spain. See Figure EYE-3 (part v) in the 2011 statistical bulletin.
Hallucinogens, GHB and ketamine
Among young adults (15–34 years), lifetime prevalence 
estimates of LSD use in Europe range from 0.1 % to 
5.4 %. Much lower prevalence levels are reported 
for last year use (69). In the few countries providing 
comparable data, most report higher levels of use for 
hallucinogenic mushrooms than for LSD among both 
the general population and school students. Lifetime 
prevalence estimates for hallucinogenic mushrooms among 
young adults range from 0.3 % to 8.1 %, and last year 
prevalence estimates are in the range of 0.0–2.2 %. 
Among 15- to 16-year-old school students, most countries 
report lifetime prevalence estimates for the use of 
hallucinogenic mushrooms of between 1 % and 4 % (70).
Estimates of the prevalence of GHB and ketamine use in 
the adult and school populations are much lower than 
those for the use of ecstasy. In the Netherlands, where 
GHB was included in the 2009 general population survey 
for the first time, 0.4 % of the adult population (15–64) 
reported having used the drug in the last year, which is 
similar to the last year prevalence of amphetamines use. 
The British Crime Survey, one of the few national surveys 
that follow ketamine, noted an increase in last year use 
of ketamine among those aged 16 to 24: from 0.8 % in 
2006/07 to 2.1 % in 2010/11.
Targeted surveys in nightlife settings provide an indication 
of the drugs that are available in these venues, although 
prevalence rates are difficult to interpret. Recent studies 
from the Czech Republic and the Netherlands, as well as 
an Internet survey conducted from the United Kingdom, 
report lifetime prevalence estimates for the use of GHB 
ranging from 4 % to 11 %, and estimates for ketamine 
ranging from 8 % to 48 %, depending on the setting 
or respondent group. In Denmark, a nightclub survey 
reported that about 10 % of those interviewed had used 
ketamine, GBH, hallucinogenic mushrooms or LSD. The 
results of a 2011 study conducted in ‘gay friendly’ dance 
clubs in south London point to high levels of use of these 
Table 6: Prevalence of ecstasy use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year
15–64 years
Estimated number of users in Europe 11.5 million 2 million
European average 3.4 % 0.6 %
Range 0.4–8.3 % 0.1–1.6 %
Lowest-prevalence countries Greece (0.4 %)
Romania (0.7 %)
Norway (1.0 %)
Poland (1.2 %)
Sweden (0.1 %)
Greece, France, Romania (0.2 %)
Denmark, Poland, Norway (0.3 %)
Highest-prevalence countries United Kingdom (8.3 %)
Ireland (6.9 %)
Netherlands (6.2 %)
Spain (4.9 %)
Slovakia (1.6 %)
Latvia (1.5 %)
Netherlands, United Kingdom (1.4 %)
Estonia (1.2 %)
15–34 years
Estimated number of users in Europe 7.5 million 1.5 million
European average 5.7 % 1.3 %
Range 0.6–12.4 % 0.2–3.1 %
Lowest-prevalence countries Greece (0.6 %)
Romania (0.9 %)
Poland, Norway (2.1 %)
Portugal (2.6 %)
Sweden (0.2 %)
Greece, France, Romania (0.4 %)
Norway (0.6 %)
Poland (0.7 %)
Highest-prevalence countries United Kingdom (12.4 %)
Netherlands (11.6 %)
Ireland (10.9 %)
Latvia (8.5 %)
Netherlands (3.1 %)
United Kingdom (3.0 %)
Latvia, Slovakia (2.7 %)
Estonia (2.3 %)
NB: European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of 
the overall number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population). 
Populations used as basis: 15–64, 338 million; 15–34, 130 million. As European estimates are based on surveys conducted between 2004 and 2010/11 
(mainly 2008–10), they do not refer to a single year. The data summarised here are available under ‘General population surveys’ in the 2012 statistical bulletin.
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substances among some subgroups of the population, with 
24 % of the respondents rating GHB as a favourite drug 
and expressing an intention to use it on the night of the 
survey, and more than 10 % giving a similar response for 
ketamine (Wood et al., 2012b). Among UK respondents to 
an Internet survey who were identified as regular clubbers, 
40 % reported last year use of ketamine and 2 % last year 
use of GHB (Mixmag, 2012).
Health consequences of amphetamines
Many of the studies on the health consequences of 
amphetamines use have been conducted in countries 
where crystal methamphetamine smoking, which is almost 
absent in Europe, is a significant part of the drug problem. 
Although many of the health effects documented in these 
studies have also been reported among amphetamines 
users in Europe, it is not clear that their findings can be 
directly translated to the European situation.
Use of illicit amphetamines has been associated with 
a range of acute adverse effects including agitation, 
headache, tremors, nausea, abdominal cramps, sweating, 
dizziness and decreased appetite (EMCDDA, 2010c). 
Users with underlying mental health problems are at 
greatest risk of acute psychological and psychiatric 
adverse effects, which may include effects ranging from 
low mood, anxiety, aggression and depression, to acute 
paranoid psychosis. As stimulant effects wear off, users 
may experience drowsiness, judgement and learning 
impairment.
The chronic adverse effects associated with the use of 
amphetamines include cardiovascular complications 
due to the cumulative risk of cardiac and coronary 
artery disease and pulmonary hypertension. In the 
context of pre-existing cardiovascular pathology, use of 
amphetamines may trigger serious and potentially fatal 
events (myocardial ischaemia and infarction). In addition, 
long-term use has been linked with damage to the brain 
and nervous system, psychosis and a range of personality 
and mood disturbances.
There is good evidence for an amphetamines dependence 
syndrome after regular intensive use. Associated 
withdrawal symptoms may include craving, and 
depression with increased suicide risk (Jones et al., 2011).
Injecting use of amphetamines increases the risk of 
infectious diseases (HIV and hepatitis) while high rates 
of sexual risk behaviour make users more vulnerable 
to sexually transmitted infections. In addition, lack of 
food and sleep can have negative health effects. Use 
of amphetamines in pregnancy is associated with low 
birthweight, prematurity and increased foetal morbidity.
Prevention in recreational settings
Despite the high levels of drug use that have been 
observed in some recreational settings, only 11 countries 
report prevention and harm-reduction strategies in these 
arenas. These strategies tend to focus either on the 
individual level or the environmental level. Projects with an 
individual-level focus include peer education interventions 
and mobile teams — as implemented in Belgium, the 
Czech Republic and the United Kingdom — which offer 
advice and information about drugs, provide medical 
treatment and distribute harm-reduction materials. Other 
reported approaches with an individual focus include 
interventions at music festivals and large recreational 
events, which target young people who are potentially 
at high risk of experiencing problems. Examples of 
interventions here include quick scans for detecting drug 
problems, first aid and ‘bad trip’ interventions.
A set of regulatory approaches target the nightlife 
environment, and often focus on the licensing of premises 
selling alcohol and the responsible serving of alcohol. 
These interventions aim to improve the security of staff 
and visitors in nightlife settings, through the establishment 
of formal cooperation between the main stakeholders in 
party environments (local authorities, police and owners of 
premises).
Environmental approaches may include crowd 
management initiatives, access to free water and 
safe late night transport. The ‘After taxi’ project in 
Slovenia subsidises taxi transportation for young people 
16–30 years of age. Evidence suggests that this might 
help to reduce accidents, but does not reduce alcohol or 
drug-related harm (Calafat el al., 2009). Other examples 
of environmental prevention approaches in recreational 
settings include the safer nightlife quality labels promoted 
by the European project Party+ in Belgium, Denmark, 
Spain, the Netherlands, Slovenia and Sweden. Evidence 
suggests that the success of regulatory measures for 
the prevention of risk behaviour in nightlife settings will 
depend on implementation factors. It is also important for 
drug prevention interventions in pubs and clubs to target 
staff members, because of their own use of and attitude to 
drugs and alcohol.
The recently launched Healthy Nightlife Toolbox comprises 
three databases (evaluated interventions, literature 
reviews and details of experts working in this field) and 
a handbook that provides guidance for creating a healthy 
57
Chapter 4: Amphetamines, ecstasy, hallucinogens, GHB and ketamine
and safe nightlife. It emphasises that preventive measures 
in recreational settings should address alcohol and illicit 
drug use together, as they cause similar problems and are 
often used in combination. It also highlights the fact that 
preventive interventions in recreational settings can have 
beneficial effects on a range of problem behaviours and 
harms, from acute health problems linked to drug and 
alcohol use, to violence, driving under the influence and 
unprotected sex or unwanted sexual contacts.
Treatment
Problem amphetamines use
The treatment options available for amphetamines users 
in Europe differ considerably between countries. In those 
northern and central European countries with a long 
history of treating amphetamines use, some programmes 
are tailored towards the needs of amphetamines users. 
In the central and eastern European countries where 
significant problem amphetamines use is more recent, 
treatment systems are primarily geared towards problem 
opioid users, although they are increasingly addressing 
the needs of amphetamines users. In western and 
southern European countries, with low levels of problem 
amphetamines use, there is a lack of dedicated services, 
which may hinder access to treatment for amphetamine 
users (EMCDDA, 2010c).
In 2011, 12 countries reported the availability of specialist 
treatment programmes for users of amphetamines who 
actively seek treatment, an increase from eight in 2008. 
National experts from the Czech Republic, Germany, 
Lithuania, Slovakia and the United Kingdom estimated that 
programmes were available to a majority of amphetamine 
users in need of treatment, while for the other seven 
countries they were available only to a minority of them. 
Bulgaria and Hungary reported that specific treatment 
programmes for amphetamine users are planned to be 
implemented in the next three years.
Psychosocial interventions provided in outpatient 
drug services are the primary treatment options for 
amphetamines users. These include motivational 
interviewing, cognitive behavioural therapy, self-control 
training and behavioural counselling. The psychological 
approaches more frequently studied for methamphetamine 
and amphetamine dependence are cognitive behavioural 
therapy and contingency management, sometimes in 
combination (Lee and Rawson, 2008). Both of these 
approaches appear to be associated with positive 
results. The more problematic users, for example those 
whose amphetamines dependence is complicated by 
co-occurring psychiatric disorders, may receive treatment 
in inpatient drug services, psychiatric clinics or hospitals. 
In Europe, pharmaceuticals such as antidepressants, 
sedatives and antipsychotics are administered for the 
treatment of abstinence symptoms at the beginning of 
detoxification, which is usually provided at specialist 
inpatient psychiatric departments.
Longer-term treatment with antipsychotics is sometimes 
prescribed in cases of lasting psychopathologies due to 
chronic use of amphetamines. European professionals 
report that the psychological symptoms such as self-harm, 
violence, agitation and depression, which are often 
presented by problem amphetamine users, may require 
a full mental health assessment, treatment and careful 
monitoring. Such cases are often handled with close 
liaison with mental health services.
Studies on treatment of amphetamines dependence
Levels of spontaneous remission from amphetamine 
dependence, without treatment intervention, was higher 
for amphetamine users when compared with users of 
other addictive substances, with almost one in two people 
remitting during a given year (Calabria et al., 2010).
Several drugs have been studied to treat amphetamine 
and methamphetamine dependence, but robust evidence 
has yet to be provided for any pharmacological 
therapy (Karila et al., 2010). While some reduction in 
amphetamine or methamphetamine use has been reported 
for therapies based on modafinil, bupropion or naltrexone, 
further research is needed to clarify the possible role 
of these substances in the treatment of amphetamines-
dependent patients.
Dexamphetamine and methylphenidate have shown 
potential as substitution therapies for amphetamine or 
methamphetamine dependence. A pilot study suggested 
that dexamphetamine may increase treatment engagement 
in patients with amphetamine dependence (Shearer et al., 
2001), while sustained release dexamphetamine increased 
retention and obtained a lower level of methamphetamine 
dependence among patients in a recent trial (Longo et al., 
2010). A randomised study showed that methylphenidate 
can effectively reduce intravenous use in patients with 
severe amphetamine dependence (Tiihonen et al., 2007).
Gamma-hydroxybutyrate dependence and treatment
Dependence on gamma-hydroxybutyrate (GHB) is 
a recognised clinical condition, with a potentially 
severe withdrawal syndrome when the drug is abruptly 
discontinued following regular or chronic use. There 
is evidence that physical dependence may occur in 
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recreational users, and cases of withdrawal symptoms 
on cessation of use GHB and its precursors have been 
documented. GHB dependence has also been reported 
among former alcoholics (Richter et al., 2009).
To date, research has exclusively focused on the 
description of GHB withdrawal syndrome and related 
complications, which can be difficult to recognise in 
emergency cases (van Noorden et al., 2009). These 
symptoms may include tremor, anxiety, insomnia and 
agitation. Patients in withdrawal may also develop 
psychosis and delirium. Mild withdrawal can be 
managed in outpatient settings, otherwise inpatient 
supervision is recommended. As yet, no standard 
protocols have been devised for the treatment of GHB 
withdrawal syndrome.
Benzodiazepines and barbiturates are the 
pharmaceuticals most commonly used to treat GHB 
withdrawal syndrome. In the Netherlands, the controlled 
detoxification of GHB using pharmaceutical GHB in an 
adjusted dose is currently being investigated.
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Introduction
Cocaine remains the second most commonly used illicit 
drug in Europe overall, although prevalence levels and 
trends differ considerably between countries. High levels 
of cocaine use are observed only in a small number of 
mostly western European countries, while elsewhere the 
use of this drug remains limited. There is also considerable 
diversity among cocaine users, including occasional 
cocaine users, socially integrated regular users and more 
marginalised and often dependent users, who inject 
cocaine or use crack cocaine.
Supply and availability
Production and trafficking
Cultivation of coca bush, the source of cocaine, continues 
to be concentrated in three Andean countries, Colombia, 
Peru and Bolivia. The UNODC (2012) estimated for the 
year 2010 that a total of 149 000 hectares of coca bush 
were under cultivation, a 6 % decrease from the estimated 
159 000 hectares in 2009. This decrease was largely 
attributed to a reduction in the area under coca cultivation 
in Colombia, which has been partially offset by increases 
in Peru and Bolivia. The 149 000 hectares of coca 
bush translated into a potential production of between 
788 tonnes and 1 060 tonnes of pure cocaine, compared 
with an estimated 842–1 111 tonnes in 2009 (UNODC, 
2012; see also Table 7).
The conversion of coca leaves into cocaine hydrochloride 
is mainly carried out in Colombia, Peru and Bolivia, 
although it may also occur in other countries. Colombia’s 
importance in the production of cocaine is corroborated 
by information on laboratories dismantled and seizures 
of potassium permanganate, a chemical reagent 
used in the manufacture of cocaine hydrochloride. 
In 2010, 2 623 cocaine laboratories were dismantled 
(UNODC, 2012) and a total of 26 tonnes of potassium 
Chapter 5
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Table 7: Production, seizures, price and purity of cocaine and crack cocaine
Cocaine powder (hydrochloride) Crack (cocaine base) (1)
Global production estimate
(tonnes of pure cocaine)
788–1 060 n.a.
Global quantity seized
(tonnes of cocaine, purity unknown)
694 n.a.
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey)
 
61 
(61)
 
0.07 
(0.07)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
 
86 000 
(88 000)
 
7 000 
(7 000)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (2)
 
45–144 
(49.9–73.4)
 
49–58
Mean purity (%) 
Range 
(Interquartile range) (2)
 
22–55 
(27.9–45.9)
 
10–62
(1) Due to the small set of countries reporting information, data should be interpreted with caution.
(2) Range of the middle half of the reported data.
NB: All data for 2010; n.a., data not available.
Sources: UNODC (2012) for global values, Reitox national focal points for European data.
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(71) See Tables SZR-9 and SZR-10 in the 2012 statistical bulletin.
(72) For purity and price data, see Tables PPP-3 and PPP-7 in the 2012 statistical bulletin.
(73) See Figure PPP-2 in the 2012 statistical bulletin. 
(74) See Figure PPP-1 in the 2012 statistical bulletin.
permanganate (81 % of global seizures) was seized in 
Colombia (INCB, 2012a).
Cocaine consignments to Europe appear to be transited 
through most countries in South and Central America, 
though mainly through Argentina, Brazil, Ecuador, Mexico 
and Venezuela. Caribbean islands are also frequently 
used in the transhipment of the drug to Europe. In recent 
years, alternative routes through West Africa (EMCDDA 
and Europol, 2010) and South Africa (INCB, 2012b) have 
been detected.
Spain, the Netherlands, Portugal and Belgium appear 
to be the main points of entry to Europe for cocaine. 
Within Europe, reports frequently mention Germany, 
France and the United Kingdom as important transit or 
destination countries. The United Kingdom estimates that 
25–30 tonnes of cocaine are imported into the country 
each year. Recent reports also indicate that cocaine 
trafficking is expanding eastward (EMCDDA and Europol, 
2010). Cocaine is increasingly being smuggled through 
south-eastern and eastern Europe, in particular along the 
Balkan routes (INCB, 2012b) and into harbours in Latvia 
and Lithuania. In particular, unusually large quantities 
of cocaine were intercepted in 2010 in Estonia, Latvia, 
Lithuania and Turkey.
Seizures
Cocaine is the most trafficked drug in the world after 
herbal cannabis and cannabis resin. In 2010, global 
seizures of cocaine remained largely stable at about 
694 tonnes (Table 7) (UNODC, 2012). South America 
continued to report the largest amount seized, accounting 
for 52 % of the global figure, followed by North America 
with 25 %, Central America with 12 % and Europe with 
9 % (UNODC, 2012).
After increasing for 20 years, the number of cocaine 
seizures in Europe peaked at around 100 000 cases in 
2008, before declining to an estimated 88 000 in 2010. 
The total quantity of the drug intercepted peaked in 
2006, then halved to 59 tonnes in 2009, largely because 
of decreases in the amounts recovered in Spain and 
Portugal (71). Quantities of cocaine intercepted in Europe 
in 2010 slightly increased to an estimated 61 tonnes, 
mainly due to a substantial increase in seizures in Belgium 
and a halt in the downward trend reported in Portugal 
and Spain. In 2010, Spain continued to be the country 
reporting both the highest number of seizures of cocaine 
and the largest quantity of the drug seized in Europe.
Purity and price
In 2010, the mean purity of cocaine samples tested ranged 
between 27 % and 46 % in half of the reporting countries. 
The lowest values were reported in Hungary (22 %), 
Denmark and the United Kingdom (England and Wales) 
(both retail only, 24 %), and the highest ones in Belgium 
(55 %), Turkey (53 %) and the Netherlands (52 %) (72). Of 
the 23 countries that provided sufficient data for analysis 
of trends in cocaine purity over the period 2005–10, 
20 reported a decline and three observed a stable or 
increasing trend (Germany, Latvia, Portugal). Overall, 
cocaine purity declined by an estimated average of 22 % in 
the European Union in the period 2005–10 (73).
The mean retail price of cocaine ranged from EUR 49 per 
gram and EUR 74 per gram in most reporting countries in 
2010. The Netherlands and Poland reported the lowest 
mean price (EUR 45), while Luxembourg reported the 
highest (EUR 144). Of the 23 countries with sufficient data to 
make a comparison, 20 reported a stabilisation or decrease 
in cocaine retail prices between 2005 and 2010. In the 
same period, the retail price of cocaine in the European 
Union declined by an estimated average of 18 % (74).
Drug trafficking through general aviation
Trafficking of drugs by air has emerged as an important 
issue in recent years, with UNODC (2011b) reporting 
that the majority of shipments of heroin, cocaine and 
amphetamine type stimulants coming from Africa are flown 
into Europe. The Airport Group of the Council of Europe’s 
Pompidou Group was set up to develop and harmonise 
tools and systems to improve drug detection in European 
airports. With the support of the Regional Intelligence 
Liaison Offices (Western Europe) and the World Customs 
Organisation, officials from 35 countries, mainly located 
in Europe, annually review data on seizures connected 
with air transport or mail operations. In 2010, about 
15 tonnes of illicit drugs, over half of which was cocaine, 
was intercepted at airports and mail centres by customs 
agencies in the participating countries.
General aviation, the non-commercial use of medium-sized 
and light aircraft, usually flown from small airfields, has 
been identified as an important issue, as it may be used 
by criminal organisations for trafficking drugs. In order to 
harmonise approaches, the Airport Group published in 
2003 a handbook on organising and carrying out checks 
on general aviation. In response to the Council of the EU 
Conclusions of 2010 encouraging Member States to focus 
on this risk, the Airport Group also formed a working 
party that has developed 20 key risk indicators of drug 
trafficking by general aviation.
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(75) See Figure GPS-13 in the 2012 statistical bulletin.
(76) See Table GPS-5 (part iii) and (part iv) in the 2012 statistical bulletin.
Prevalence and patterns of use
In some European countries, a substantial number of 
people use cocaine experimentally, only once or twice 
(Van der Poel et al., 2009). Among more regular cocaine 
users, two broad groups can be distinguished. The first 
group is made up of socially integrated users, who tend 
to use cocaine at weekends, parties or other special 
occasions, sometimes in large amounts. Many of these 
users report controlling their cocaine use by setting rules, 
for example, about the amount, frequency or context of 
use. The second group is composed of intensive cocaine 
and crack users belonging to more socially marginalised 
or disadvantaged groups, including former or current 
opioid users, who use crack or inject cocaine.
Cocaine use among the general population
Over the last 10 years, cocaine has established itself as 
the most commonly used illicit stimulant drug in Europe, 
although most users are found in a small number of 
high-prevalence countries, some of which have large 
populations. It is estimated that about 15.5 million 
Europeans have used cocaine at least once in their life; 
on average, 4.6 % of adults aged 15–64 (see Table 8 for 
a summary of the data). National figures vary from 0.3 % 
to 10.2 %, with half of the 24 reporting countries, 
including most central and eastern European countries, 
reporting low levels of lifetime prevalence (0.5–2.5 %).
About 4 million Europeans are estimated to have used the 
drug in the last year (1.2 % on average). Recent national 
surveys report last year prevalence estimates of between 
0.1 % and 2.7 %. The prevalence estimate for last month 
cocaine use in Europe represents about 0.5 % of the adult 
population or about 1.5 million individuals.
Levels of last year cocaine use above the European 
average are reported by Ireland, Spain, Italy and the 
United Kingdom. In all of these countries, last year 
prevalence data show that cocaine is the most commonly 
used illicit stimulant drug.
Cocaine use among young adults
In Europe, it is estimated that about 8 million young adults 
(15–34), or an average of 6.3 %, have used cocaine 
at least once in their life. National figures vary from 
0.7 % to 13.6 %. The European average for last year 
use of cocaine among this age group is estimated at 
2.1 % (about 3 million) and for last month use at 0.8 % 
(1 million).
Use is particularly high among young males (15–34), with 
last year prevalence of cocaine use reported at between 
4 % and 6.5 % in Denmark, Ireland, Spain, Italy and the 
United Kingdom (75). In 16 of the reporting countries, the 
male to female ratio for last year prevalence of cocaine 
use among young adults is at least two to one (76).
Targeted surveys highlight the elevated levels of cocaine 
use among regular attendees in clubs and other 
recreational settings. For example, a 2010 city level 
study of visitors to pubs in Amsterdam reported last year 
cocaine use prevalence of 24 %. In the Czech Republic, 
of the more than 1 000 respondents to a 2010 online 
questionnaire promoted by electronic dance music media, 
29 % reported having used cocaine in the last 12 months. 
An online survey carried out in 2011 reported that 42 % 
Wastewater analysis: a 19-city study
Sewage epidemiology or wastewater analysis is a rapidly 
developing scientific discipline with potential for monitoring 
population level trends in illicit drug consumption. By 
sampling a source of wastewater (e.g. a sewage influent to 
a wastewater treatment plant), scientists can estimate the total 
quantity of drugs consumed by a community by measuring 
the levels of illicit drug metabolites excreted in urine.
In March 2011, a European pilot study collected and 
analysed wastewater samples from 19 cities in 12 European 
countries (1), representing a combined population of 
approximately 15 million Europeans (Thomas et al., in press).
The use of cocaine was assessed by measuring the 
concentration of the cocaine metabolite benzoylecgonine 
in the wastewater. The results varied widely between cities 
and countries, with the highest levels being for cities in 
Belgium and the Netherlands, where cocaine consumption 
in the community was estimated at 500–2 000 mg per 
1 000 population per day. The lowest estimates were 
for cities in northern and eastern European countries 
(2–146 mg per 1 000 population per day). In most cities, 
levels of cocaine use increased during the weekend, 
reflecting the recreational use of this drug.
The results of wastewater studies need to be interpreted 
cautiously. Findings from a city-specific snapshot cannot 
be extrapolated to represent national consumption 
levels. In addition, results from different cities may not 
always be comparable, due to sampling differences 
and uncertainties associated to the reliability of inter-
laboratory measurements. However, while such methods 
do not provide the detailed prevalence data yielded by 
drug surveys (e.g. lifetime, recent, current use), their ability 
to provide objective and timely estimates of illicit drug 
consumption in a targeted population make them a useful 
complement to existing monitoring tools.
(1) For more information see the EMCDDA website.
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(77) Heavy episodic drinking, also known as binge drinking, is here defined as drinking six glasses or more of an alcoholic beverage on the same 
occasion at least once a week during the past year.
(78) See Table EYE-11 in the 2012 statistical bulletin.
of the more than 7 000 UK respondents had used cocaine 
during the last year (Mixmag, 2012).
In recreational settings, cocaine use is strongly linked with 
the consumption of alcohol and other illicit drugs. Data 
from general population surveys in nine countries have 
revealed prevalence levels of cocaine use among heavy 
episodic drinkers (77) that are two to nine times those of 
the general population (EMCDDA, 2009b). The British 
Crime Survey (2010/11) reported that adults who drank 
alcohol regularly were more likely to find it acceptable to 
take cocaine than adults who drank less often or not at all; 
in addition, an association between increasing frequency 
of visits to a nightclub or pub and increasing levels of 
cocaine use was identified.
International comparisons
Compared with some other parts of the world for which 
reliable data exist, the estimated last year prevalence 
of cocaine use among young adults in Europe (2.1 %) is 
below the levels reported for young adults in Australia 
(4.8 %) and the United States (4.0 % among 16- to 
34-year-olds), but close to that reported for Canada 
(1.8 %). Two European countries, Spain (4.4 %) and the 
United Kingdom (4.2 %), report figures similar to those of 
Australia and the United States (Figure 9).
Cocaine use among school students
Lifetime prevalence of cocaine use among 15- to 16-year-
old school students in the most recent ESPAD school survey 
is between 1 % and 2 % in 13 of the 24 participating EU 
Member States, Croatia and Norway. All except one of 
the other 12 countries report prevalence levels of between 
3 % and 4 %, while both the United Kingdom ESPAD and 
English national school survey report 5 % (78). The Spanish 
national school survey reports 3 %. For comparison, 
lifetime use of the drug among school students of a similar 
Table 8: Prevalence of cocaine use in the general population — summary of the data
Age group Time frame of use
Lifetime Last year Last month
15–64 years
Estimated number of users in Europe 15.5 million 4 million 1.5 million
European average 4.6 % 1.2 % 0.5 %
Range 0.3–10.2 % 0.1–2.7 % 0.0–1.3 %
Lowest-prevalence countries Romania (0.3 %)
Lithuania (0.5 %)
Greece (0.7 %)
Poland (0.8 %)
Greece, Romania (0.1 %)
Hungary, Lithuania, Poland,  
Finland (0.2 %)
Czech Republic (0.3 %)
Greece, Romania, Finland (0.0 %)
Czech Republic, Estonia,  
Lithuania, Poland, Sweden (0.1 %)
Highest-prevalence countries Spain (10.2 %)
United Kingdom (8.9 %)
Italy (7.0 %)
Ireland (6.8 %)
Spain (2.7 %)
United Kingdom (2.2 %)
Italy (2.1 %)
Ireland (1.5 %)
Spain (1.3 %)
United Kingdom (0.8 %)
Italy, Cyprus (0.7 %)
Austria (0.6 %) 
15–34 years
Estimated number of users in Europe 8 million 3 million 1 million
European average 6.3 % 2.1 % 0.8 %
Range 0.7–13.6 % 0.2–4.4 % 0.0–2.0 %
Lowest-prevalence countries Lithuania, Romania (0.7 %)
Greece (1.0 %)
Poland (1.3 %)
Czech Republic (1.6 %)
Greece, Romania (0.2 %)
Lithuania, Poland (0.3 %)
Hungary (0.4 %)
Czech Republic (0.5 %)
Romania, Finland (0.0 %)
Greece, Lithuania, Poland,  
Norway (0.1 %)
Czech Republic, Estonia,  
Hungary (0.2 %)
Highest-prevalence countries Spain (13.6 %)
United Kingdom (12.8 %)
Ireland (9.4 %)
Denmark (8.9 %)
Spain (4.4 %)
United Kingdom (4.2 %)
Italy (2.9 %)
Ireland (2.8 %)
Spain (2.0 %)
United Kingdom (1.6 %)
Cyprus (1.3 %)
Italy (1.1 %)
NB: European estimates are computed from national prevalence estimates weighted by the population of the relevant age group in each country. To obtain estimates of the 
overall number of users in Europe, the EU average is applied for countries lacking prevalence data (representing not more than 3 % of the target population for lifetime 
and last year estimates, but 18 % for the last month estimate). Populations used as basis: 15–64, 338 million; 15–34, 130 million. As European estimates are based 
on surveys conducted between 2004 and 2010/11 (mainly 2008–10), they do not refer to a single year. The data summarised here are available under ‘General 
population surveys’ in the 2012 statistical bulletin.
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(79) See Tables EYE-10 to EYE-30 in the 2012 statistical bulletin.
(80) See Table GPS-2 in the 2012 statistical bulletin.
(81) See Figure GPS-14 (part i) in the 2012 statistical bulletin.
age in the United States is estimated at 3 %. Where data 
are available for older school students (17–18), lifetime 
prevalence of cocaine use is generally higher, rising 
to 7 % in Spain (79).
Trends in cocaine use
For more than a decade, reports showed increasing trends 
in cocaine use for the small number of European countries 
with the highest prevalence levels, before reaching a peak 
in 2008/09. Recent surveys of cocaine use reveal some 
positive signs in these countries, and raise the possibility 
that the drug’s popularity is declining. Qualitative studies 
carried out in recreational settings also suggest there may 
be some shift in the image of cocaine away from that of 
a high-status drug (in Denmark and the Netherlands).
Seven countries report last year cocaine prevalence 
among young adults (15–34) above the EU average 
of 2.1 % (80). In their most recent surveys, Denmark, 
Ireland, Spain, Italy and the United Kingdom all observed 
a decline or stabilisation in last year cocaine use among 
young adults, echoing the trend observed in Canada and 
the United States, but not Australia, where an increase 
is reported (Figure 10). Among the other two highest-
prevalence countries, Cyprus reported an increase in 
their most recent survey, from 0.7 % in 2006 to 2.2 % in 
2009; while the Netherlands reported last year cocaine 
prevalence among young adults at 2.4 % in 2009, 
because of changes in methodology, comparison with 
earlier surveys is not appropriate.
Cocaine use is relatively low and, in most cases, stable 
in 12 other countries with three repeated surveys. 
Possible exceptions to this include Bulgaria, France and 
Sweden, which have reported signs of an increase, and 
Norway, where the trend appears to be downward. 
It should be borne in mind, however, that small changes 
at low prevalence must be interpreted with caution. 
In Bulgaria, last year use of cocaine among young adults 
rose from 0.7 % in 2005 to 1.5 % in 2008; in France 
from 1.2 % in 2005 to 1.9 % in 2010; and in Sweden 
from zero in 2000 to 1.2 % in 2008 (81). Norway reported 
a decrease from 1.8 % in 2004 to 0.8 % in 2009.
Figure 9: Last year and lifetime prevalence of cocaine use among 
young adults (15–34) in the European Union, Australia, Canada 
and the United States
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estimates weighted by the population of the relevant age group 
in each country. As European estimates are based on surveys 
conducted between 2004 and 2010/11 (mainly 2008–10), 
they do not refer to a single year. The surveys in non-European 
countries were conducted in 2010. The age range of the US 
survey is 16 to 34 years (recalculated from original data).
Sources: Reitox national focal points, AIHW (2011), CADUMS (2010), 
SAMHSA (2010).
Figure 10: Trends in last year prevalence of cocaine use among 
young adults (15–34) in the five EU Member States with the 
highest figures, Australia, Canada and the United States
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NB: See Figure  GPS-14 (part ii) in the 2012 statistical bulletin for 
further information. The age ranges for non-European surveys 
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Sources: Reitox national focal points, AIHW (2011), CADUMS (2010), 
SAMHSA (2010).
65
Chapter 5: Cocaine and crack cocaine
(82) Defined as those who were over the age of 20 and had used cocaine on at least 30 days in the last year or at least 10 days in the last month, or 
those who were under 20 and had used cocaine 10 or more days in the last year and at least one day in the last month.
(83) Defined as those who used the drug more than once a week.
Of the 23 countries that participated in the 2011 round 
and either the 1995 or 1999 round of ESPAD, 18 saw an 
increase in lifetime prevalence of cocaine use of between 
one and three percentage points, whereas none showed 
a decrease. Although the prevalence levels remain low 
overall, the general increase across countries requires 
continued vigilance.
Health consequences of cocaine use
The health consequences of cocaine use are likely to be 
underestimated; this may be due to the often unspecific 
or chronic nature of the pathologies typically arising 
from long-term use of cocaine (see Chapter 7). Regular 
use, including by snorting, can be associated with 
cardiovascular, neurological and psychiatric problems, 
and with the risk of accidents and the transmission of 
infectious diseases through unprotected sex (Brugal et 
al., 2009), and possibly through the sharing of straws 
(Aaron et al., 2008). Studies in countries with high 
levels of use indicate that a considerable proportion of 
cardiac problems in young people could be related to 
cocaine use.
Cocaine injection and crack use are associated with 
the highest health risks among cocaine users, including 
cardiovascular and mental health problems (EMCDDA, 
2007a). When compared with the wider population of 
cocaine users, recent hospital emergency data from Spain 
shows an over-representation of users who either inject or 
smoke the drug.
Problem use
The more harmful forms of cocaine use include regular 
or long-term use of the drug or its use by injection. As 
there are no recent indirect national estimates of problem 
cocaine use for any European country, the main sources 
of information available on the extent of the more harmful 
forms of cocaine use are general population surveys, data 
on drug users entering treatment and studies on crack 
cocaine use.
A number of countries have collected data on intensive 
use of cocaine in general population surveys. While 
such surveys tend to miss marginalised users, they do 
have the potential to reach socially integrated intensive 
cocaine users. A 2009 Spanish general population 
survey, using frequency of use measures, estimated over 
140 500 intensive users of cocaine (82), or around 4.5 
cases per 1 000 population aged 15–64. A city-level 
study in Oslo, Norway, also based on a frequency of 
use measure in a set of surveys (among the general 
population, prison inmates and injecting drug users), 
identified 1 600–2 000 problem users of cocaine (83), or 
four per 1 000 population aged 15–64. In Germany, the 
prevalence of cocaine-related problems was estimated 
at around two cases per 1 000 population aged 15–64, 
using the Severity of Dependence Scale.
Crack use is unusual among socially integrated 
cocaine users, and occurs mainly among marginalised 
and disadvantaged groups such as sex workers and 
problem opioid users. In Europe, it is largely an urban 
phenomenon (Connolly et al., 2008; Prinzleve et al., 
2004), with signs of very low overall prevalence. 
In London, crack use is considered to be a major 
component of the city’s drugs problem. Regional crack 
cocaine estimates are only available for England, 
where there were an estimated 184 000 problem crack 
cocaine users in 2009/10, which corresponds to 5.4 
(5.2–5.7) cases per 1 000 population aged 15–64. 
A majority of these crack users were also reported to be 
opioid users.
Cocaine-related emergencies: potential for early 
intervention?
A recent European review identified a threefold increase 
in cocaine-related hospital emergencies in some countries 
since the end of the 1990s, with a peak around 2008 in 
Spain and the United Kingdom (Mena et al., 2012). This 
corresponds with trends in prevalence of use in the general 
population, and with reports of cocaine-related deaths. 
Five of the six countries that reported the highest numbers 
of hospital emergencies related to cocaine in 2008–10 
(Denmark, Ireland, Spain, Netherlands, United Kingdom) 
also report a prevalence of cocaine use above the 
European average. Also consistent with prevalence data 
is the fact that most cocaine-related emergencies were 
among young adults, and two thirds were males.
Some European countries now monitor cocaine-related 
harm using data from admissions to hospital emergency 
departments and patient hospitalisations. Case data may 
also come from toxicology departments, services providing 
first aid to drug users, calls to poison centres or police drug 
squad records. Spain and the Netherlands, in particular, 
provide relatively robust data. Other countries often rely on 
sentinel systems based on a selection of hospitals.
Although heterogeneous, European hospital emergency 
data provide a useful indicator of trends, and also 
highlight an area with largely unexplored potential: that of 
assessment, early intervention and referral of thousands of 
cocaine-using patients every year.
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(84) See Tables TDI-5 (part i) and (part ii) and TDI-24 in the 2012 statistical bulletin; data for Spain refer to 2009.
(85) See Figures TDI-1 and TDI-3 in the 2012 statistical bulletin.
(86) See Tables TDI-4 (part ii), TDI-10 (part iii), TDI-11 (part iii) and TDI-18 (part ii) in the 2012 statistical bulletin.
(87) See Tables TDI-17 and TDI-18 (part ii) in the 2012 statistical bulletin.
(88) See Table TDI-115 in the 2012 statistical bulletin.
Treatment demand
Further insights into the more problematic forms of 
cocaine use may be gained from data on the number and 
characteristics of people entering treatment due to cocaine 
use. Nearly all reported cocaine clients are treated in 
outpatient centres, although some might be treated in 
private clinics for which data are not available. Many 
problematic cocaine users, however, do not seek treatment 
(Reynaud-Maurupt and Hoareau, 2010).
Cocaine was cited as the principal reason for entering 
treatment by 15 % of all reported drug users entering 
treatment in 2010. Among those entering treatment for the 
first time in their life, the proportion of primary cocaine 
users was higher (21 %).
Wide differences exist between countries in the 
proportion and number of cocaine clients, with the highest 
proportions reported by Spain (44 %), Italy (29 %) and the 
Netherlands (26 %). Cocaine clients represent between 
10 % and 15 % of all drug clients in Belgium, Ireland, 
Cyprus, Luxembourg, Malta, Portugal and the United 
Kingdom. Elsewhere in Europe, cocaine accounts for less 
than 10 % of drug treatment entrants, with seven countries 
reporting that less than 1 % of all treatment entrants 
identify it as their primary drug. Overall, five countries 
(Germany, Spain, Italy, Netherlands, United Kingdom) 
account for about 90 % of all cocaine clients reported by 
29 European countries (84).
Based on 25 countries that have provided data over 
the period 2005–10, the trend in the reported number 
of clients entering treatment for primary cocaine use 
increased until 2008 (from 55 000 to 71 000 clients), 
stabilised in 2009 (70 000) and slightly decreased 
in 2010 (67 000) (85). The number of cocaine clients 
declined in 13 countries between 2007–08 and 2010, 
with some countries (Spain, Netherlands, Portugal, United 
Kingdom) reporting a reduction of up to 40 % in the 
number entering treatment for the first time in their life. 
In the Netherlands, the number of new cocaine clients 
decreased between 2009 and 2010, while the number of 
cocaine clients readmitted to treatment, especially those 
mentioning opioids as a secondary drug, is reported to be 
stable (Ouwehand et al., 2011).
Profile of outpatient treatment clients
Clients entering outpatient treatment for primary use of 
cocaine present a high male to female ratio (about five 
males to every female), and one of the highest mean 
ages (33) among drug treatment clients. Primary users of 
cocaine report their first cocaine use at a mean age of 22, 
with 87 % starting before the age of 30 (86).
Most cocaine clients report snorting (65 %) or smoking 
(27 %) the drug as their main route of administration, and 
only 6 % report primarily injecting the drug. Almost half of 
cocaine clients have used the drug up to six times a week 
in the month before entering treatment, about a quarter 
have used it daily, and a quarter have not used it or have 
used it only occasionally during that period (87).
Cocaine is often used in combination with other drugs, 
especially alcohol, cannabis, other stimulants and heroin. 
A Dutch analysis carried out in 2011 reported that most 
cocaine clients use cocaine together with other substances 
(64 %), most commonly alcohol (Ouwehand et al., 2011).
A subgroup of cocaine users entering outpatient 
treatment in Europe are the 7 500 primary users of crack 
cocaine (88); they represent 13 % of all cocaine clients 
and less than 2 % of all drug clients entering outpatient 
centres. Most crack cocaine clients (about 5 000) entered 
treatment in the United Kingdom: they accounted for 
36 % of the country’s primary cocaine clients and 4 % 
of all drug outpatient clients. The remaining 2 000 crack 
cocaine clients are reported mainly by France and the 
Netherlands, where they represent 23 % and 30 % of 
cocaine clients, respectively, and by Spain and Italy 
(3 % and 1 % of cocaine clients). Crack cocaine clients 
also often use the drug together with other substances, 
including injected heroin (EMCDDA, 2007a; Escot and 
Suderie, 2009).
Treatment and harm reduction
Historically, treatment for drug use problems in Europe has 
focused on opioid dependence. However, with growing 
public health concern about cocaine and crack cocaine 
use, many countries are paying more attention to problems 
related to these drugs. The primary treatment options 
for cocaine dependence are psychosocial interventions, 
including motivational interviewing, cognitive behavioural 
therapies, behavioural self-control training, relapse 
prevention interventions and counselling.
Eleven Member States, including all those with high levels 
of cocaine use and treatment entry, report that, alongside 
general treatment services, specific treatment programmes 
are available for cocaine or crack cocaine users. 
However, while national experts from Germany, Italy, 
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Lithuania and the United Kingdom estimated that these 
specific programmes were available to the majority of 
cocaine users in need of treatment, experts from Belgium, 
Denmark, Ireland, Spain, Austria, Romania and Slovenia 
estimated that they were available only to a minority.
Some countries report tailoring their cocaine treatment 
responses to the needs of particular client groups; in 
the United Kingdom, for example, specialist treatment 
agencies prioritise treatment services for problem drug 
users, including crack cocaine users. Both Denmark and 
Austria report providing treatment for cocaine users within 
a polydrug use programme. In Denmark, a treatment 
model for cocaine, cannabis and alcohol problems has 
been piloted. Clinical guidelines are to be developed and 
the model will be rolled out in a number of municipalities 
during the next four years, with a budget of around 
EUR 1 million. In addition, Bulgaria, Malta and the 
Netherlands report that specific treatment programmes for 
cocaine users are planned for the next three years.
Studies on treatment of cocaine dependence
The EMCDDA and the Cochrane Group on Drugs and 
Alcohol recently published an overview of reviews of 
the pharmacological treatment of cocaine dependence 
(Amato et al., in press). This analysed the acceptability, 
efficacy and safety of psychostimulants, anticonvulsants, 
antipsychotics, dopamine agonists and disulfiram to treat 
cocaine dependence. Most of these substances have the 
potential to block or reduce the reward effect of cocaine 
in the brain. In addition, antipsychotics may alleviate 
cocaine-induced psychosis-like symptoms. These studies 
are not directly comparable, as they have different aims 
and outcome measures, ranging from reduction of use, 
reduction or treatment of withdrawal symptoms, and 
identification of substitution treatments.
The review of studies on psychostimulants identified 
some positive results for helping cocaine users achieve 
abstinence. In particular, results for treatment of 
opioid-cocaine codependent patients with bupropion 
and dexamphetamine were promising. However, 
psychostimulants were not found to be effective for 
substitution therapy. The evaluations of antipsychotic 
and anticonvulsant drugs for cocaine dependent patients 
were inconclusive. The current evidence does not support 
the use of dopamine agonists for treating cocaine 
dependence. While disulfiram showed positive results for 
retaining patients in treatment, any benefits appear to 
be outweighed by the substance’s potential for harmful 
side-effects.
Among the non-pharmacological interventions for treating 
cocaine dependency, contingency management continues 
to be the psychosocial intervention with the highest 
efficacy (Vocci and Montoya, 2009). A recent Belgian 
study reported that after six months of participation in 
a contingency management programme with community 
reinforcement, the rate of abstinence among cocaine 
users was three times higher than for clients in standard 
treatment (Vanderplasschen et al., 2011).
Harm reduction
Harm-reduction interventions aimed at more socially 
integrated cocaine users, mostly powder cocaine 
users, can be implemented through specific outreach 
programmes in nightlife settings. Two examples are the 
recent ‘Know the score’ cocaine awareness campaign in 
Scotland and the Belgian Partywise campaign ‘How is 
your friend on coke?’ These campaigns are oriented 
towards raising awareness and providing information 
(see Chapter 4 for more on interventions in recreational 
settings).
Interventions aimed at reducing the harms caused by 
problem cocaine and crack cocaine use are a new area 
of work in many Member States. Generally, the services 
and facilities provided for cocaine injectors have been 
developed to serve the needs of opioid users. Cocaine 
Vaccines against illicit drugs
Animal research on anti-drug vaccines dates back to 
1972 (Berkowitz and Spector), but interest in developing 
a pharmacological response to cocaine addiction has 
recently brought the topic to centre stage. Anti-drug 
vaccines work by inducing the production of antibodies 
in the bloodstream and, when successful, can reduce the 
psychoactive effects of drugs and inhibit craving  
(Fox et al., 1996). 
Currently, anti-drug vaccines are being studied for cocaine, 
nicotine, methamphetamine and heroin (Shen et al., 2011). 
The most advanced vaccines address cocaine and nicotine 
dependence, and have proved to be effective in helping 
patients to remain abstinent. The main limitation observed 
is that the antibody response in the majority of patients is 
low (Hatsukami et al., 2005; Martell et al., 2005). Studies, 
however, are being carried out to improve this, and 
commercial products could be available soon, at least for 
nicotine (Polosa and Benowitz, 2011). Research on anti-
methamphetamine vaccines is still in the preclinical phase, 
where it is focused on antibody characterisation. Anti-
opioid vaccines have been developed that are effective 
in rats, and studies are now concentrating on strategies 
to reduce the number of applications needed to maintain 
blood antibody concentration (Stowe et al., 2012).
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injecting, however, is associated with specific risks. In 
particular, it involves a potentially higher frequency of 
injecting, chaotic injecting behaviour and increased sexual 
risk behaviours. Safer-use recommendations need to be 
tailored to the needs of this group. Due to the potential 
high frequency of injecting, the supply of sterile equipment 
to injectors should not be restricted, but rather based on 
local assessment of cocaine use patterns and the social 
situation of injectors (Des Jarlais et al., 2009).
Provision of specific harm-reduction programmes for 
crack cocaine smokers in Europe is limited. Some drug 
consumption facilities in three countries (Germany, Spain, 
Netherlands) provide facilities for inhalation of drugs, 
including crack cocaine. Hygienic inhalation devices 
including clean crack pipes or ‘crack kits’ (glass stem with 
mouth piece, metal screen, lip balm and hand wipes) 
are reported to be sporadically provided to drug users 
who are smoking crack cocaine by some low-threshold 
facilities in Belgium, Germany, Spain, France, Luxembourg 
and the Netherlands. Foil is also made available to 
heroin or cocaine smokers at some low-threshold facilities 
in 13 EU Member States. In the United Kingdom, the 
Advisory Council on the Misuse of Drugs recently 
reviewed the use of foil as a harm-reduction intervention, 
finding evidence that its provision may promote smoking 
over injecting use (ACMD, 2010).
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Introduction
Heroin use, particularly injecting the drug, has been 
closely associated with public health and social problems 
in Europe since the 1970s. Today, this drug still accounts 
for the greatest share of morbidity and mortality related 
to drug use in the European Union. After two decades of 
mostly increasing heroin problems, Europe saw a decline 
in heroin use and associated harms during the late 1990s 
and the early years of the present century. Over the last 
decade, however, the trend has become less clear. The 
picture is still a mixed one, but increasingly it has been 
noted that, in parts of Europe, new recruitment into heroin 
use has fallen, the availability of the drug has declined 
and, recently, some counties have experienced acute 
shortages. This has been accompanied by reports of 
heroin being replaced by other drugs, including synthetic 
opioids, such as fentanyl, but also the injection of stimulant 
drugs, including amphetamine, methamphetamine and 
synthetic cathinones. Any increase in the injection of 
stimulant drugs brings with it concerns about an increase 
in health risks.
Supply and availability
Two forms of imported heroin have historically been 
available in Europe: the more common of these is brown 
heroin (its chemical base form), originating mainly 
from Afghanistan. Less common is white heroin (a salt 
form), which traditionally came from south-east Asia. 
Although white heroin has become rare, some countries 
have recently reported white crystalline heroin products 
probably originating from south-west Asia. Some limited 
production of opioid drugs also still takes place in Europe, 
principally home-made poppy products (e.g. poppy straw, 
concentrate from crushed poppy stalks or heads) reported 
in Estonia, Lithuania and Poland.
Production and trafficking
As well as accounting for most of Europe’s heroin supply, 
Afghanistan remains the principal global source for this 
drug. Other producing countries include Myanmar, which 
mainly supplies markets in east and south-east Asia, Laos 
and Pakistan, followed by Mexico and Colombia, which 
are considered the largest suppliers of heroin to the United 
States (UNODC, 2012). Potential global opium production 
is estimated to have increased from 4 700 tonnes in 2010 
to 7 000 tonnes in 2011, reaching levels comparable to 
those of previous years. Much of this increase is due to 
a recovery in potential opium production in Afghanistan, 
which has risen from 3 600 tonnes in 2010 to 5 800 tonnes 
in 2011 (UNODC, 2012). The most recent estimate of global 
potential heroin production is 467 tonnes (see Table 9), up 
from an estimated 384 tonnes in 2010 (UNODC, 2012).
Heroin arrives in Europe mainly by two trafficking routes, 
although there is increasing diversity in the methods 
and routes used for smuggling the drug. The historically 
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Table 9: Production, seizures, price and purity of 
heroin
Production and seizures Heroin
Global production estimate (tonnes) 467
Global quantity seized (tonnes) 81
Quantity seized (tonnes) 
EU and Norway  
(Including Croatia and Turkey)
 
6 
(19)
Number of seizures 
EU and Norway  
(Including Croatia and Turkey)
 
50 000 
(55 000)
Price and purity in Europe (1) Heroin base (brown)
Mean retail price (EUR per gram) 
Range 
(Interquartile range) (2)
 
23–160 
(24.6–73.6)
Mean purity (%) 
Range 
(Interquartile range) (2)
 
13–57 
(17.7–28.0)
(1) Since few countries report the retail price and the purity of heroin 
hydrochloride (white), the data are not presented here. They can be 
consulted in Tables  PPP-2 and PPP-6 in the 2012 statistical bulletin.
(2) Range of the middle half of the reported data.
NB: Data are for 2010, except the global production estimate (2011).
Sources: UNODC (2012) for global values, Reitox national focal points for 
European data.
71
Chapter 6: Opioid use and drug injection
(89) See Tables SZR-7 and SZR-8 in the 2012 statistical bulletin.
(90) See Tables PPP-2 and PPP-6 in the 2012 statistical bulletin for purity and price data.
important Balkan route brings heroin produced in 
Afghanistan through Pakistan, Iran and Turkey, and then 
towards other transit or destination countries, mainly in 
western and southern Europe. Heroin is also trafficked 
via the Silk Route through Central Asia and towards 
Russia. Some of this heroin is then smuggled through 
Belarus, Poland and Ukraine to destinations such as the 
Scandinavian countries. Africa appears to be becoming 
more important, and is now the main transit area for 
smuggling heroin into Europe by air (INCB, 2012b). 
Within the European Union, the Netherlands, and to 
a lesser extent Belgium, are secondary distribution hubs.
Seizures
Worldwide reported seizures of opium decreased 
from 653 tonnes in 2009 to 492 tonnes in 2010. Iran 
accounted for about 80 % of the total and Afghanistan for 
nearly 12 %. In 2010, global reported seizures of heroin 
(81 tonnes) and morphine (19 tonnes) increased, each by 
5 tonnes (UNODC, 2012).
In Europe, an estimated 55 000 seizures resulted in 
the interception of 19 tonnes of heroin in 2010, two 
thirds of which (12.7 tonnes) was reported by Turkey. 
The United Kingdom (followed by Spain) continued to 
report the highest number of seizures (89). Data for the 
years 2005–10 from 28 reporting countries show an 
overall increase in the number of seizures, although 
there was a slight decrease in 2010. Between 2005 
and 2010, quantities seized in the European Union have 
been fluctuating, with a marked decrease reported in 
2010, mainly due to the decline in amounts intercepted in 
Bulgaria and the United Kingdom. Turkey also reported 
a substantial decline in the amount recovered in 2010; 
this needs to be understood in the context of earlier 
interdiction activities which appear to have disrupted the 
heroin market in parts of Europe.
Global seizures of acetic anhydride used in the 
manufacture of heroin increased from about 21 000 litres 
in 2009 to 59 700 litres in 2010. Figures for the European 
Union have varied greatly in recent years: from a peak 
of about 151 000 litres in 2008 to 912 litres in 2009; 
a single seizure of about 21 100 litres in Bulgaria 
accounted for almost all of the 21 200 litres seized 
in 2010 (INCB, 2012a).
Over the last decade, Estonia has reported that heroin 
has largely been replaced by fentanyl on the illicit 
market. More recently, Slovakia has reported a similar 
phenomenon, although the number of seizures and 
quantities seized remain small. In 2010, Slovakia reported 
17 fentanyl seizures; in Estonia, half a kilogram of this 
synthetic opioid was seized.
Purity and price
The mean purity of brown heroin tested in 2010 ranged 
between 17 % and 28 % for most reporting countries; lower 
mean values were reported in France (13 %) and Austria 
(retail only, 13 %) with higher values in Malta (30 %), Spain 
(32 %) and Turkey (57 %). Between 2005 and 2010, the 
purity of brown heroin increased in four countries, remained 
stable in four others and decreased in two. The mean purity 
of white heroin was generally higher (25–45 %) in the five 
European countries reporting data (90).
The retail price of brown heroin continued to be 
considerably higher in the Nordic countries than in the 
rest of Europe, with Sweden reporting a mean price 
of EUR 160 per gram (resulting from a sharp increase 
in 2010) and Denmark, EUR 83 per gram in 2010. Overall, 
it ranged from EUR 24 per gram to EUR 74 per gram in 
half of the reporting countries. Over the period 2005–10, 
the retail price of brown heroin decreased in 10 of the 
14 European countries reporting time trends. The mean 
price of white heroin was generally higher (EUR 61–251 
per gram) in the three European countries reporting data.
Problem drug use
Problem drug use is defined by the EMCDDA as ‘injecting 
drug use or long duration or regular use of opioids, 
cocaine or amphetamines’. Injecting drug use and the use 
of opioids form the greater part of problem drug use in 
Europe although, in a few countries, users of amphetamines 
or cocaine are important components. Problem drug users 
are mostly polydrug users, and prevalence figures are much 
higher in urban areas and among marginalised groups. 
Given the relatively low prevalence and the hidden nature of 
problem drug use, statistical extrapolations are required to 
obtain prevalence estimates from the available data sources 
(mainly drug treatment data and law enforcement data).
Problem opioid use
Most European countries are now able to provide 
prevalence estimates of problem opioid use. Recent 
national estimates vary between less than one and seven 
cases per 1 000 population aged 15–64 (Figure 11). The 
highest estimates of problem opioid use are reported by 
Ireland, Latvia, Luxembourg and Malta, and the lowest by 
Cyprus, Hungary, Poland and Finland. Turkey reports less 
than one case per 1 000 population aged 15–64.
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(91) Reported estimates from 18 countries result in an average rate of 3.1 (3.0–3.2) cases per 1 000 population aged 15–64. Incorporating weighted 
estimates of problem drug use from a further eight countries increases the average rate to 4.2 (3.9–4.4), which has been applied to the 2010 
population of the European Union and Norway.
(92) See Tables TDI-5 and TDI-22 in the 2012 statistical bulletin.
(93) See Table TDI-113 in the 2012 statistical bulletin.
(94) See Tables TDI-10, TDI-21, TDI-32 and TDI-103 in the 2012 statistical bulletin.
The average prevalence of problem opioid use in the 
European Union and Norway, computed from national 
studies, is estimated to be 4.2 (between 3.9 and 4.4) 
cases per 1 000 population aged 15–64. This 
corresponds to some 1.4 million problem opioid users in 
the European Union and Norway in 2010 (91).
By comparison, estimates for Europe’s neighbouring 
countries are high, with Russia at 16.4 problem opioid 
users per 1 000 population aged 15–64 (UNODC, 
2011b), and Ukraine at 10–13 per 1 000 population 
aged 15–64 (UNODC, 2010). Both Australia and 
the United States report higher estimates of problem 
opioid use, 6.3 and 5.8 cases per 1 000 population 
aged 15–64, while the equivalent figure for Canada is 
3.0 cases. Comparisons between countries should be 
made with caution, as definitions of the target population 
may vary. For example, if non-medical use of prescription 
opioids was added, the prevalence figure would rise 
to 39–44 per 1 000 North Americans aged 15–64 
(UNODC, 2011b).
Opioid users entering treatment
Opioids, mainly heroin, were cited as the primary drug 
by more than 200 000 clients reported entering specialist 
drug treatment in 29 European countries in 2010, or 48 % 
of all reported treatment entrants. However, considerable 
differences exist across Europe, with opioid clients 
accounting for more than 70 % of those entering treatment 
in seven countries, between 40 % and 70 % in 12, and 
less than 40 % in 10 countries (Figure 12). Almost 80 % 
of all opioid users entering drug treatment in Europe are 
reported by just five countries: Germany, Spain, France, 
Italy and the United Kingdom (92).
Opioids other than heroin are cited as the primary drug 
by a high proportion of treatment entrants in a number of 
countries: fentanyl in Estonia, buprenorphine in Finland, 
and other opioids in Denmark, Latvia and Austria (93).
Opioid users entering specialist treatment are on average 
33 years old, with female clients being younger in 
most countries (94). Across Europe, male opioid clients 
outnumber their female counterparts by a ratio of about 
Figure 11: Estimates of the annual prevalence of problem opioid use (among the population aged 15–64)
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(95) See Tables TDI-33, TDI-106 (part i) and TDI-107 (part i) in the 2012 statistical bulletin.
(96) See Figures TDI-1 and TDI-3 in 2012 statistical bulletin.
(97) See Table DRD-2 (part i) in the 2012 statistical bulletin.
three to one. The great majority of opioid clients report 
having started to use the drug before the age of 30, with 
almost half (46 %) of all opioid clients having done so 
before the age of 20 (95). In general, opioid users report 
higher levels of homelessness and unemployment and 
lower levels of education than primary users of other 
drugs, and they are usually concentrated in urban areas.
Trends in problem opioid use
Data from nine countries with repeated estimates of 
the prevalence of problem opioid use over the period 
2005–10 suggest a relatively stable situation. However, 
prevalence measures may not be sensitive to trends in 
drug use initiation, and need to be placed in the context 
provided by other data sources. In the period 2005–10, 
the number of clients who entered specialist drug 
treatment for primary heroin use for the first time in their 
life in 24 European countries increased from 51 000 in 
2005 to a peak of 61 000 in 2007, before decreasing 
to 46 000 in 2010 (96). This decline is most apparent in 
western European countries.
The time between first use of heroin and entering treatment 
can be considerable. Because of this, the number of heroin 
users entering treatment for the first time reflects both the 
historical trend in heroin initiation (incidence) and the 
contemporary picture. A caveat to this interpretation is that 
it may be influenced by changes in reporting practices, 
and the European figures disproportionately reflect trends 
in larger countries. Nonetheless, despite considerable 
variation between countries, the evidence suggests that, 
overall, new heroin use in Europe is in decline.
This analysis can also be viewed alongside trends in other 
indicators, including injecting drug use (see following), 
drug-induced deaths and drug-related offences, although, 
arguably, these data sources are better indicators of 
prevalence than incidence. A decrease in the number of 
heroin-related drug law offences can be seen in Europe 
in recent years. The data on drug-induced deaths is more 
equivocal. Increases, or a stable situation, was noted by 
countries up to 2008; in 2009, an overall stable situation 
was evident and provisional data for 2010 suggests 
a more recent fall (97).
Opioid market indicators also provide complementary 
information here. Acute heroin shortages reported by 
a number of countries in late 2010 and early 2011 
(EMCDDA, 2011a) and a recent decline in heroin 
seizures point to changes in heroin availability in Europe 
that might also be associated with a shift in drug use 
patterns. These include reports of increased injecting of 
cathinones (Hungary), mixtures containing caffeine and 
creatine (Romania), increased use of benzodiazepines and 
other medications (Ireland, Slovenia, United Kingdom), 
increased injecting of amphetamines (Hungary, Latvia) 
and worrying reports of use of the synthetic opioid 
fentanyl (e.g. Estonia, Slovakia).
All things considered, the information suggests that Europe 
is seeing a gradual decline in new heroin use, which has 
occurred against the backdrop of increasing availability 
and coverage of treatment. The heroin population as 
a whole appears to be both ageing and characterised 
overall by a relatively high level of service contact. Although 
this phenomenon is most apparent in the pre-2004 EU 
Member States, recent data now suggest that it may also be 
occurring in many of the newer Member States.
Injecting drug use
Injecting drug users are among those at highest risk of 
experiencing health problems from their drug use, such 
as blood-borne infections (e.g. HIV/AIDS, hepatitis) or 
drug overdoses. In most European countries, injection is 
commonly associated with opioid use, although in a few 
countries, it is associated with use of amphetamines.
Figure 12: Primary opioid users as a percentage of all reported 
drug treatment entrants in 2010
    >80 %
61–80 %
41–60 %
21–40 %
  0–20 %
NB: Data expressed as a percentage of those for whom primary drug 
is known (92 % of the reported clients). Data for 2010 or most 
recent year available. Data for Lithuania refer to clients entering 
treatment for the first time in their lives. Primary opioid users 
may be under-reported in some countries including Belgium, 
the Czech Republic, Germany and France, as many are treated 
by general practitioners or psychiatric services that are not 
reported to the treatment demand indicator.
Sources: Reitox national focal points.
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(98) See Figure PDU-2 in the 2012 statistical bulletin.
(99) See Table PDU-6 (part iii) in the 2012 statistical bulletin.
Only 14 countries were able to provide recent estimates of 
the prevalence of injecting drug use (98). The available data 
suggest large differences between countries, with estimates 
ranging from less than one to five cases per 1 000 population 
aged 15–64. In the 13 countries which have reported an 
estimate of current injectors, there were, on average, about 
2.4 injecting drug users per 1 000 population aged 15–64. 
In addition to active injectors, there are a large number of 
former injecting drug users in Europe (e.g. Sweeting et al., 
2008), but figures are not available.
About 37 % of primary opioid clients (mainly heroin 
users) entering specialist drug treatment in 2010 reported 
injecting as their usual mode of administration. Levels of 
injecting among opioid users vary between countries, 
from 7 % in the Netherlands to 94 % in Latvia. High 
proportions of injectors are found in central and eastern 
Europe as well as in some northern countries (Figure 13).
Drawing conclusions on time trends in the prevalence of 
injecting drug use based on repeated prevalence estimates 
is difficult because of the lack of data and, in some cases, 
the statistical uncertainty in the estimates. Of the eight 
countries with sufficient data to analyse trends, injecting 
levels appear to have decreased in the United Kingdom 
and remained relatively stable in Greece, Cyprus, Hungary, 
Slovakia, Croatia and Norway. The Czech Republic 
reported an increase in the number of injectors, mostly 
methamphetamine users, between 2005 and 2010 (99).
Considering data available for a number of other 
indicators, there appears to be an overall decrease in 
opioid injection and, in particular, in heroin injection 
in Europe. Most European countries have reported 
a decrease in the proportion of injectors among primary 
heroin clients entering drug treatment for the first time in 
their lives between 2005 and 2010, a trend confirmed by 
a longer term analysis (2000–09) of heroin users entering 
specialised treatment for the first time in Europe (EMCDDA, 
2012c). The decrease in heroin injection is observed in all 
countries, although the decline is more marked in western 
European countries. In 2009, while the western countries 
reported that heroin smoking had become the main route of 
drug administration for more than half of the heroin clients 
(53 %), in eastern countries, 70 % of heroin clients reported 
injection to be the main route of administration (EMCDDA, 
2012c). Furthermore, recent studies from Ireland and 
Norway identify an increasing time interval between first 
heroin use and first heroin injection (Bellerose et al., 2011; 
Bretteville-Jensen and Skretting, 2010).
Figure 13: Injecting as usual mode of administration among 
primary opioid users entering treatment in 2010
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41–60 %
21–40 %
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NB: Data expressed as a percentage of reported clients for whom 
the route of administration is known. Data for 2010 or most 
recent year available. See Table TDI-5 (part iii) and (part iv) in 
the 2012 statistical bulletin.
Sources: Reitox national focal points.
Injection and other routes of administration
Data collected on drug users entering treatment provide the 
largest and most comprehensive source of information on the 
drug-taking behaviour of those with drug-related problems in 
Europe (1).
Overall, injecting was the second most commonly reported route 
of administration by drug users entering treatment primarily 
for problems with opioids in 2010. Of the 140 000 primary 
opioid clients entering treatment in outpatient centres, for whom 
the route of administration is known, 36 % reported injecting 
the drug, while 45 % reported smoking or inhaling it and 
19 % cited sniffing or ingesting the drug orally. In contrast, 
3 % of the 53 000 cocaine users entering treatment in the same 
settings reported injecting the drug, 68 % reported sniffing it, 
and the remainder reported smoking or inhaling it. Among the 
9 000 users of amphetamines or other non-cocaine stimulants, 
24 % reported injecting as the main route of administration, 
while 40 % ingested the drug orally, 32 % sniffed it and 
4 % reported other means of administration.
Patterns of drug use have changed over time. An analysis 
of treatment entry data between 2000 and 2009 showed 
a decrease in drug injection among primary heroin clients in 
all European countries (from 58 % to 36 %), particularly in 
western Europe (EMCDDA, 2012c). In addition, among opioid 
users entering treatment in outpatient settings since 2009, those 
smoking the drug outnumbered those injecting it (2).
(1) It should be noted that treatment entry data cannot be 
extrapolated to the whole population of drug users in treatment, 
and may not be representative of the wider population of drug 
users, which includes those not in treatment. More information 
on the size of the total treated population is available on the 
EMCDDA website.
(2) See Table TDI-17 in the 2010, 2011, 2012 statistical bulletins.
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(100) See Table TDI-24 in the 2012 statistical bulletin.
(101) See Table HSR-3 in the 2012 statistical bulletin.
(102) See Figure HSR-1 in the 2012 statistical bulletin.
Treatment of problem opioid use
Provision and coverage
Both drug-free and substitution treatments for opioid users 
are available in all EU Member States, Croatia, Turkey 
and Norway. In most countries, treatment is conducted in 
outpatient settings, which can include specialised centres, 
general practitioners’ surgeries and low-threshold facilities. 
In a few countries, residential treatment plays an important 
role in the treatment of opioid dependence (100). A small 
number of countries offer heroin-assisted treatment for 
a selected group of chronic heroin users.
For opioid users, drug-free treatment is generally preceded 
by a detoxification programme, which provides them 
with pharmaceutical assistance to manage the physical 
withdrawal symptoms. This therapeutic approach 
generally requires individuals to abstain from all 
substances, including substitution medication. Patients 
participate in daily activities and receive intensive 
psychological support. While drug-free treatment can take 
place in outpatient and inpatient settings, the types most 
commonly reported are residential and hospital-based 
drug-free treatment.
The most common type of treatment for opioid 
dependence in Europe is substitution treatment, typically 
integrated with psychosocial care and provided at 
specialist outpatient centres. Sixteen countries report 
that it is also provided by general practitioners. In some 
countries, general practitioners provide this treatment 
in a shared-care arrangement with specialist treatment 
centres. The total number of opioid users receiving 
substitution treatment in the European Union, Croatia, 
Turkey and Norway is estimated at 709 000 (698 000 for 
EU Member States) in 2010, up from 650 000 in 2008, 
and about half a million in 2003 (101). The vast majority 
of substitution treatments continue to be provided in the 
15 pre-2004 EU Member States (about 95 % of the total), 
and medium-term trends (2003–10) show continuous 
increases (Figure 14). The greatest increases in provision 
among these countries were observed in Greece, Austria 
and Finland, where treatment numbers almost tripled.
An even higher rate of increase was observed in the 
12 countries that have joined the European Union since 
2004. In these countries, the number of substitution clients 
rose from 7 800 in 2003 to 20 400 in 2010, with much 
of the increase occurring after 2005. Proportionally, the 
expansion of substitution treatment in these countries over 
the seven-year period was highest in Estonia (sixteenfold 
from 60 to over 1 000 clients, though still reaching only 
5 % of opioid injectors) and Bulgaria (eightfold). The 
smallest increases were reported in Lithuania, Hungary 
and Slovakia.
A comparison of the estimated number of problem opioid 
users with the number of clients in substitution treatment 
suggests varying coverage levels in Europe. Of the 
18 countries for which reliable estimates of the number of 
problem opioid users are available, nine report a number 
of clients in substitution treatment corresponding to about 
50 % or more of the target population (102). Six of those 
countries are pre-2004 EU Member States, and the 
remaining countries are the Czech Republic, Malta and 
Norway.
While, on average, about half of all problem opioid 
users in the European Union and Norway have access 
to substitution treatment, substantial differences exist 
between countries, with considerably lower coverage 
levels in Greece (28 %), Lithuania (17 %), Slovakia (12 %), 
Poland (8 %) and Latvia (2 %).
Estimates of the proportion of problem opioid users in 
any type of treatment are possible for eight countries 
Figure 14: Clients in opioid substitution treatment in the  
15 pre-2004 and the 12 newer EU Member States — estimated 
numbers and indexed trends
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(103) See Table HSR-3 in the 2012 statistical bulletin.
(Figure 15). In Ireland, Cyprus, Hungary, the Netherlands 
and the United Kingdom (England), it is estimated that more 
than 60 % of problem opioid users are in treatment, while 
this proportion is estimated to be less than 40 % in Greece. 
The data also suggests differences in the treatment of 
choice for opioid dependence. Treatments other than opioid 
substitution, mostly drug-free modalities, represent less than 
10 % of all treatments provided to problem opioid users in 
Germany, Greece, Italy and the United Kingdom (England). 
In Ireland, Cyprus and the Netherlands, treatments other 
than opioid substitution treatment represent between 15 % 
and 25 % of all treatments for problem opioid users, while 
in Hungary this proportion is 43 %. Correspondingly, 
while both Greece and Hungary report low coverage 
estimates for opioid substitution treatment (around 30 %), 
the proportions of problem opioid users that are estimated 
to be not in contact with any treatment service differ 
considerably: from over 60 % in Greece compared with 
around 25 % in Hungary. This illustrates the need to 
consider both the level of substitution treatment available 
and the availability of other treatment approaches.
Lengthy waiting times for substitution treatment can be 
a significant barrier to treatment access. According 
to a survey carried out in 2011, limited availability of 
treatment and the lack of resources, as well as delays 
due to procedural reasons, are the main causes for 
lengthy waiting times. Experts from 12 of the 29 reporting 
countries estimated that the average waiting time was 
less than two weeks, and in a further six countries it was 
estimated to be between two weeks and one month. In 
another five countries (Lithuania, Hungary, Romania, 
Finland, Norway), the waiting time was one to six months, 
while waiting times in Greece exceeded six months. 
National average waiting times may, however, mask 
considerable regional variation. For example, in Athens 
and Thessaloniki, waiting times were estimated to have 
reached about three years, due to limited capacity, though 
shorter waiting times in 2010 were reported in other 
Greek cities. Experts from four countries could not provide 
an estimate of waiting times.
In Europe, methadone is the most commonly prescribed 
opioid substitute, received by up to three quarters of 
substitution clients. Buprenorphine-based substitution 
medications are prescribed to up to a quarter of European 
substitution clients, and are the principal substitution 
medications in the Czech Republic, Greece, France, 
Cyprus, Finland and Sweden (103). The combination 
buprenorphine-naloxone is available in 15 countries. 
Treatments with slow-release morphine (Bulgaria, 
Austria, Slovenia), codeine (Germany, Cyprus) and 
diacetylmorphine (Belgium, Denmark, Germany, 
Spain, Netherlands, United Kingdom) represent a small 
proportion of all treatments.
Opioid detoxification, effectiveness and outcomes
There is increasing evidence that opioid detoxification 
has better outcomes when supported by psychotherapy 
and followed by pharmacological relapse prevention. 
A recent review of studies found that this treatment 
combination can help patients to complete treatment, 
to reduce their use of opioids, and to remain abstinent 
at follow-up (Amato et al., 2011). Furthermore, the 
number of clinical absences during treatment was lower 
in the patients offered psychosocial support. Day and 
Strang (2011) found that inpatient settings were more 
effective than outpatient settings in helping clients 
to complete detoxification (51 % versus 36 % in the 
outpatient group).
Prevention of relapse after heroin detoxification can 
be supported by naltrexone, an opioid antagonist. 
However, medication compliance and retention rates 
Figure 15: Treatment coverage of problem opioid users in 
selected European countries: proportion (%) of the estimated 
problem opioid-using population in or out of treatment
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Sources: Reitox national focal points.
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with naltrexone treatment in the overall study populations 
remain low. Naltrexone was found to be effective for 
those obliged to comply with treatment in order to avoid 
major consequences, for example health professionals, 
and individuals under legal supervision (Minozzi et 
al., 2011). While, overall, detoxification for opioid 
dependence seems to be less effective than substitution 
treatment, the World Health Organisation (2009), 
nevertheless, recommends that detoxification is offered 
as an option to motivated clients seeking treatment.
Quality of life in drug users in substitution treatment
Opioid-dependent drug users, as a group, experience a lower 
quality of life compared to that of the general population and 
people with other medical illnesses. This has been the focus 
of recent studies in Germany, Latvia and the United Kingdom, 
with the results providing support for the value of substitution 
treatment. Poor quality of life factors are also predictors 
of relapse, especially among older drug users (EMCDDA, 
2010d). A recent systematic review (De Maeyer et al., 2010) 
showed that participation in treatment improved individuals’ 
quality of life starting from the first months of treatment. All 
of the substitution treatment options appeared to be equally 
effective in improving quality of life, although those prescribed 
methadone usually experienced improvements earlier (after 
about one month) than those receiving buprenorphine. In 
subjective reports, however, buprenorphine was rated more 
highly than methadone, possibly due to the lack of a need 
to administer the drug daily. Attaining good quality of life 
outcomes is a key target in drug treatment, and this can 
benefit from further research into the relative effectiveness of 
the available substitution options.
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Introduction
Drug use is associated, both directly and indirectly with 
a range of negative health and social consequences. 
Problems are disproportionately found among long-term 
users of opioids, some forms of stimulants and among 
those who inject. The use of opioid drugs in particular is 
associated with drug overdose deaths, and the scale of this 
problem is illustrated by the fact that, over the last decade, 
Europe has experienced about one overdose death every 
hour. However, it is also important to remember that chronic 
drug users are also at a far greater risk of dying from other 
causes, including organic diseases, suicide, accidents and 
trauma. Regardless of the substance used, drug injecting 
continues to be an important vector for the transmission 
of infectious diseases, including HIV and hepatitis C, with 
new HIV outbreaks recently experienced by some European 
countries underlining the importance of maintaining 
effective public health responses in this area.
Drug-related infectious diseases
The EMCDDA is systematically monitoring infection 
with HIV and hepatitis B and C viruses among injecting 
drug users (104). The morbidity and mortality caused 
by these infections are among the most serious health 
consequences of drug use. Other infectious diseases 
may also disproportionately affect drug users, including 
hepatitis A and D, sexually transmitted diseases, 
tuberculosis, tetanus, botulism, anthrax and human 
T-lymphotropic virus infection.
HIV and AIDS
By the end of 2010, the rate of reported new HIV 
diagnoses among injecting drug users remained low in 
most countries of the European Union, and the overall EU 
situation compares positively both in a global and wider 
European context (Figure 16).
(104) For details on methods and definitions, see the 2012 statistical bulletin.
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Figure 16: HIV infections newly diagnosed in injecting drug users in 2010 in Europe and Central Asia
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NB: Colour indicates the rate per million of population of reported newly diagnosed HIV cases attributed to the injecting drug use risk group that were 
diagnosed in 2010. Data for Albania, Turkey and the Russian Federation are for 2009.
Source: ECDC and WHO, 2011.
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(105) Data for Austria and Turkey are not available. For the EU Member States plus Croatia, Turkey and Norway, the rate was 2.52 cases per million 
population, or 1 204 newly reported cases in 2010.
(106) See Tables INF-1 and INF-108 and Figure INF-3 (part i) in the 2012 statistical bulletin.
(107) See the box ‘HIV outbreaks in Greece and Romania’. 
(108) Data for Spain do not have national coverage. The recent increase in Estonia may be due to changes in the surveillance system since 2009; 
however, to what extent is unclear.
(109) Trend data are not available for Estonia, France, Ireland, the Netherlands and Turkey. See Table INF-108 in the 2012 statistical bulletin.
The average rate of newly diagnosed cases in the 
26 EU Member States able to provide data for 2010 
reached a new low of 2.54 per million, or 1 192 newly 
reported cases (105). This compares with rates of 
19.7 per million in the US (CDC, 2009), 104.3 per million 
in Russia, both for 2009, and 151.5 per million in Ukraine 
in 2010 (ECDC and WHO, 2011). The available data 
on the prevalence of HIV in samples of injecting drug 
users in the European Union also compare positively with 
prevalence in neighbouring countries in the east (106), 
although comparisons between countries should be 
undertaken with caution due to differences in study 
methodology and coverage.
This may, at least partly, follow from the increased 
availability of prevention, treatment and harm-reduction 
measures, including substitution treatment and needle 
and syringe programmes. Other factors, such as the 
decline in injecting drug use that has been reported in 
several countries, may also have played an important role 
(EMCDDA, 2010e).
Despite this overall positive picture, new data suggest that 
HIV transmission related to injecting drug use continued in 
2010, with two countries in particular (Greece, Romania) 
reporting new outbreaks of HIV infection among injecting 
drug users in 2011 (107). In both countries, these outbreaks 
were preceded by increases in the prevalence of the 
hepatitis C virus (HCV) among injecting drug users, 
suggesting that rising HCV prevalence may act as an early 
indicator of increases in injecting risks among injecting 
drug user populations, possibly before HIV has started to 
spread (Vickerman et al., 2010).
Trends in HIV infection
Data on reported newly diagnosed cases related to 
injecting drug use for 2010 suggest that, overall, infection 
rates are still falling in the European Union, following 
a peak in 2001–02. Of the five countries reporting 
the highest rates of newly diagnosed infections among 
injecting drug users between 2005 and 2010, Spain 
and Portugal continued their downward trend, while, 
among the others, only Latvia reported a small increase 
(Figure 17) (108).
These data are positive, but they must be viewed in the 
knowledge that potential for new HIV outbreaks among 
injectors continues to exist in some countries. Taking 
a two-year perspective (between 2008 and 2010), 
increases were observed in Estonia, from 26.8 cases 
per million to 46.3 per million, and in Lithuania, from 
12.5 cases per million to 31.8 per million. Bulgaria, a 
country with, historically, a very low rate of infection, also 
saw a peak of 9.7 per million in 2009, before falling back 
to 7.4 per million in 2010.
Prevalence data from samples of drug injectors are 
available for 25 European countries over the period 
2005–10 (109), and although sampling differences mean 
this information needs to be carefully interpreted, it does 
provide a complementary data source. In 17 of these 
countries, HIV prevalence estimates remained unchanged. 
In seven (Germany, Spain, Italy, Latvia, Poland, Portugal, 
Norway), HIV prevalence data showed a decrease. 
Only one country (Bulgaria) reported increasing HIV 
prevalence: in the capital city, Sofia, consistent with the 
increase in cases of newly diagnosed infections. The 
increases in HIV transmission in Greece and Romania 
reported in 2011 were not observed in HIV prevalence 
or case reporting data before 2011. Possible further 
indications of ongoing HIV transmission were observed 
among small samples of young injecting drug users (aged 
under 25) in six countries: prevalence levels above 5 % 
were recorded in Estonia, France, Latvia, Lithuania and 
Poland, and increasing prevalence in Bulgaria, over the 
period 2005–10.
Figure 17: Trends in newly reported HIV infections in injecting drug 
users in the five EU Member States reporting the highest rates
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NB: Data reported by end of October 2011, see Figure INF-2 in the 
2012 statistical bulletin.
Source: ECDC and WHO, 2011.
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(110) See Table INF-104 (part iii) and Figure INF-1 (part i) in the 2012 statistical bulletin.
(111) See Tables INF-2 and INF-111 and Figure INF-6 (part i) in the 2012 statistical bulletin.
(112) See Tables INF-112 and INF-113 and Figure INF-6 (part ii) and (part iii) in the 2012 statistical bulletin.
(113) See Tables INF-105 and INF-106 in the 2012 statistical bulletin.
AIDS incidence and access to HAART
Information on the incidence of AIDS, though a poor 
indicator of HIV transmission, can be important for showing 
the new occurrence of symptomatic disease. High incidence 
rates of AIDS may indicate that many injecting drug users 
infected with HIV do not receive highly active antiretroviral 
treatment (HAART) at a sufficiently early stage in their 
infection to obtain maximum benefit from the treatment. 
A global review suggests that this may still be the case in 
some European countries (Mathers et al., 2010).
Latvia continues to be the country reporting the highest 
incidence of AIDS related to injecting drug use, with an 
estimated 27.1 new cases per million population in 2010, 
up from 20.8 per million a year earlier. Relatively high 
AIDS incidence among injecting drug users is also reported 
for Estonia (9.7 new cases per million population), Portugal 
(8.3), Lithuania (6.0) and Spain (5.7), although the 2005 to 
2010 trend was downward in all of these countries (110).
Hepatitis B and C
Viral hepatitis, in particular infection caused by the 
hepatitis C virus (HCV), is highly prevalent in injecting 
drug users across Europe (Figure 18). HCV antibody 
levels among national samples of injecting drug users in 
2009–10 varied from 14 % to 70 %, with seven of the 
11 countries with national data (Greece, Italy, Cyprus, 
Austria, Portugal, Finland, Norway), reporting prevalence 
over 40 % (111), a level that may indicate that injecting 
risks are sufficient for HIV transmission (Vickerman et al., 
2010). HCV antibody prevalence levels of over 40 % were 
also reported in the most recent national data available 
for Denmark, Luxembourg and Croatia and in nine other 
countries providing sub-national data (2005–10). The 
Czech Republic, Hungary, Slovenia (all national, 2009–10) 
and Turkey (sub-national, 2008) report HCV prevalence of 
under 25 % (5–24 %), although infection rates at this level 
still constitute a significant public health problem.
Over 2005–10, declining HCV prevalence in injecting 
drug users at either national or sub-national level was 
reported in six countries, while five others observed an 
increase (Bulgaria, Greece, Cyprus, Austria, Romania). 
Italy reported a decline at national level between 2005 
and 2009 — more recent data are not available — with 
increases in three of the 21 regions (Abruzzo, Umbria, 
Valle d’Aosta).
Studies on young injectors (under 25) suggest a decline in 
prevalence of HCV at sub-national level in Slovakia, which 
may indicate falling transmission rates. Increases among 
young injecting drug users were reported in Bulgaria, 
Greece, Cyprus and Austria, although sample sizes in 
Greece, Cyprus and Austria were small. Increasing HCV 
prevalence among new injecting drug users (injecting for 
less than two years) was reported in Greece (nationally 
and in one region) (112). These studies, while difficult to 
interpret for methodological reasons, do illustrate that 
many injectors continue to contract the virus early in their 
injecting career, suggesting that the time window for 
initiating HCV prevention measures may often be small.
Trends in notified cases of hepatitis B and C are difficult to 
interpret as data quality is low. However, some insight into 
the epidemiology of these infections may be provided by 
the proportion of injecting drug users among all notified 
cases where risk factors are known (Wiessing et al., 
2008). Averaged across the 16 countries for which data 
are available for the period 2009–10, injecting drug use 
accounts for 48 % of all HCV cases and 32 % of the acute 
HCV cases notified (where the risk category is known). 
For hepatitis B, injecting drug users represent 6 % of all 
notified cases and 12 % of acute cases. These data confirm 
that injecting drug users continue to form an important 
at-risk group for viral hepatitis infection in Europe (113).
HIV outbreaks in Greece and Romania
In 2011, early warning systems detected outbreaks of HIV 
transmission in Greece and Romania prompting speedy 
responses in both countries. Responding to a call from 
the European Commission, the ECDC and the EMCDDA 
produced a rapid assessment of the risks of further HIV 
outbreaks in Europe (EMCDDA and ECDC, 2012).
The numbers of newly diagnosed drug injectors infected 
with HIV increased from 9–19 per year until 2010 to 
241 cases in 2011 in Greece, and from 1–6 cases per 
year until 2010 to 114 cases in 2011 in Romania. While 
these increases occurred against a background of low 
levels, or reductions, in the provision of prevention services 
in Greece and Romania, other factors, such as increased 
stimulant use, may also have played a role.
In response to the outbreaks, Greece substantially 
increased the coverage of needle and syringe programmes 
and drug treatment capacity, with 22 new opioid 
substitution units launched by December 2011.
The rapid risk assessment report suggested that the 
possibility exists for similar outbreaks to occur in some 
other EU countries, given the increases in reported 
hepatitis C infection (an indicator of injection risk) and low 
coverage of HIV prevention services.
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Other infections
In addition to viral infections, injecting drug users are 
vulnerable to bacterial diseases. The outbreak of anthrax 
among injecting drug users in Europe (see EMCDDA, 
2010a) has highlighted an ongoing problem with severe 
illness due to spore-forming bacteria among injectors. 
A European study on four bacterial infections (botulism, 
tetanus, Clostridium novyi, and anthrax) found large 
variations in rates in injecting drug users between 
countries in 2000–09, with an unexplained concentration 
of reported cases in the northwest of Europe: Ireland, 
United Kingdom and Norway (Hope et al., 2012).
In Europe, tuberculosis, a bacterial disease usually 
attacking the lungs, is predominantly concentrated in 
high-risk groups, such as migrants, homeless people, drug 
users and prisoners. Being HIV-positive increases the risk 
of developing the disease by a factor of 20 to 30 (WHO, 
2010). Data on the prevalence of active tuberculosis 
among drug users in treatment are available for five 
countries, where it varies from zero (Austria, Slovakia) 
to 3.1 % (Lithuania), with intermediate levels in Greece 
(0–0.5 %) and Portugal (0.1–1 %). In addition, Norway 
reported that cases are ‘very rare’. Moreover, four 
countries report the proportion of ‘drug users’ among new 
tuberculosis cases with known risk factor information in 
2010: 0.9 % in Hungary, 1.2 % in Belgium (injecting drug 
users), 3.3 % in the United Kingdom (England and Wales, 
problem drug users) and 5.9 % in Latvia.
Preventing and responding to infectious 
diseases
The prevention of infectious diseases among drug users 
is an important public health goal of the European Union 
and a component of most Member States’ drug policies. 
Countries aim to prevent and control the spread of 
infectious diseases among drug users by a combination 
of approaches including: the provision of sterile drug 
injection equipment; vaccination, testing and treatment 
of infectious diseases; and drug treatment, particularly 
opioid substitution treatment. In addition, outreach or 
low-threshold agencies provide information, education 
and behavioural interventions. These measures have been 
promoted by EU agencies as the core interventions for HIV 
and hepatitis prevention, treatment and care for injecting 
drug users (ECDC and EMCDDA, 2011).
Interventions
The effectiveness of opioid substitution therapy in reducing 
HIV transmission and self-reported injecting risk behaviour 
has been confirmed in several studies and reviews. There 
is growing evidence that the combination of opioid 
Figure 18: Prevalence of HCV antibodies among injecting drug users
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(114) See Table HSR-5 (part i) and (part ii) in the 2012 statistical bulletin.
(115) See Figure HSR-3 in the 2012 statistical bulletin.
(116) See the box ‘Hepatitis C treatment for injecting drug users: new pharmaceuticals’.
(117) See Table HSR-6 in the 2012 statistical bulletin.
substitution treatment and needle and syringe programmes 
is more effective in reducing HIV or HCV incidence and 
injecting risk behaviour than either approach alone (ECDC 
and EMCDDA, 2011).
In Europe, the availability and coverage of needle and 
syringe programmes are increasing: of the 30 countries 
responding to a survey in 2011, 26 indicate needle 
and syringe programmes as a priority, compared with 
23 countries in 2008. In Sweden, where syringe exchange 
programmes have been operational since 1986, but 
limited to Skåne County, a new programme in Stockholm 
was scheduled to open in 2011. Overall, while experts 
consider current levels of syringe provision as meeting 
the needs of the majority of injecting drug users in two 
thirds of European countries, national experts in five 
countries indicated that free, sterile syringes and other 
clean drug injection equipment would be available only 
to a minority of injecting drug users. Nonetheless, during 
the period 2008–11, the number of countries reporting full 
or extensive coverage of needle and syringe programmes 
increased by a third, from 15 to 20.
Information on the number of syringes distributed by 
specialised programmes in 2005 and 2010 is available 
for 22 EU countries and Norway (114). In this subset of 
countries, a large increase was seen in the number of 
syringes given out: from 34.5 million in 2005 to more 
than 51 million in 2010 (37 %). This overall increase may 
hide different subregional trends: in the 10 countries for 
which reliable injecting drug use estimates are available, 
the number of syringes handed out by specialised 
programmes in 2010 is equivalent to 110 syringes per 
injecting drug user (115).
In Europe, few active injecting drug users receive 
hepatitis C antiviral treatment. However, advances in the 
treatment of the disease (116) and a growing evidence base 
for its effectiveness among injecting drug users, including 
modelling studies that suggest the possibility of reducing 
the transmission of the virus (Martin et al., 2011), indicate 
the potential for extending strategies to treat hepatitis C 
among injecting drug users.
Voluntary counselling combined with confidential testing is 
identified by national experts as a priority in responding 
to hepatitis C in injecting drug users in 19 countries. 
Since 2008, there has been an increase of over 50 % in 
the number of countries where experts indicate sufficient 
HCV-testing coverage, and a small increase in the 
number of countries reporting that at least half of the 
target population would receive infectious disease risk 
counselling. Among injecting drug users taking part in 
the Unlinked Anonymous Monitoring survey in England 
in 2010, 83 % reported having undertaken a voluntary 
confidential HCV test, compared with 49 % in 2000. 
Furthermore, 55 % of those infected with HCV were 
aware of their status in 2010, compared with 40 % in 
2000 (HPA, 2011). In Budapest, a unique harm-reduction 
programme was initiated in 2010, with female outreach 
workers providing HIV and hepatitis B and C testing 
targeted at females who inject drugs or are related to 
injecting drug users.
In contrast to HCV, a safe and effective vaccine exists to 
prevent the spread of hepatitis B virus (HBV). Currently, 
25 European countries incorporate hepatitis B into national 
vaccination programmes, and 16 report that specific HBV 
vaccination programmes for injecting drug users exist (117).
Drug-related deaths and mortality
Drug use is one of the major causes of health problems 
and mortality among young people in Europe. Mortality 
related to drug use comprises the deaths caused directly 
or indirectly by the use of drugs. This includes deaths 
from drug overdoses (drug-induced deaths), HIV/AIDS, 
Hepatitis C treatment for injecting drug users: 
new pharmaceuticals
Patients with chronic hepatitis C virus (HCV) infection, 
including injecting drug users, can be treated using 
pharmacological therapy.
First introduced in 2001, pegylated interferons (PEG-IFN) 
alpha-2a and alpha-2b have become the standard 
treatment for chronic hepatitis C. In Europe, these two forms 
of PEG-IFN are licensed for use with differing doses of 
oral ribavirin (depending on the HCV genotype), and with 
slightly different dose recommendations. PEG-IFN alpha 
plus ribavirin is considered the best treatment available. 
It has been shown to be effective in at least 50 % of those 
treated (Rosen, 2011), achieving comparable response 
rates in HCV-infected injecting drug users (Hellard et al., 
2009). Successfully treated patients maintain low viral 
loads for several months after treatment, and can have 
a reasonable quality of life, provided that they maintain 
a healthy lifestyle. The combined therapy, however, may 
be toxic, and it is partly to overcome the side effects, but 
also to enhance existing HCV treatment, that researchers 
are exploring other therapeutic strategies. The interventions 
under study include the protease inhibitors telaprevir and 
boceprevir, approved the United States in 2011, after 
positive results in clinical trials (Rosen, 2011).
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(118) See the 2011 ‘Selected issue’ on mortality related to drug use.
(119) For information on mortality cohort studies, see the Key indicators on the EMCDDA website.
(120) The European estimate is based on 2010 data for 20 of the 27 EU Member States, and 2009 data for seven others and Norway. Belgium is 
excluded as no data are available. For more information, see Table DRD-2 (part i) in the 2012 statistical bulletin. 
(121) As most of the drug-induced deaths reported to the EMCDDA are opioid overdoses (mainly heroin), the general characteristics of the reported deaths 
are presented here to describe and analyse deaths related to heroin use.  
See Figure DRD-1 in the 2012 statistical bulletin.
(122) See Figures DRD-2 and DRD-3 and Table DRD-1 (part i) in the 2012 statistical bulletin.
accidents, violence, suicide and chronic health problems 
caused by repeated use of drugs (118). Such deaths are 
mainly concentrated among problem drug users, although 
some (e.g. traffic accidents) occur among occasional users.
Estimates of overall drug-related mortality can be derived 
in various ways, for example by combining information 
from mortality cohort studies with estimates of drug-use 
prevalence. Another approach is to use existing general 
mortality statistics and estimate the proportion related to 
drug use. Mortality cohort studies track the same groups 
of problem drug users over time and, through linkage with 
mortality registries, try to identify the causes of all deaths 
occurring in the group. This type of study can determine 
overall and cause-specific mortality rates for the cohort, 
and can estimate the group’s excess mortality compared to 
the general population (119).
Depending on recruitment settings (e.g. drug treatment 
facilities) and enrolment criteria (e.g. injecting drug users, 
heroin users), most cohort studies show mortality rates in 
the range of 1–2 % per year among problem drug users. 
Drawing on an analysis of data from over 30 cohort 
studies following patients up to 2010, it was estimated 
that 10 000–20 000 opioid users die each year in Europe 
(EMCDDA, 2011c). Typically, annual mortality rates are 
10–20 per 1 000 person-years, representing an excess 
mortality 10 to 20 times greater than expected. Most 
deaths occur among males in their mid-thirties. Four broad 
categories of cause of death can be identified: overdose, 
disease, suicide and trauma. The relative importance of 
the different causes of death varies across populations, 
between countries and over time. Generally, though, the 
main and most well-documented cause of death among 
problem drug users in Europe is drug overdose.
Drug-induced deaths
The most recent estimates suggest that there were about 
7 000 overdoses or drug-induced deaths in 2010 in the 
EU Member States and Norway, indicating a decrease 
when compared with the more than 7 600 cases reported 
in 2009 (120). The numbers are likely to be conservative 
as national data may be affected by under-reporting 
or under-ascertainment of drug-induced deaths. In the 
EU Member States and Norway, between 6 300 and 
8 400 drug-induced deaths were reported each year 
during the period 1996–2009. In 2009, the most recent 
year for which data are available for almost all countries, 
more than half of all reported drug-induced deaths were 
accounted for by Germany and the United Kingdom.
In 2010, the average EU mortality rate due to overdoses 
is estimated at 20 deaths per million population aged 
15–64 years, with considerable differences between 
countries. Rates of over 20 deaths per million are found 
in 14 out of 30 European countries, and rates of over 
40 deaths per million in seven countries.
Deaths related to opioids
Heroin
Opioids, mainly heroin or its metabolites, are present in 
the majority of drug-induced deaths reported in Europe. 
In the 23 countries providing data in 2009 or 2010, 
opioids accounted for the large majority of all cases, 
with 15 countries reporting proportions of 80 % or more, 
of which six were over 90 %. Substances often found in 
addition to heroin include alcohol, benzodiazepines, other 
opioids and, in some countries, cocaine. This suggests that 
a substantial proportion of all drug-induced fatalities occur 
in a context of polydrug use.
Men account for most overdose deaths reported in Europe 
(80 % overall) (121). Patterns differ between countries, 
with a higher proportion of males reported in southern 
countries (Greece, Italy, Portugal, Romania, Croatia) and 
in Estonia, Latvia and Lithuania, as well as in Turkey. In 
the Member States that have joined the EU since 2004, 
reported drug-induced deaths are also more likely to occur 
among males and in younger people.
Denmark, Spain, the Netherlands and Norway report 
higher proportions of older cases of drug-induced deaths. 
In the majority of countries, the average age of those 
dying from heroin overdoses is mid-thirties and, in many 
countries, the average age is increasing. This suggests 
a stabilisation or decrease in the number of young heroin 
users, and an ageing cohort of problem opioid users. 
Overall, 11 % of overdose deaths reported in Europe 
occur among those aged under 25 years, and 57 % 
among those aged 35 and over (122).
A number of factors are associated with heroin overdoses, 
both fatal and non-fatal. These include injection, 
simultaneous use of other substances, in particular 
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(123) See Table DRD-108 in the 2012 statistical bulletin.
(124) For data on deaths related to drugs other than heroin, see Table DRD-108 in the 2012 statistical bulletin.
(125) For more information on new substances and the European early warning system, see Chapter 8. 
(126) See Figures DRD-8 and DRD-11 in the 2012 statistical bulletin.
alcohol and benzodiazepines, co-morbidity, previous 
experience of overdose, not being in drug treatment and 
homelessness. The time immediately after release from 
prison or discharge from drug treatment is a particularly 
risky period for overdoses, as illustrated by a number 
of longitudinal studies (EMCDDA, 2011c). There is also 
increased risk of death associated with being alone at the 
time of overdose.
Other opioids
Besides heroin, a range of other opioids are found in 
toxicological reports, including methadone (EMCDDA, 
2011a) and, more rarely, buprenorphine (123). There 
is increasing international concern (particularly in 
Australia, Canada and the United States) about deaths 
associated with the misuse of prescription painkillers 
such as oxycodone. In Europe, while evidence of 
deaths resulting from the use of prescribed opioid 
analgesics remains limited, there have been ‘outbreaks’ 
of overdoses linked to synthetic opioids, such as 
illegally produced 3-methylfentanyl in Estonia, in recent 
years, pointing to the need to closely monitor changes 
in patterns of drug use that may be associated with 
elevated risks of mortality.
Deaths related to other drugs
Deaths caused by acute cocaine poisoning seem to be 
relatively uncommon, and cocaine is very rarely identified 
as the only substance contributing to a drug-induced 
death. But, as cocaine overdoses are more difficult to 
define and identify than those related to opioids, they may 
be under-reported (see Chapter 5).
For 2010, at least 640 deaths related to cocaine were 
reported in 16 countries. Due to the limited comparability 
in the available data, it is difficult to describe the 
European trend. The most recent data for Spain and the 
United Kingdom, the two countries with the highest levels 
of cocaine prevalence, confirm a decrease in deaths 
related to the drug observed since 2008.
Deaths in which stimulants other than cocaine are 
present, such as amphetamines and ecstasy (MDMA), 
are infrequently reported and, in many of these cases, 
the drug has not been identified as the direct cause of 
death (124). The advent of the availability of currently 
uncontrolled psychoactive substances has also been 
associated in media and toxicological reports of drug-
related deaths, although monitoring in this area is 
difficult. Deaths associated with cathinones, including 
mephedrone and MDPV have been reported, but not 
in great numbers. Some deaths have also been linked 
to other new substances, a recent example of which is 
4-methylamphetamine, where mortality data has prompted 
the EMCDDA and Europol to undertake a European-level 
assessment (125).
Trends in drug-induced deaths
Drug-induced deaths increased sharply in Europe during 
the 1980s and early 1990s, paralleling the increase in 
heroin use and drug injection, and thereafter remained 
at high levels (126). Between 2000 and 2003, most 
EU Member States reported a decrease, followed by 
a subsequent increase from 2003 until 2008/09 when 
levels stabilised. Preliminary data available for 2010 
suggest an overall figure below that for 2009, with 
a continued decrease in the numbers of deaths reported 
in Germany, Spain, Italy, the Netherlands, Austria, 
the United Kingdom and Turkey.
A majority of the countries with above-average mortality 
rates in 2010 are located in the north of Europe, while 
many of the countries with rates below the European 
average are located in southern Europe. Data are 
presented in Figure 19 for a selection of countries that 
joined the European Union before 2004 and Norway. 
Due to methodological differences, caution must be 
exercised when comparing countries.
Assessing trends in the newer EU Member States and 
candidate countries is more difficult, as the number of 
reported deaths is small and improvements in reporting 
capacity may reduce the comparability of data over 
time. Despite these difficulties, an increase has been 
observed in the mortality rate linked to drug-induced 
deaths in Estonia and, to a lesser extent, in the Czech 
Republic, Lithuania, Hungary, Croatia and Turkey.
The sustained numbers of reported drug-induced deaths 
in some countries are difficult to explain, especially 
given the indications of decreases in injecting drug use 
and increases in the numbers of opioid users in contact 
with treatment and harm-reduction services. Possible 
explanations include: increased levels of polydrug use 
(EMCDDA, 2009b) or high-risk behaviour; increases 
in the numbers of relapsing opioid users leaving prison 
or treatment; and an ageing cohort of more vulnerable 
drug users.
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(127) See Table DRD-5 (part iii) in the 2012 statistical bulletin. 
(128) See treatment guidelines on the Best practice portal.
(129) Naloxone reverses the effects of opioids, and is widely used in hospitals and emergency medicine. 
Deaths indirectly related to drug use
By combining existing data from Eurostat and HIV/AIDS 
surveillance, the EMCDDA has estimated that about 
1 830 people died of HIV/AIDS attributable to drug use 
in the European Union in 2009 (127), with almost 90 % 
of these deaths occurring in Spain, France, Italy and 
Portugal. Among the countries with estimated rates far 
above the other countries, mortality rates due to HIV/
AIDS attributed to injecting drug use decreased in Spain, 
Italy and Portugal, but they increased in Latvia and 
Lithuania, compared with 2008. The recently reported 
outbreaks of HIV cases among injecting drug users in 
Greece and Romania (EMCDDA and ECDC, 2012) needs 
close monitoring with regard to patient care and levels of 
HIV/AIDS-related deaths.
Other diseases that also account for a proportion of 
deaths among drug users include chronic conditions 
such as liver diseases, mainly due to infection with the 
hepatitis C virus (HCV) and often worsened by heavy 
alcohol use and HIV co-infection. The consequences of 
HCV infection can be particularly serious for drug users, 
with evidence suggesting that it can double their risk of 
a drug-related death, and that it may account for the 
elevated risk of drug-related death among older drug 
users (Merrall et al., 2012). Deaths caused by other 
infectious diseases are rarer. Causes of death among drug 
users such as suicide and trauma as well as homicide 
have received much less attention, despite indications of 
a considerable impact on mortality.
While the long-term trend in HIV-related mortality among 
drug users is downwards, other causes of mortality have 
shown little sign of decreasing in recent years, despite 
the scaling up of treatment, notably opioid substitution 
treatment, and other services. A number of interrelated 
factors may help explain this intractable problem. In 
addition to those mentioned earlier, specifically on the risk 
factors for drug-induced deaths, these factors include: the 
use of alcohol and other drugs; high levels of ill-health; 
co-morbidity; and social exclusion and marginalisation. 
More effort is required to better understand and target 
both the direct and indirect factors associated with 
mortality among problem drugs users if this major health 
cost associated with drug consumption is to be reduced 
in Europe.
Reducing drug-related deaths
Reducing the loss of life due to drug use is a key policy 
priority in the majority of European countries, with 
16 reporting that it is a focus in their national or regional 
drug policy documents, or that it is the subject of 
a specific action plan. In some other European countries, 
such as Austria and Norway, increases in drug-related 
deaths observed in previous years have raised awareness 
of the need for improved responses.
Being in drug treatment significantly reduces the mortality 
risk of drug users and, due to its better pharmacological 
safety profile, buprenorphine is the recommended 
medication for opioid maintenance in some countries (128). 
A buprenorphine-naloxone (129) combination has 
obtained marketing authorisation in half of the European 
Figure 19: Trends in mortality rates in the general population due 
to drug-induced deaths in a selection of pre-2004 EU Member 
States and Norway — countries with rates above the EU average 
in 2010 (top) and below EU average (bottom)
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NB: The EU average is computed for the 27 EU Member States and 
Norway. The 2010 figure is provisional, as data were available 
for only 20 countries. Data are presented for Norway and the 
pre-2004 Member States with more than 100 drug-induced 
deaths reported in the most recent year.
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(130) See Table HSR-1 in the 2012 statistical bulletin.
(131) For more information, see the Mobile Fixerum website.
countries (130). Considerable risks have also been 
identified, related to drug tolerance, for drug users 
entering or leaving treatment. Studies show that the risk 
of drug-induced death on relapse after treatment or in the 
weeks after release from prison is substantially elevated.
Alongside improving access to drug treatment, other 
interventions to reduce overdose risks among drug 
users include the provision of training, and overdose 
risk information. Overdose training combined with 
a take-home dose of naloxone is an intervention that 
can prevent deaths from opioid overdose. In 2011, two 
thirds of European countries reported that ambulance 
personnel are trained in naloxone use; in just over half 
of these countries, naloxone is reported to be one of the 
standard medications carried in ambulances. Only Italy, 
Romania and the United Kingdom report the existence 
of community-based harm-reduction programmes that 
provide take-home naloxone to opioid users, their 
family members and carers. Legal barriers remain in 
place in other European countries, including Estonia, 
which has the highest drug-related mortality rate among 
adults (15–64) in the European Union. However, it 
was demonstrated in the United Kingdom that, with 
minimal training, healthcare professionals, including 
drug workers, can increase their knowledge, skills 
and confidence for managing an opioid overdose and 
administering naloxone (Mayet at al., 2011).
The majority of countries report the distribution of 
overdose risk information — often in several languages in 
order to reach migrant drug users — through specialised 
drugs agencies and websites and, more recently, also 
through telephone messaging and e-mail. Between 2008 
and 2011, three additional countries reported full or 
extensive coverage of overdose risk information materials.
Additional care and support may also be required to 
meet the needs of vulnerable groups of drug users, such 
as HCV-infected and older drug users. Overdose risk 
assessment by trained drug or health workers can assist the 
early identification of high-risk individuals, and potentially 
act as a catalyst for reducing harm. While national experts 
indicate that provision of overdose risk assessment is 
sufficient to meet the needs of the majority of opioid users 
in less than half of the European countries, this marks 
a significant increase (44 %) between 2008 and 2011.
Highly targeted interventions, such as supervised 
injecting facilities, reach specific subgroups of highly 
marginalised drug users and contribute to reducing 
morbidity and mortality. In Denmark, a mobile injection 
room, providing a safer injecting environment and medical 
supervision was established in Copenhagen in 2011 by 
a private organisation (131). Similar to the supervised drug 
consumption facilities in Germany, Spain, Luxembourg, the 
Netherlands and Norway, the new facility in Denmark is 
equipped to reduce the impact of non-fatal overdoses.
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Introduction
Within Europe, and globally, new drugs and new patterns 
of drug use are attracting increasing political, media 
and public attention. In part, this has been fuelled by 
developments in communication technologies, which have 
impacted on all aspects of modern life including, now, the 
nature of the drug market and consumer demand. Against 
this rapidly shifting background, the provision of timely 
and objective information on new drugs and emerging 
trends has become even more important. The European 
response to this is based on an early warning network, 
which uses information from a range of sources, including 
forensic science, surveys, Internet monitoring, and hospital 
emergency data.
Action on new drugs
The European Union’s early warning system has been 
developed as a rapid-response mechanism to the 
emergence of new psychoactive substances. Following 
a review of the system in 2011, the European Commission 
is working on a new instrument to replace Council 
Decision 2005/387/JHA (132).
New psychoactive substances
Between 2005 and 2011, 164 new psychoactive substances 
were formally notified through the early warning system. 
In 2011, for the third consecutive year, a record number of 
substances (49) were detected for the first time in Europe, up 
from 41 substances in 2010 and 24 in 2009.
This marked increase in the number of substances notified 
is occurring in the context of a continually developing 
‘legal high’ phenomenon, and reflects both the number 
of substances that have been launched on the European 
drugs market and the improved reporting capacities of 
national early warning systems. The presence of some of 
these new drugs on the market has been detected through 
test purchases of ‘legal high’ products on the Internet 
and from specialised shops. In most cases, however, 
they were detected through forensic analysis of seizures. 
No first identifications in biological samples (blood, 
urine) were reported in 2010 or 2011, whereas a quarter 
of the substances notified in 2009 were detected in 
biological samples.
(132) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances, 
OJ L 127, 20.5.2005, p. 32.
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New drugs discourse: new psychoactive 
substances or ‘legal highs’?
There are a number of terms used to describe new drugs, and 
some EMCDDA definitions for concepts in common usage are 
provided below.
Within the terms of the European Union’s early warning system, 
a new psychoactive substance is defined as a new narcotic 
drug or a new psychotropic drug that has not been scheduled 
under the 1961 and 1971 United Nations international drug 
control conventions, and which may pose a threat to public 
health comparable to the substances listed therein (1).
The term ‘designer drug’ appeared in the 1980s with 
the emergence of the ‘ecstasy’ compounds (MDMA and 
others) on the illicit drug market. It refers to unregulated 
psychoactive substances designed to mimic the effects of 
controlled drugs by slightly altering their chemical structure 
in order to circumvent existing controls. The term implied that 
these substances are typically manufactured from chemical 
precursors in a clandestine laboratory.
The EMCDDA defines ‘legal highs’ as an umbrella term for 
unregulated psychoactive substances or products claiming 
to contain them, which are specifically intended to mimic the 
effects of controlled drugs. The term encompasses a wide 
range of synthetic and plant-derived substances, which 
are usually sold on the Internet or in smart or head shops. 
Describing these substances as ‘legal’ can be incorrect or 
misleading: some products may contain substances controlled 
under drug legislation, while others may be covered by 
medicines or food safety laws (EMCDDA, 2011a).
Other terms used include ‘herbal highs’, which emphasises 
the purported natural origin of a product.
To circumvent consumer and marketing regulations, new 
psychoactive substances are also sold under various 
product labels, such as ‘research chemicals’, ‘bath salts’ and 
‘plant food’.
(1) Council Decision 2005/387/JHA provides a legally binding 
definition of the substances it covers.
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As in 2010, about two thirds of the newly notified 
substances reported in 2011 were synthetic cannabinoids or 
synthetic cathinones; these two groups also represent two 
thirds of all new substances reported to the early warning 
system since 2005 (EMCDDA and Europol, 2011). Synthetic 
cannabinoids are the largest of the six different groups 
monitored (see Figure 20). Also monitored are a number 
of medicines (e.g. phenazepam and etizolam), metabolites 
or precursors of medicines (5-hydroxytryptophan) and 
substances based on medicines (e.g. camfetamine — 
a derivative of fencamfamine). An example of this is 
methoxetamine, a ketamine derivative reported in 2010 
and actively monitored by the early warning system, 
a substance with a potential for acute (Wood et al., 2012a) 
and chronic toxicity similar to that seen with ketamine.
Production and supply of new drugs
Most new psychoactive substances appearing on 
the European illicit drugs market are reported to be 
synthesised outside Europe, with China and, to a lesser 
extent, India being identified as the primary source 
countries. European law enforcement agencies have 
uncovered facilities associated with the importation, 
mixing and packaging of these substances. Reports 
indicate the involvement of organised crime in both the 
tableting and marketing of these substances, which are 
sold mainly as ‘legal highs’ on the Internet and in smart 
and head shops. In some cases, however, they are sold 
as illicit drugs such as ‘ecstasy’, using logos typically 
associated with this type of drug.
European law enforcement involvement in transnational 
cases related to the trafficking, mixing and packaging of 
new psychoactive substances are reported to have increased 
in recent years. Investigations focusing on mephedrone found 
that the drug was largely manufactured in China, often 
entering European countries in which it was controlled via 
a third country where it was not (Europol). Minor seizures, 
mainly of cathinones and synthetic cannabinoids, were 
reported by Germany, Estonia and Hungary, and from 
Denmark, concerning mCPP (133). Larger seizures, involving 
mainly unspecified new psychoactive substances, were 
reported by Latvia (about 5 kg) and Spain (seizure from 
a head shop totalling 96 kg) as well as a seizure of more 
than 20 kg of mephedrone originating from India in the 
Czech Republic. Other production-related facilities were 
dismantled or seized in Belgium, Ireland, Poland (5 kg of 
mephedrone) and the Netherlands, where 150 kg of white 
powders and approximately 20 000 packages containing 
several synthetic cannabinoids were seized at one facility.
(133) 1-(3-chlorophenyl)piperazine.
Figure 20: Main groups of new psychoactive substances identified through the early warning system since 2005
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(134) The search terms used were ‘legal highs’, ‘herbal highs’ (Spice, kratom and salvia), GBL (gamma-butyrolactone), hallucinogenic mushrooms, mephedrone 
and the pipradrol-related substances: 2-DPMP (desoxypipradrol), desoxy-D2PM (2-(diphenylmethyl)pyrrolidine) and D2PM (diphenylprolinol).
On occasion, seized substances, sold as ‘plant food’ 
or ‘research chemicals’, have been found to contain 
controlled drugs, in particular cathinones and piperazines. 
One example is the detection of PMMA in ‘legal high’ 
products, which clearly poses a threat to users (EMCDDA 
and Europol, 2011; Sedefov et al., 2011). A recent report 
in the United Kingdom showed that 19 % of Internet test 
purchases of samples advertised for sale as ‘legal highs’ 
contained a controlled substance, while 22 % contained 
piperazines, 20 % cathinones, and 18 % synthetic 
cannabinoids (Serious Organised Crime Agency, 2011). 
However, the extent to which organised crime is involved 
in the trade of new substances is unclear. Currently, 
the market seems to be largely driven by opportunist 
entrepreneurs taking advantage of the Internet to market 
and sell their products.
Internet availability
The online availability of ‘legal highs’ is monitored 
regularly by the EMCDDA through targeted Internet 
studies (snapshots) (see EMCDDA 2011a). The most recent 
snapshot was conducted in January 2012, using 20 of the 
23 official EU languages, as well as Norwegian, Russian 
and Ukrainian (134).
The number of online shops offering to supply customers 
in at least one EU Member State with psychoactive 
substances or products likely to contain them has 
continued to increase. In the January 2012 snapshot, 
693 online shops were identified, up from 314 in 
January 2011 and 170 in January 2010.
Three natural products — kratom, salvia and hallucinogenic 
mushrooms — continue to be the ‘legal highs’ most 
frequently offered online, followed by eight synthetic 
substances, the availability of which increased in the 
course of 2011 (Table 10). The 2012 snapshot identified 
a notable increase in the availability of different synthetic 
cathinones, which may suggest an ongoing search by online 
operators for a replacement for mephedrone. Mephedrone 
itself continued to be available online and appears to have 
rebounded following a major decline in online availability 
from March 2010 to July 2011, as the substance was placed 
under control by an increasing number of EU Member States 
(EMCDDA, 2011a). ‘Spice-like’ products were identified in 
21 online shops in 2012, which represents a considerable 
reduction from the 55 online shops that offered these 
products in 2009.
The Internet is a global marketplace and online shops 
selling new substances appear to have their origins 
in many countries. However, market behaviour and 
preferences are not necessarily global, as many product 
lines appear to target specific geographical markets. For 
example, the product ‘Kronic’ is almost exclusively sold by 
Australian and New Zealand-based operators.
While these data may give some indication of the 
availability of ‘legal highs’ online, information is not 
available on actual sales. To gauge the levels of use of 
new psychoactive substances in Europe, whether acquired 
through the Internet or by other means, the available data 
on use prevalence must be examined.
Prevalence
Prevalence data on new psychoactive substances are 
scarce and often suffer methodological limitations, 
including lack of common definitions, and use of self-
selected or non-representative samples. In 2011, national 
representative studies were conducted for the first time 
on the prevalence of ‘legal highs’ and new psychoactive 
substances among the general population (Ireland, United 
Kingdom) and students (Spain). The results indicate that 
prevalence levels are generally low, but there may be 
a potential for rapid rise of use in certain sub-populations.
Also in 2011, a European survey of youth attitudes, which 
interviewed more than 12 000 young people (15–24), 
estimated that 5 % of young Europeans had used ‘legal 
highs’ at some time, with about half of the countries falling 
in the range 3–5 %. The highest estimates were reported 
Table 10: Ten new psychoactive substances or 
‘legal highs’ most commonly offered for sale 
in online shops surveyed in 2011 and 2012
Number of online shops offering the product
January 
2012
July  
2011
January 
2011
Kratom (natural) 179 128 92
Salvia (natural) 134 110 72
Hallucinogenic  
mushrooms (natural)
95 72 44
Methoxetamine 
(arylcyclohexylamine)
68 58 14
MDAI (aminoindane) 65 61 45
6-APB (benzofuran) 54 49 35
MDPV (cathinone) 44 32 25
4-MEC (cathinone) 43 32 11
Methiopropamine 
(thiophene)
39 28 5
5-IAI (aminoindane) 38 27 25
Source: EMCDDA.
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(135) In Northern Ireland, the category ‘legal highs’ includes party pills, herbal highs, party powders, kratom and Salvia divinorum, whereas in Ireland, 
it also includes herbal smoking mixtures or incense, bath salts, plant feeds or other powders, magic mint, divine mint or Sally D, and other new 
psychoactive substances mentioned by the respondent. 
by Ireland (16 %) followed by Latvia, Poland and the 
United Kingdom (all at nearly 10 %) (Gallup, 2011).
In Spain, the 2010 national survey on drug use among 
school students aged 14 to 18 years introduced a special 
module on emerging drugs. The nine substances studied 
were: ketamine, ‘Spice’, piperazines, mephedrone, nexus 
(2C-B), methamphetamine, magic mushrooms, ‘research 
chemicals’ and ‘legal highs’. Overall, 3.5 % of students 
reported ever in lifetime use of one or more of these 
drugs, (2.5 % last year). Low levels of ‘Spice’ products use 
were reported: 1.1 % for lifetime and 0.8 % for last year 
prevalence. Mephedrone use was also very low in this 
group (0.4 % lifetime use).
Mephedrone and ‘legal highs’ were included for the first 
time in a joint household survey in Ireland and Northern 
Ireland (United Kingdom) conducted in 2010/11, after 
mephedrone was put under control (NACD and PHIRB, 
2011). The sample included over 7 500 respondents, 
aged 15–64. In Northern Ireland, lifetime prevalence was 
estimated at 2 % and last year prevalence at 1 % for both 
mephedrone and ‘legal highs’ (135). Lifetime prevalence 
levels were higher among those aged 15–24, reaching 
6 % for both mephedrone and ‘legal highs. In Ireland, 
new psychoactive substances (last year use, 4 %) were 
the second most frequently reported illicit drugs after 
cannabis (6 %). The highest levels of last year use of new 
psychoactive substances were reported by 15- to 24-year-
olds (10 %).
Results from the 2010/11 British Crime Survey (Smith 
and Flatley, 2011), show that among the general 
population (16–59) in England and Wales, last year 
use of mephedrone (1.4 %) was at a level similar to 
that of ecstasy. Among the 16–24 age group, last year 
prevalence of mephedrone was the same as that of 
powder cocaine (4.4 %). Most of those who reported 
using mephedrone in the last year also reported having 
used another illicit drug (mainly cannabis, cocaine or 
ecstasy). An important caveat to understanding the 
significance of these results is that the data collection 
for the survey covered pre- and post-mephedrone ban 
periods.
A small number of Internet surveys and studies with 
self-selected convenience samples monitoring the use 
and availability of new psychoactive substances have 
been carried out. An online survey on ‘legal highs’ 
conducted among 860 respondents with experience in 
‘legal highs’ in Germany showed that herbal blends were 
the most prevalent ‘legal high’ products, followed by 
‘research chemicals’ and ‘bath salts’ and similar products. 
Similarly, a study carried out in nightlife settings in the 
Czech Republic found herbal substances to be the most 
commonly mentioned ‘legal highs’, with 23 % of the 
1 099 respondents reporting that they had used Salvia 
divinorum. Also in the Czech Republic, 4.5 % of a sample 
of 1 091 Internet users aged 15 to 34 reported use of 
a new psychoactive substance.
Other studies are often focused on the use of one type 
of substance, such as ‘Spice’, BZP (benzylpiperazine) or 
mephedrone. In 2011, for the first time, the US Monitoring 
the Future annual school survey reported on the 
prevalence of synthetic cannabinoids use among young 
people. Among 12th graders, past-year use of products 
containing synthetic cannabinoids (Spice and K2) was 
found to be just over 11 %.
The 2011 round of an online drug-use survey for 
UK clubbing magazine Mixmag and the Guardian 
newspaper (Mixmag, 2012) which draws on previous 
Mixmag surveys (EMCDDA, 2009a, 2010a) collected 
15 500 responses from around the world but mostly 
Pooled, anonymous urine samples: an objective 
source of information on drug use
New approaches to identifying and measuring drug use 
in the population based on wastewater analysis have the 
potential to overcome some of the limitations of population 
surveys. The reliability of data based on self-reporting of 
drug use can be affected by variations in the content of 
the drugs that are used. This is particularly so for synthetic 
drugs and new psychoactive substances, where the user 
may not know the substance being consumed. Analysis 
of communal wastewater from sewage plants has been 
used to determine population-level use of illicit drugs 
such as MDMA and cocaine. However, this technique is 
problematic for new psychoactive substances, as little is 
known about their metabolism and stability.
A pilot study to assess the feasibility of using pooled 
urine to identify the drugs being used in the nightlife 
settings in London was undertaken in 2011 (Archer 
et al., 2012). The study detected both established illicit 
drugs and new psychoactive substances, including 
mephedrone, TFMPP (3-trifluoromethylphenylpiperazine) 
and 2-AI (2-aminoindane). The drugs present at the highest 
concentrations in the samples were mephedrone, ketamine 
and MDMA. In addition to parent drugs, metabolites of the 
relevant parent drugs were also detected.
This study demonstrates the feasibility of using pooled urine 
samples to identify the drugs in use in nightlife settings. 
This methodology has potential to provide objective data 
on drug use in these settings, and particularly to detect 
new psychoactive substances.
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from the United Kingdom. In 2010/11, reported levels of 
use of mephedrone in the last year and last month were 
three times higher among clubbers (30 % and 13 %) than 
non-clubbers (10 % and 3 %) (Mixmag, 2012). Clearly, 
data from self-selecting samples such as these cannot 
be regarded as representative in any way; such surveys 
do, however, provide an interesting window on drug use 
among those responding.
Responses to new drugs
Across Europe, measures are beginning to be developed 
to reduce both the demand for, and the supply of, new 
psychoactive substances. Individual Member States have 
taken initiatives to improve and accelerate their legal 
responses to new psychoactive substances, products and 
the establishments selling them (see Chapter 1).
In 2011, the First international multidisciplinary forum on 
new drugs highlighted the need to strengthen demand 
reduction responses to new psychoactive substances, 
including prevention, harm reduction and treatment. 
However, the availability of a wide range of compounds 
with varying content and quality complicates the provision 
of clear preventive or harm-reduction messages.
In the United Kingdom, ‘legal high’ facts, emergency 
help and drug treatment information are provided by the 
online service ‘Talk to Frank’; in Ireland, prevention and 
harm-reduction information on new drugs has been in 
circulation since 2010.
In Poland, from 2008, the National Bureau for Drug 
Prevention has prepared and launched three prevention 
campaigns: a web-based campaign providing 
information on possible consequences and threats 
of using ‘legal highs’, meetings between parents and 
school representatives which provided information on 
new psychoactive substances and which were mediated 
by counsellors or teachers, and a universal prevention 
programme targeting the school population aged 15–18 
implemented by teachers and school counsellors.
The Recreational Drugs European Network (ReDNet) project 
is a multi-site research study with the aim of improving the 
level of information available to young people (16–24) and 
professionals on the effects of these new recreational drugs 
and the potential health risks associated with their use. It 
uses a number of innovative information communication 
technologies for the dissemination of non-judgemental 
information to target groups.
There is a need to better understand the possible acute 
and chronic health implications of the use of new 
substances. Medical care for acute toxicity is required, 
but there is also a need for specific training on medical 
management of individuals who become unwell within 
recreational settings and guidance on when pre-hospital 
emergency services should be called. Nevertheless, 
given the similarities to amphetamines and MDMA, it is 
likely that management strategies akin to the treatment 
responses for these more well-known drugs would be 
also useful for users of some types of new psychoactive 
substances.
Treatment for individuals who have had exposure to new 
psychoactive drugs and seek formal help is primarily 
supportive, and there is limited information available 
on what constitutes appropriate psychosocial treatment 
for users of ‘legal highs’. In the United Kingdom, 
a multidisciplinary specialist clinic for users of club 
drugs including ‘legal highs’ has been piloted, offering 
a range of responses including brief interventions, 
pharmacological therapies, and planned care support, 
demonstrating good retention and outcomes.
Estimating psychoactivity
With an increasing number of new substances reported 
to the EU early warning system, it becomes important to 
establish at an early stage whether the substances possess 
psychoactive properties. The potential use of inexpensive 
methods for the prediction of  properties (toxicity, 
pharmacology, psychoactivity) of new drugs, without 
the need to conduct  experimental studies in animals or 
humans, is currently being explored.
One technique under investigation is the use of 
mathematical models to predict the behaviour of new 
substances. The models are based on the ‘similarity 
principle’, which assumes that molecules with closely 
related chemical structures possess similar psychochemical 
properties and activity. In this way, knowledge about 
a known substance is used to predict the effects of an 
unknown one.
The possibility of predicting the mode of action of novel 
compounds, of which little is known, appears promising. 
In a recent study, the psychoactive potential of the 
medicine ostarine was assessed using computational 
methods (Mohd-Fauzi and Bender, 2012). The analysis 
involved two stages: the first stage focused on predicting 
whether the medicine was likely to target proteins known 
to be involved in psychoactive effects; the second step 
explored the likelihood that the substance would permeate 
the central nervous system. The results of the study 
indicated that ostarine was unlikely to cause psychoactive 
effects in humans.
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(136) Hyperlinks to online sources can be found in the PDF version of the annual report, available on the EMCDDA website (http://www.emcdda.europa.
eu/publications/annual-report/2012).
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